eprosartan profile

ID Source	ID
PubMed CID	5281037
CHEMBL ID	813
SCHEMBL ID	4025
CHEBI ID	4814
CHEBI ID	94094
MeSH ID	M0187027

Synonym
BIDD:GT0030
STK618317
4-({2-butyl-5-[(1e)-2-carboxy-3-(thiophen-2-yl)prop-1-en-1-yl]-1h-imidazol-1-yl}methyl)benzoic acid
AKOS005552473
eprozar
gtpl588
sk&f-108566
teveten
4-({2-butyl-5-[(1e)-2-carboxy-3-(2-thienyl)prop-1-en-1-yl]-1h-imidazol-1-yl}methyl)benzoic acid
D04040
eprosartan (usan/inn)
C07467
eprosartan
133040-01-4
DB00876
(e)-3-[2-n-butyl-1-{(4-carboxyphenyl)methyl}-1h-imidazol-5-yl]-2-(2-thienyl)methyl-2-propenoic acid
(e)-2-butyl-1-(p-carboxybenzyl)-alpha-2-thenylimidazole-5-acrylic acid
(e)-alpha{[2-butyl-1-[(4-carboxyphenyl)methyl]-1h-imidazole-5-yl]methylene}-2-thiopheneproprionic acid
NCGC00164557-01
2-thiophenepropanoic acid, alpha-((2-butyl-1-((4-carboxyphenyl)methyl)-lh-imidazol-5-yl)methylene)-, (e)-
sk&f 108566
CHEBI:4814 ,
HMS2089O10
sk-108566
CHEMBL813 ,
L000248
bdbm50011977
4-[[2-butyl-5-[(e)-3-hydroxy-3-oxo-2-(thiophen-2-ylmethyl)prop-1-enyl]imidazol-1-yl]methyl]benzoic acid
eprosartan [usan:inn:ban]
hsdb 7521
unii-2kh13z0s0y
2kh13z0s0y ,
BCP9000656
BCPP000239
eprosartan [inn]
eprosartan [hsdb]
eprosartan [mi]
2-thiophenepropanoic acid, .alpha.-((2-butyl-1-((4-carboxyphenyl)methyl)-lh-imidazol-5-yl)methylene)-, (e)-
(e)-2-butyl-1-(p-carboxybenzyl)-.alpha.-2-thenylimidazole-5-acrylic acid
eprosartan [usan]
eprosartan [vandf]
eprosartan [who-dd]
[3h]-eprosartan
[3h]eprosartan
gtpl3940
[3h]sk&f 108566
BRD-K67977190-066-01-5
SCHEMBL4025
AB01275448-01
(e)-alpha-[[2-butyl-1-[(4carboxyphenyl)methyl]-1h-imidazol-5-yl]methylene]-2-thiophene propanoic acid
(e)-alpha-[[2-butyl-1-[(4-carboxyphenyl)-methyl]-1h-imidazol-5-yl]methylene]-2-thiophene propanoic acid
OROAFUQRIXKEMV-LDADJPATSA-N
(e)-4-((2-butyl-5-(2-carboxy-3-(thiophen-2-yl)prop-1-en-1-yl)-1h-imidazol-1-yl)methyl)benzoic acid
4-({2-butyl-5-[(1e)-2-carboxy-2-(thiophen-2-ylmethyl)eth-1-en-1-yl]-1h-imidazol-1-yl}methyl)benzoic acid
AB01275448_02
(e)-4-((2-butyl-5-(2-carboxy-3-(thiophen-2-yl)prop-1-enyl)-1h-imidazol-1-yl)methyl)benzoic acid
DTXSID0022989
sr-05000001450
CHEBI:94094
SR-05000001450-1
J-006289
NCGC00164557-06
(e)-3-[2-butyl-1-[(4-carboxyphenyl)methyl]imidazol-5-yl]-2-(2-thienylmethyl)-2-propenoic acid
4-[[2-butyl-5-(2-carboxy-3-thiophen-2-ylprop-1-enyl)-1-imidazolyl]methyl]benzoic acid
teveten; sk&f108566
BCP02353
Q784717
NCGC00164557-13
4-[[2-butyl-5-[(e)-2-carboxy-3-thiophen-2-ylprop-1-enyl]imidazol-1-yl]methyl]benzoic acid
NCGC00164557-11
(alphae)-alpha-[[2-butyl-1-[(4-carboxyphenyl)methyl]-1h-imidazol-5-yl]methylene]-2-thiophenepropanoic acid
skb 108566
HY-117743
BS-20679
4-({2-butyl-5-[(1e)-2-carboxy-2-[(thiophen-2-yl)methyl]eth-1-en-1-yl]-1h-imidazol-1-yl}methyl)benzoic acid
EN300-7397751
CS-0067582
2-thiophenepropanoic acid, alpha-[[2-butyl-1-[(4-carboxyphenyl)methyl]-1h-imidazol-5-yl]methylene]-, (alphae)-

Role	Description
antihypertensive agent	Any drug used in the treatment of acute or chronic vascular hypertension regardless of pharmacological mechanism.
angiotensin receptor antagonist	A hormone antagonist that blocks angiotensin receptors.
xenobiotic	A xenobiotic (Greek, xenos "foreign"; bios "life") is a compound that is foreign to a living organism. Principal xenobiotics include: drugs, carcinogens and various compounds that have been introduced into the environment by artificial means.
environmental contaminant	Any minor or unwanted substance introduced into the environment that can have undesired effects.

Class	Description
dicarboxylic acid	Any carboxylic acid containing two carboxy groups.
imidazoles	A five-membered organic heterocycle containing two nitrogen atoms at positions 1 and 3, or any of its derivatives; compounds containing an imidazole skeleton.
thiophenes	Compounds containing at least one thiophene ring.

Pathway	Proteins	Compounds
Eprosartan Action Pathway	7	4

Protein	Taxonomy	Measurement	Average (mM)	Bioassay(s)
Spike glycoprotein	Severe acute respiratory syndrome-related coronavirus	Potency	39.8107	AID1479145

Protein	Taxonomy	Measurement	Average (mM)	Bioassay(s)
ATP-binding cassette sub-family C member 3	Homo sapiens (human)	IC50	6.6500	AID1473740
Multidrug resistance-associated protein 4	Homo sapiens (human)	IC50	133.0000	AID1473741
Bile salt export pump	Homo sapiens (human)	IC50	134.0000	AID1443980; AID1473738
Type-1A angiotensin II receptor	Rattus norvegicus (Norway rat)	IC50	0.1244	AID37697; AID37819
Type-1B angiotensin II receptor	Rattus norvegicus (Norway rat)	IC50	0.1244	AID37697; AID37819
Type-2 angiotensin II receptor	Rattus norvegicus (Norway rat)	IC50	0.1217	AID37697; AID39361
Canalicular multispecific organic anion transporter 1	Homo sapiens (human)	IC50	57.9000	AID1473739

Protein	Taxonomy	Measurement	Average (mM)	Bioassay(s)
Type-1 angiotensin II receptor	Homo sapiens (human)	Affinity	0.0092	AID243379

Assay ID	Title	Year	Journal	Article
AID625288	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice	2011	PLoS computational biology, Dec, Volume: 7, Issue:12 ISSN: 1553-7358	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID37697	Inhibition of [125I]AII binding to Angiotensin II receptor, type 1 of rat mesenteric arteries	1993	Journal of medicinal chemistry, Jun-25, Volume: 36, Issue:13 ISSN: 0022-2623	Potent nonpeptide angiotensin II receptor antagonists. 2. 1-(Carboxybenzyl)imidazole-5-acrylic acids.
AID625291	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal	2011	PLoS computational biology, Dec, Volume: 7, Issue:12 ISSN: 1553-7358	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625283	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests	2011	PLoS computational biology, Dec, Volume: 7, Issue:12 ISSN: 1553-7358	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID39361	In vitro inhibition of [125I]AII specific binding towards Angiotensin II receptor in rat mesenteric membranes.	1991	Journal of medicinal chemistry, Apr, Volume: 34, Issue:4 ISSN: 0022-2623	1-(carboxybenzyl)imidazole-5-acrylic acids: potent and selective angiotensin II receptor antagonists.
AID444058	Volume of distribution at steady state in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3 ISSN: 1520-4804	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID444051	Total clearance in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3 ISSN: 1520-4804	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID182790	Dose dependent inhibition of pressor responses to Ang-II in conscious normotensive rat by bolus intravenous administration	1996	Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3 ISSN: 0022-2623	Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy.
AID540209	Volume of distribution at steady state in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7 ISSN: 1521-009X	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID237841	Oral bioavailability	2005	Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13 ISSN: 0022-2623	Pharmacophore, drug metabolism, and pharmacokinetics models on non-peptide AT1, AT2, and AT1/AT2 angiotensin II receptor antagonists.
AID625290	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty	2011	PLoS computational biology, Dec, Volume: 7, Issue:12 ISSN: 1553-7358	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588210	Human drug-induced liver injury (DILI) modelling dataset from Ekins et al	2010	Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12 ISSN: 1521-009X	A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID625281	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12 ISSN: 1553-7358	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID540210	Clearance in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7 ISSN: 1521-009X	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID588220	Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset	2008	Toxicology mechanisms and methods, , Volume: 18, Issue:2-3 ISSN: 1537-6524	Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID182791	Dose dependent inhibition of pressor responses to Ang-II receptor in conscious normotensive rat by intraduodenal administration	1996	Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3 ISSN: 0022-2623	Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy.
AID444053	Renal clearance in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3 ISSN: 1520-4804	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID625285	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12 ISSN: 1553-7358	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1474166	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index	2016	Drug discovery today, Apr, Volume: 21, Issue:4 ISSN: 1878-5832	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID444054	Oral bioavailability in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3 ISSN: 1520-4804	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1073308	Inhibition of HIV1 integrase/LEDGF-75 (unknown origin) interaction	2014	Journal of medicinal chemistry, Feb-13, Volume: 57, Issue:3 ISSN: 1520-4804	Inhibiting the HIV integration process: past, present, and the future.
AID568878	Inhibition of angiotensin 2-induced response in intraduodenally dosed normotensive rat	2010	Bioorganic & medicinal chemistry, Dec-15, Volume: 18, Issue:24 ISSN: 1464-3391	Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonists--a perspective.
AID625280	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12 ISSN: 1553-7358	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID243379	Binding affinity for AT1 receptor	2005	Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13 ISSN: 0022-2623	Pharmacophore, drug metabolism, and pharmacokinetics models on non-peptide AT1, AT2, and AT1/AT2 angiotensin II receptor antagonists.
AID425653	Renal clearance in human	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15 ISSN: 1520-4804	Physicochemical determinants of human renal clearance.
AID237099	Time required for elimination of 50% of the compound	2005	Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13 ISSN: 0022-2623	Pharmacophore, drug metabolism, and pharmacokinetics models on non-peptide AT1, AT2, and AT1/AT2 angiotensin II receptor antagonists.
AID425652	Total body clearance in human	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15 ISSN: 1520-4804	Physicochemical determinants of human renal clearance.
AID37819	Antagonistic activity against [125I]AngII binding to Angiotensin II receptor, type 1 in rat adrenal cortical membrane	1996	Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3 ISSN: 0022-2623	Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy.
AID239885	pKa value against human Angiotensin II receptor type 1	2005	Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13 ISSN: 0022-2623	Pharmacophore, drug metabolism, and pharmacokinetics models on non-peptide AT1, AT2, and AT1/AT2 angiotensin II receptor antagonists.
AID1443980	Inhibition of human BSEP expressed in fall armyworm sf9 cell plasma membrane vesicles assessed as reduction in vesicle-associated [3H]-taurocholate transport preincubated for 10 mins prior to ATP addition measured after 15 mins in presence of [3H]-tauroch	2010	Toxicological sciences : an official journal of the Society of Toxicology, Dec, Volume: 118, Issue:2 ISSN: 1096-0929	Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
AID1216814	Metabolic activation assessed as CYP2C9 activation-induced cytotoxicity in human HepG2 cells transfected with human AdCYP2C9 at MOI 10 for 2 days in presence of siNrf2 at 25 to 100 uM after 24 hrs by WST-8 assay	2011	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5 ISSN: 1521-009X	CYP2C9-mediated metabolic activation of losartan detected by a highly sensitive cell-based screening assay.
AID166943	Inhibition of angiotensin II induced vasoconstriction of rabbit aorta	1993	Journal of medicinal chemistry, Jun-25, Volume: 36, Issue:13 ISSN: 0022-2623	Potent nonpeptide angiotensin II receptor antagonists. 2. 1-(Carboxybenzyl)imidazole-5-acrylic acids.
AID588209	Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset	2010	Chemical research in toxicology, Jul-19, Volume: 23, Issue:7 ISSN: 1520-5010	Developing structure-activity relationships for the prediction of hepatotoxicity.
AID568877	Inhibition of angiotensin 2-induced response in iv dosed normotensive rat	2010	Bioorganic & medicinal chemistry, Dec-15, Volume: 18, Issue:24 ISSN: 1464-3391	Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonists--a perspective.
AID236277	Volume distribution was determined	2005	Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13 ISSN: 0022-2623	Pharmacophore, drug metabolism, and pharmacokinetics models on non-peptide AT1, AT2, and AT1/AT2 angiotensin II receptor antagonists.
AID247113	Maximal effect produced by the drug in human	2005	Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13 ISSN: 0022-2623	Pharmacophore, drug metabolism, and pharmacokinetics models on non-peptide AT1, AT2, and AT1/AT2 angiotensin II receptor antagonists.
AID182944	In vivo inhibition of pressor response to angiotensin II in conscious normotensive rats	1993	Journal of medicinal chemistry, Jun-25, Volume: 36, Issue:13 ISSN: 0022-2623	Potent nonpeptide angiotensin II receptor antagonists. 2. 1-(Carboxybenzyl)imidazole-5-acrylic acids.
AID1473738	Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1 ISSN: 1096-0929	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID625284	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure	2011	PLoS computational biology, Dec, Volume: 7, Issue:12 ISSN: 1553-7358	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1474167	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status	2016	Drug discovery today, Apr, Volume: 21, Issue:4 ISSN: 1878-5832	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID183608	in vivo inhibition of the pressor response to AII in conscious normotensive rats upon intravenous administration	1991	Journal of medicinal chemistry, Apr, Volume: 34, Issue:4 ISSN: 0022-2623	1-(carboxybenzyl)imidazole-5-acrylic acids: potent and selective angiotensin II receptor antagonists.
AID1473739	Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1 ISSN: 1096-0929	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID625292	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score	2011	PLoS computational biology, Dec, Volume: 7, Issue:12 ISSN: 1553-7358	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID444052	Hepatic clearance in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3 ISSN: 1520-4804	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID27037	Half life of compound was determined	2003	Journal of medicinal chemistry, Jun-05, Volume: 46, Issue:12 ISSN: 0022-2623	Angiotensin II AT1 receptor antagonists. Clinical implications of active metabolites.
AID625286	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12 ISSN: 1553-7358	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID29138	Acid dissociation value was evaluated	2003	Journal of medicinal chemistry, Jun-05, Volume: 46, Issue:12 ISSN: 0022-2623	Angiotensin II AT1 receptor antagonists. Clinical implications of active metabolites.
AID1473741	Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1 ISSN: 1096-0929	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID39652	Inhibition against Angiotensin II receptor, type 1	2003	Journal of medicinal chemistry, Jun-05, Volume: 46, Issue:12 ISSN: 0022-2623	Angiotensin II AT1 receptor antagonists. Clinical implications of active metabolites.
AID39050	In vitro inhibition of AII-induced vasoconstriction of rabbit aorta.	1991	Journal of medicinal chemistry, Apr, Volume: 34, Issue:4 ISSN: 0022-2623	1-(carboxybenzyl)imidazole-5-acrylic acids: potent and selective angiotensin II receptor antagonists.
AID625279	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia	2011	PLoS computational biology, Dec, Volume: 7, Issue:12 ISSN: 1553-7358	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID568875	Antagonist activity at angiotensin AT1 receptor in rat mesenteric artery membranes	2010	Bioorganic & medicinal chemistry, Dec-15, Volume: 18, Issue:24 ISSN: 1464-3391	Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonists--a perspective.
AID444055	Fraction absorbed in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3 ISSN: 1520-4804	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID625287	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly	2011	PLoS computational biology, Dec, Volume: 7, Issue:12 ISSN: 1553-7358	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID37820	Antagonistic activity against [125I]AngII binding to Angiotensin II receptor, type 1 in rat mesenteric artery	1996	Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3 ISSN: 0022-2623	Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy.
AID27862	Total clearance value was evaluated	2003	Journal of medicinal chemistry, Jun-05, Volume: 46, Issue:12 ISSN: 0022-2623	Angiotensin II AT1 receptor antagonists. Clinical implications of active metabolites.
AID625282	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12 ISSN: 1553-7358	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID444050	Fraction unbound in human plasma	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3 ISSN: 1520-4804	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID444057	Fraction escaping hepatic elimination in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3 ISSN: 1520-4804	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID23918	Renal clearance value was evaluated	2003	Journal of medicinal chemistry, Jun-05, Volume: 46, Issue:12 ISSN: 0022-2623	Angiotensin II AT1 receptor antagonists. Clinical implications of active metabolites.
AID320852	Antagonist activity at rat AT1 receptor expressed in CHO cells assessed as angiotensin 2-evoked increase in intracellular calcium level	2008	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 18, Issue:3 ISSN: 1464-3405	Selenosartans: novel selenophene analogues of milfasartan and eprosartan.
AID540211	Fraction unbound in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7 ISSN: 1521-009X	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID444056	Fraction escaping gut-wall elimination in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3 ISSN: 1520-4804	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID625289	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease	2011	PLoS computational biology, Dec, Volume: 7, Issue:12 ISSN: 1553-7358	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID568876	Antagonist activity at angiotensin AT1 receptor in rat adrenal cortical membranes	2010	Bioorganic & medicinal chemistry, Dec-15, Volume: 18, Issue:24 ISSN: 1464-3391	Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonists--a perspective.
AID540213	Half life in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7 ISSN: 1521-009X	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID540212	Mean residence time in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7 ISSN: 1521-009X	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID237981	Percentage modification of drug adsorbed after administration to human	2005	Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13 ISSN: 0022-2623	Pharmacophore, drug metabolism, and pharmacokinetics models on non-peptide AT1, AT2, and AT1/AT2 angiotensin II receptor antagonists.
AID39791	Relative binding affinity of compound to Angiotensin II receptor, type 1 was determined	2003	Journal of medicinal chemistry, Jun-05, Volume: 46, Issue:12 ISSN: 0022-2623	Angiotensin II AT1 receptor antagonists. Clinical implications of active metabolites.
AID1473740	Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1 ISSN: 1096-0929	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5 ISSN: 1521-0111	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5 ISSN: 1521-0111	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347160	Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 ISSN: 1091-6490	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 ISSN: 2472-5560	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347159	Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 ISSN: 1091-6490	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1745855	NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay	2023	Disease models & mechanisms, 03-01, Volume: 16, Issue:3 ISSN: 1754-8411	In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745854	NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS	2023	Disease models & mechanisms, 03-01, Volume: 16, Issue:3 ISSN: 1754-8411	In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID504749	qHTS profiling for inhibitors of Plasmodium falciparum proliferation	2011	Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043 ISSN: 1095-9203	Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1346995	Human AT1 receptor (Angiotensin receptors)	1992	The Journal of pharmacology and experimental therapeutics, Jan, Volume: 260, Issue:1 ISSN: 0022-3565	Pharmacological characterization of the nonpeptide angiotensin II receptor antagonist, SK&F 108566.

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	63 (22.42)	18.2507
2000's	158 (56.23)	29.6817
2010's	45 (16.01)	24.3611
2020's	15 (5.34)	2.80

Publication Type	This drug (%)	All Drugs (%)
Trials	83 (27.95%)	5.53%
Reviews	49 (16.50%)	6.00%
Case Studies	5 (1.68%)	4.05%
Observational	2 (0.67%)	0.25%
Other	158 (53.20%)	84.16%

Substance	Classes	Roles	Relationship Strength
tartronic acid	dicarboxylic acid; dicarboxylic fatty acid	plant metabolite	low
alpha-isopropylmalate	2-hydroxy carboxylic acid; 3-hydroxy carboxylic acid; dicarboxylic acid	metabolite	low
itaconic acid	dicarboxylic acid; dicarboxylic fatty acid; olefinic compound	fungal metabolite; human metabolite	low
2-succinylbenzoate	dicarboxylic acid		low
porphobilinogen	aralkylamino compound; dicarboxylic acid; pyrroles	Escherichia coli metabolite; metabolite; mouse metabolite	low
meglutol	3-hydroxy carboxylic acid; dicarboxylic acid; tertiary alcohol	anticholesteremic drug; antimetabolite; EC 1.1.1.34/EC 1.1.1.88 (hydroxymethylglutaryl-CoA reductase) inhibitor; human metabolite; plant metabolite	low
cromolyn	chromones; dicarboxylic acid	anti-asthmatic drug; calcium channel blocker	low
benzylsuccinic acid	dicarboxylic acid	bacterial xenobiotic metabolite	low
diethyl malonate	dicarboxylic acid		low
lauroyl peroxide	dicarboxylic acid		low
diglycolic acid	dicarboxylic acid		low
thiodipropionic acid	dicarboxylic acid		low
chlorendic acid	bridged compound; dicarboxylic acid; organochlorine compound	carcinogenic agent	low
pamoic acid	dicarboxylic acid		low
diphenic acid	dicarboxylic acid		low
kainic acid	dicarboxylic acid; L-proline derivative; non-proteinogenic L-alpha-amino acid; pyrrolidinecarboxylic acid	antinematodal drug; excitatory amino acid agonist	low
monomethyl succinate	dicarboxylic acid		low
2,2-dimethylmalonate	dicarboxylic acid	fatty acid synthesis inhibitor	low
ethylmalonic acid	dicarboxylic acid; dicarboxylic fatty acid	human metabolite	low
2,6-naphthalenedicarboxylic acid	dicarboxylic acid		low
calcium propionate	dicarboxylic acid		low
olsalazine	azobenzenes; dicarboxylic acid	non-steroidal anti-inflammatory drug; prodrug	low
thiodiacetic acid	dicarboxylic acid		low
nedocromil	dicarboxylic acid; organic heterotricyclic compound	anti-allergic agent; anti-asthmatic drug; non-steroidal anti-inflammatory drug	low
perindoprilat	dicarboxylic acid; dipeptide; L-alanine derivative; organic heterobicyclic compound	antihypertensive agent; drug metabolite; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor	low
beta-aminoglutaric acid	dicarboxylic acid	algal metabolite; marine metabolite	low
bromosuccinic acid	2-bromocarboxylic acid; dicarboxylic acid		low
2,5-furandicarboxylic acid	dicarboxylic acid; furans	human urinary metabolite	low
gamma-glutamyltyrosine	dicarboxylic acid; dipeptide; phenols; primary amino compound; secondary carboxamide	human metabolite	low
alpha-methylene glutarate	dicarboxylic acid; dicarboxylic fatty acid		low
dihydrokainate	dicarboxylic acid		low
quinaprilat	dicarboxylic acid; isoquinolines; tertiary carboxamide	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; vasodilator agent	low
n-(2-acetamido)iminodiacetic acid	ADA; dicarboxylic acid; tricarboxylic acid amide		low
3-carboxy-4-methyl-5-propyl-2-furanpropionic acid	dicarboxylic acid; furoic acid	human metabolite; uremic toxin	low
methotrexate	dicarboxylic acid; monocarboxylic acid amide; pteridines	abortifacient; antimetabolite; antineoplastic agent; antirheumatic drug; dermatologic drug; DNA synthesis inhibitor; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; immunosuppressive agent	low
lanthionine ketimine	1,4-thiazine; dicarboxylic acid; sulfur-containing amino acid	anti-inflammatory agent; human urinary metabolite; neuroprotective agent	low
aminopterin	dicarboxylic acid	EC 1.5.1.3 (dihydrofolate reductase) inhibitor; mutagen	low
hawkinsin	cycloalkene; cysteine derivative; dicarboxylic acid; diol; secondary allylic alcohol; tertiary allylic alcohol	biomarker; human urinary metabolite	low
4-aminobenzoylglutamic acid	dicarboxylic acid; dipeptide; N-acyl-L-alpha-amino acid; substituted aniline		low
2,2'-(3-methylcyclohexane-1,1-diyl)diacetic acid	dicarboxylic acid		low
formiminoglutamic acid	dicarboxylic acid; L-glutamic acid derivative		low
gibberellin a12	C20-gibberellin; dicarboxylic acid		low
citraconic acid	dicarboxylic acid; dicarboxylic fatty acid	human metabolite	low
3-methylglutaconic acid	dicarboxylic acid		low
succimer	dicarboxylic acid; dithiol; sulfur-containing carboxylic acid	chelator	low
Diethyl 2-(2-furyl)-4-hydroxy-4-methyl-6-oxo-1,3-cyclohexanedicarboxylate	dicarboxylic acid		low
spiraprilat	azaspiro compound; dicarboxylic acid; dipeptide; dithioketal; pyrrolidinecarboxylic acid; secondary amino compound; tertiary carboxamide	antihypertensive agent; drug metabolite; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor	low
2-succinyl-6-hydroxycyclohexa-2,4-diene-1-carboxylic acid	dicarboxylic acid		low
bilirubin	biladienes; dicarboxylic acid	antioxidant; human metabolite; mouse metabolite	low
betalamic acid	betalain; dicarboxylic acid		low
7432 s	cephalosporin; dicarboxylic acid	antibacterial drug	low
traumatic acid	dicarboxylic acid	plant hormone	low
bay u9773	benzoic acids; dicarboxylic acid; organic sulfide; polyunsaturated fatty acid; secondary alcohol	leukotriene antagonist	low
enalaprilat anhydrous	dicarboxylic acid; dipeptide	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor	low
benazeprilat	benzazepine; dicarboxylic acid; lactam	EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor	low
ramiprilat	azabicycloalkane; cyclopentapyrrole; dicarboxylic acid; dipeptide	bradykinin receptor B2 agonist; cardioprotective agent; drug metabolite; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; matrix metalloproteinase inhibitor	low
trandolaprilat	dicarboxylic acid; dipeptide; organic heterobicyclic compound; secondary amino compound; tertiary carboxamide	antihypertensive agent; drug metabolite; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; human xenobiotic metabolite	low
imidaprilat	dicarboxylic acid; dipeptide; imidazolidines; N-acylurea; secondary amino compound	antihypertensive agent; drug metabolite; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor	low
poricoic acid a	dicarboxylic acid; secondary alcohol; tricyclic triterpenoid	fungal metabolite	low
poricoic acid g	dicarboxylic acid; secondary alcohol; tricyclic triterpenoid	fungal metabolite	low
(6R,7R)-7-[[(2R)-2-carboxy-2-(4-hydroxyphenyl)-1-oxoethyl]amino]-7-methoxy-3-[[(1-methyl-5-tetrazolyl)thio]methyl]-8-oxo-5-oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid	dicarboxylic acid; secondary carboxamide		low
ferrous fumarate	dicarboxylic acid		low
salvianolic acid B	1-benzofurans; catechols; dicarboxylic acid; enoate ester; polyphenol	anti-inflammatory agent; antidepressant; antineoplastic agent; antioxidant; apoptosis inducer; autophagy inhibitor; cardioprotective agent; hepatoprotective agent; hypoglycemic agent; neuroprotective agent; osteogenesis regulator; plant metabolite	low
1,4-thiomorpholine-3,5-dicarboxylic acid	dicarboxylic acid; sulfur-containing carboxylic acid; thiomorpholines		low
bay 58-2667	aromatic ether; benzoic acids; dicarboxylic acid; tertiary amino compound	antihypertensive agent; soluble guanylate cyclase activator; vasodilator agent	low
ly 404039	bridged compound; dicarboxylic acid; non-proteinogenic amino acid derivative; organic heterobicyclic compound; sulfone	antipsychotic agent; anxiolytic drug; dopamine agonist; metabotropic glutamate receptor agonist	low
carboxyibuprofen	dicarboxylic acid	drug metabolite	low
nigranoic acid	dicarboxylic acid; tetracyclic triterpenoid	antineoplastic agent; HIV-1 reverse transcriptase inhibitor; metabolite	low
fertaric acid	aromatic ether; cinnamate ester; dicarboxylic acid; phenols; tetraric acid derivative		low
histamine	aralkylamino compound; imidazoles	human metabolite; mouse metabolite; neurotransmitter	low
1-(2-trifluoromethylphenyl)imidazole	imidazoles		low
1-methylimidazole	imidazoles		low
4-imidazolemethanol	imidazoles; primary alcohol		low
alosetron	imidazoles; pyridoindole	antiemetic; gastrointestinal drug; serotonergic antagonist	low
azathioprine	aryl sulfide; C-nitro compound; imidazoles; thiopurine	antimetabolite; antineoplastic agent; carcinogenic agent; DNA synthesis inhibitor; hepatotoxic agent; immunosuppressive agent; prodrug	low
bay h 4502	biphenyls; imidazoles		low
brimonidine	imidazoles; quinoxaline derivative; secondary amine	adrenergic agonist; alpha-adrenergic agonist; antihypertensive agent	low
carcinine	beta-alanine derivative; imidazoles; monocarboxylic acid amide; organonitrogen compound; organooxygen compound	antioxidant; crustacean metabolite	low
cgp 20712a	imidazoles		low
cimetidine	aliphatic sulfide; guanidines; imidazoles; nitrile	adjuvant; analgesic; anti-ulcer drug; H2-receptor antagonist; P450 inhibitor	low
clobenpropit	imidazoles; imidothiocarbamic ester; organochlorine compound	H3-receptor antagonist; H4-receptor agonist	low
clotrimazole	conazole antifungal drug; imidazole antifungal drug; imidazoles; monochlorobenzenes	antiinfective agent; environmental contaminant; xenobiotic	low
dacarbazine	imidazoles; monocarboxylic acid amide; triazene derivative	alkylating agent; antineoplastic agent; carcinogenic agent; prodrug	low
dimetridazole	C-nitro compound; imidazoles	antiparasitic agent; antiprotozoal drug	low
econazole	dichlorobenzene; ether; imidazoles; monochlorobenzenes		low
etanidazole	C-nitro compound; imidazoles; monocarboxylic acid amide	alkylating agent; antineoplastic agent; prodrug; radiosensitizing agent	low
flutrimazole	imidazole antifungal drug; imidazoles; monofluorobenzenes	EC 1.14.13.70 (sterol 14alpha-demethylase) inhibitor	low
tele-methylhistamine	imidazoles; primary amino compound	human metabolite; mouse metabolite	low
alpha-methylhistamine	aralkylamino compound; imidazoles	animal metabolite; H3-receptor agonist	low
imetit	imidazoles; imidothiocarbamic ester	H3-receptor agonist; H4-receptor agonist	low
isoconazole	dichlorobenzene; ether; imidazoles		low
ketoconazole	dichlorobenzene; dioxolane; ether; imidazoles; N-acylpiperazine; N-arylpiperazine		low
losartan	biphenylyltetrazole; imidazoles	angiotensin receptor antagonist; anti-arrhythmia drug; antihypertensive agent; endothelin receptor antagonist	low
metronidazole	C-nitro compound; imidazoles; primary alcohol	antiamoebic agent; antibacterial drug; antimicrobial agent; antiparasitic agent; antitrichomonal drug; environmental contaminant; prodrug; radiosensitizing agent; xenobiotic	low
miconazole	dichlorobenzene; ether; imidazoles		low
pd 169316	imidazoles		low
ronidazole	C-nitro compound; carbamate ester; imidazoles	antiparasitic agent; antiprotozoal drug	low
sb 220025	aminopyrimidine; imidazoles; organofluorine compound; piperidines	angiogenesis inhibitor; anti-inflammatory agent; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor	low
sb 239063	imidazoles		low
sb 202190	imidazoles; organofluorine compound; phenols; pyridines	apoptosis inducer; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor	low
sk&f 86002	imidazoles		low
sulconazole	dichlorobenzene; imidazoles; monochlorobenzenes; organic sulfide		low
tinidazole	imidazoles	antiamoebic agent; antibacterial drug; antiparasitic agent; antiprotozoal drug	low
tioconazole	dichlorobenzene; ether; imidazoles; thiophenes		low
tizanidine	benzothiadiazole; imidazoles	alpha-adrenergic agonist; muscle relaxant	low
tolazoline	imidazoles	alpha-adrenergic antagonist; antihypertensive agent; vasodilator agent	low
phentolamine	imidazoles; phenols; substituted aniline; tertiary amino compound	alpha-adrenergic antagonist; vasodilator agent	low
azomycin	C-nitro compound; imidazoles	antitubercular agent	low
5-methylbenzimidazole	imidazoles		low
2-methyl-5-nitroimidazole	C-nitro compound; imidazoles		low
4-methylimidazole	imidazoles	carcinogenic agent; reaction intermediate	low
zolimidine	imidazoles		low
1,2-dimethylimidazole	imidazoles		low
4-nitroimidazole	C-nitro compound; imidazoles		low
metomidate	imidazoles		low
nimorazole	C-nitro compound; imidazoles		low
ipronidazole	C-nitro compound; imidazoles		low
ornidazole	C-nitro compound; imidazoles; organochlorine compound; secondary alcohol	antiamoebic agent; antibacterial drug; antiinfective agent; antiprotozoal drug; antitrichomonal drug; epitope	low
1-(trimethylsilyl)-1h-imidazole	imidazoles; N-silyl compound	chromatographic reagent	low
lofexidine	aromatic ether; carboxamidine; dichlorobenzene; imidazoles	alpha-adrenergic agonist; antihypertensive agent	low
benzonidazole	C-nitro compound; imidazoles; monocarboxylic acid amide	antiprotozoal drug	low
etomidate	imidazoles		low
enilconazole	dichlorobenzene; ether; imidazoles		low
4-methylhistamine	aralkylamino compound; imidazoles	histamine agonist; metabolite	low
climbazole	aromatic ether; hemiaminal ether; imidazoles; ketone; monochlorobenzenes		low
butoconazole nitrate	aryl sulfide; conazole antifungal drug; imidazole antifungal drug; imidazoles; organic nitrate salt		low
butoconazole	aryl sulfide; conazole antifungal drug; dichlorobenzene; imidazole antifungal drug; imidazoles; monochlorobenzenes		low
oxmetidine	benzodioxoles; imidazoles; pyrimidone	anti-ulcer drug; H2-receptor antagonist	low
fenticonazole	aryl sulfide; dichlorobenzene; ether; imidazoles		low
alpidem	imidazoles		low
2-(2-methoxy-4-(methylsulfinyl)phenyl)-1h-imidazo(4,5-c)pyridine	imidazoles		low
sertaconazole	1-benzothiophenes; dichlorobenzene; ether; imidazoles		low
medetomidine	imidazoles		low
zoledronic acid	1,1-bis(phosphonic acid); imidazoles	bone density conservation agent	low
n-acetylhistamine	acetamides; imidazoles	human metabolite	low
5-imidazolepropionic acid	imidazoles; monocarboxylic acid		low
secnidazole	C-nitro compound; imidazoles; secondary alcohol	epitope	low
nitrefazole	imidazoles		low
eberconazole	dibenzannulene; imidazoles; organochlorine compound		low
prochloraz	amide fungicide; aromatic ether; conazole fungicide; imidazole fungicide; imidazoles; trichlorobenzene; ureas	antifungal agrochemical; EC 1.14.13.70 (sterol 14alpha-demethylase) inhibitor; environmental contaminant; xenobiotic	low
methylimidazoleacetic acid	imidazoles; monocarboxylic acid	GABA agonist; metabolite	low
5-(3-methyl-1-triazeno)imidazole-4-carboxamide	imidazoles; monocarboxylic acid amide; triazene derivative	alkylating agent; antineoplastic agent	low
1-(3-aminopropyl)imidazole	imidazoles		low
1-ethyl-2-benzimidazolinone	imidazoles		low
2-methylhistamine	aralkylamino compound; imidazoles	histamine agonist; metabolite	low
imidazoleacetic acid	imidazoles; monocarboxylic acid	metabolite; mouse metabolite	low
mizoribine	imidazoles	anticoronaviral agent	low
1-(2-(3-(4-methoxyphenyl)propoxy)-4-methoxyphenylethyl)-1h-imidazole	ether; imidazoles; monomethoxybenzene	TRP channel blocker	low
exp3174	biphenylyltetrazole; imidazoles; organochlorine compound	metabolite	low
1-(2-hydroxyethyl)-2-hydroxymethyl-5-nitroimidazole	C-nitro compound; imidazoles		low
histidinal	amino aldehyde; imidazoles		low
alpha-methylhistamine	aralkylamino compound; imidazoles	H3-receptor agonist	low
tipifarnib	imidazoles; monochlorobenzenes; primary amino compound; quinolone	antineoplastic agent; apoptosis inducer; EC 2.5.1.58 (protein farnesyltransferase) inhibitor	low
histidinol	amino alcohol; imidazoles	EC 2.3.1.97 (glycylpeptide N-tetradecanoyltransferase) inhibitor; Escherichia coli metabolite; human metabolite; Saccharomyces cerevisiae metabolite	low
sb 203580	imidazoles; monofluorobenzenes; pyridines; sulfoxide	EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; geroprotector; Hsp90 inhibitor; neuroprotective agent	low
fk 1052	imidazoles; organic heterotricyclic compound	antiemetic; serotonergic antagonist	low
cimicoxib	aromatic ether; imidazoles; organochlorine compound; organofluorine compound; sulfonamide	cyclooxygenase 2 inhibitor; non-steroidal anti-inflammatory drug	low
dabuzalgron	aromatic ether; imidazoles; monochlorobenzenes; sulfonamide	alpha-adrenergic agonist	low
l 778,123	imidazoles; monochlorobenzenes; nitrile; piperazinone; tertiary amino compound	antineoplastic agent; EC 2.5.1.58 (protein farnesyltransferase) inhibitor; EC 2.5.1.59 (protein geranylgeranyltransferase type I) inhibitor	low
1-methylpropyl-2-imidazolyl disulfide	imidazoles		low
2-pentan-3-yl-1H-imidazole	imidazoles		low
2-(1-adamantyl)imidazole	imidazoles		low
6-(4-chlorophenyl)-2,3-dihydroimidazo[2,1-b]thiazole	imidazoles		low
bromodeoxytopsentin	aromatic ketone; bromoindole; imidazoles; indole alkaloid	antibacterial agent; EC 2.7.1.40 (pyruvate kinase) inhibitor; marine metabolite	low
pifithrin-beta	imidazoles		low
bms 214662	benzenes; benzodiazepine; imidazoles; nitrile; sulfonamide; thiophenes	antineoplastic agent; apoptosis inducer; EC 2.5.1.58 (protein farnesyltransferase) inhibitor	low
histidyl-proline diketopiperazine	dipeptide; homodetic cyclic peptide; imidazoles; pyrrolopyrazine	anti-inflammatory agent; dopamine uptake inhibitor; human blood serum metabolite	low
s 1033	(trifluoromethyl)benzenes; imidazoles; pyridines; pyrimidines; secondary amino compound; secondary carboxamide	anticoronaviral agent; antineoplastic agent; tyrosine kinase inhibitor	low
N-[1-methyl-5-(4-methylphenyl)-2-imidazolyl]-4-oxo-4-(1-piperidinyl)butanamide	imidazoles		low
2-[[5-(4-fluorophenyl)-1-methyl-2-imidazolyl]thio]-1-(1-piperidinyl)ethanone	imidazoles		low
2-[[5-(4-chlorophenyl)-1-(2-methoxyethyl)-2-imidazolyl]thio]-N-(thiophen-2-ylmethyl)acetamide	imidazoles		low
2-(4-chlorophenyl)-3-(2-furanylmethyl)imidazo[4,5-b]quinoxaline	imidazoles		low
2-(4-methoxyphenyl)-3-propylimidazo[4,5-b]quinoxaline	imidazoles		low
etomidate	ethyl ester; imidazoles	intravenous anaesthetic; sedative	low
4-(3-amino-2-imidazo[1,2-a]pyridinyl)-2-methoxyphenol	imidazoles		low
aeg 3482	imidazoles		low
2-(3,4-dichlorophenyl)imidazo[1,2-a]pyrimidine	imidazoles		low
1-hydroxy-2-phenyl-1,5,6,7-tetrahydro-4H-benzimidazol-4-one	imidazoles		low
3-(4-methoxyphenyl)imidazo[1,5-a]pyridine	imidazoles		low
N-(2-phenyl-3-imidazo[1,2-a]pyridinyl)carbamic acid methyl ester	imidazoles		low
N-[3-(6-imidazo[2,1-b]thiazolyl)phenyl]butanamide	imidazoles		low
N-(6-phenyl-5-imidazo[2,1-b]thiazolyl)benzamide	imidazoles		low
2-phenyl-3-imidazo[1,2-a]pyridinecarboxaldehyde	imidazoles		low
N-(2-phenyl-6-imidazo[1,2-a]pyridinyl)acetamide	imidazoles		low
N,N-dimethylcarbamic acid [4-[6-(trifluoromethyl)-2-imidazo[1,2-a]pyridinyl]phenyl] ester	imidazoles		low
2-(2-furanyl)-3-(4-methylphenyl)imidazo[4,5-b]quinoxaline	imidazoles		low
2-[(1,5-diphenyl-2-imidazolyl)thio]-N-(2-furanylmethyl)acetamide	imidazoles		low
4-chloro-2-[[(1-methyl-5-phenyl-2-imidazolyl)amino]methyl]phenol	imidazoles		low
5-(4-bromophenyl)-1-methyl-N-(3-pyridinylmethyl)-2-imidazolamine	imidazoles		low
N'-methyl-N-[1-methyl-5-(4-methylphenyl)-2-imidazolyl]-N'-(phenylmethyl)butanediamide	imidazoles		low
5-(4-fluorophenyl)sulfonyl-1-(2-methylpropyl)-4-nitro-2-propan-2-ylimidazole	imidazoles		low
2-(3,5-dinitrophenyl)-3-(2-phenylethyl)imidazo[4,5-b]quinoxaline	imidazoles		low
2-(4-methylsulfonylphenyl)-6-imidazo[1,2-a]pyridinecarboxylic acid methyl ester	imidazoles		low
1-[[[1-(6-methyl-2-pyridinyl)-4-imidazolyl]-oxomethyl]amino]-3-phenylthiourea	imidazoles		low
metiamide	imidazoles		low
4,5-dichloro-2-methyl-1-(2-phenoxyethyl)imidazole	imidazoles		low
2-Chloro-6-(1H-imidazol-1-yl)benzonitrile	imidazoles		low
[1-Benzyl-2-(methylsulfanyl)-1H-imidazol-5-yl]methanol	imidazoles		low
2-(1-benzyl-1H-imidazol-5-yl)phenol	imidazoles		low
1-[2-(2,5-dimethyl-1H-pyrrol-1-yl)-4-nitrophenyl]-1H-imidazole	imidazoles		low
2-[4-(trifluoromethoxy)phenyl]imidazo[1,2-a]pyrimidine	imidazoles		low
6-methyl-2-[4-(1-piperidinylsulfonyl)phenyl]imidazo[1,2-a]pyridine	imidazoles		low
1-[(4-tert-butylphenyl)methyl]-4-(4-nitrophenyl)imidazole	imidazoles		low
burimamide	imidazoles		low
carnidazole	C-nitro compound; imidazoles		low
2-methoxy-4-[5-methyl-3-(2-oxolanylmethylamino)-2-imidazo[1,2-a]pyridinyl]phenol	imidazoles		low
4-[3-(1,3-benzodioxol-5-ylmethylamino)-7-methyl-2-imidazo[1,2-a]pyridinyl]phenol	imidazoles		low
2-[[5-(4-fluorophenyl)-1-methyl-2-imidazolyl]thio]-1-(2-methyl-2,3-dihydroindol-1-yl)ethanone	imidazoles		low
N-[3-(diethylamino)propyl]-6-(4-fluorophenyl)-3-methyl-2-imidazo[2,1-b]thiazolecarboxamide	imidazoles		low
N-(1,3-benzodioxol-5-yl)-3-methyl-6-phenyl-2-imidazo[2,1-b]thiazolecarboxamide	imidazoles		low
N-[5-(ethylthio)-1,3,4-thiadiazol-2-yl]-2-[[1-(3-methylphenyl)-2-imidazolyl]thio]acetamide	imidazoles		low
4-[[2-(4-methoxyphenyl)-6-imidazo[2,1-b][1,3]benzothiazolyl]-oxomethyl]-1-piperazinecarboxylic acid ethyl ester	imidazoles		low
4-[3-(2,3-dihydro-1,4-benzodioxin-6-ylamino)-2-imidazo[1,2-a]pyrimidinyl]phenol	imidazoles		low
5-(1,3-benzodioxol-5-yl)-3-[3-(methylthio)phenyl]-1H-imidazol-2-one	imidazoles		low
2-(2-ethoxyphenyl)-8-oxo-9-phenyl-7H-purine-6-carboxamide	imidazoles		low
1-phenyl-2-[[4-(trifluoromethyl)phenyl]methylthio]imidazole	imidazoles		low
1-[6-(4-chlorophenyl)-5-imidazo[2,1-b]thiazolyl]-N-[(3,4-dichlorophenyl)methoxy]methanimine	imidazoles		low
1-[4-(2-chlorophenoxy)butyl]imidazole	aromatic ether; imidazoles; monochlorobenzenes		low
4-[(3-methyl-5-nitro-4-imidazolyl)amino]phenol	C-nitro compound; imidazoles		low
4-(4-ethoxyphenyl)-1-(4-methoxyphenyl)-2-(methylthio)imidazole	imidazoles		low
4-[(7-methyl-2-phenyl-3-imidazo[1,2-a]pyridinyl)methyl]morpholine	imidazoles		low
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1h-imidazol-2-yl)benzamide	benzamides; benzodioxoles; imidazoles; pyridines	EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor	low
1-(3,4-dihydro-2H-quinolin-1-yl)-2-[[1-(4-ethoxyphenyl)-2-imidazolyl]thio]ethanone	imidazoles		low
2-[[1-(3-methoxyphenyl)-2-imidazolyl]thio]-N-(5-methyl-3-isoxazolyl)acetamide	imidazoles		low
N-(4-tert-butylphenyl)-2-[4-(1-imidazolyl)phenoxy]acetamide	imidazoles		low
2-[[4-(3,4-dimethylphenyl)-1-phenyl-2-imidazolyl]thio]-N-(1,1-dioxo-3-thiolanyl)acetamide	imidazoles		low
6-(4-methoxyphenyl)-N,3-dimethyl-2-imidazo[2,1-b]thiazolecarboxamide	imidazoles		low
neticonazole	aromatic ether; benzenes; conazole antifungal drug; enamine; imidazole antifungal drug; imidazoles; methyl sulfide	antifungal drug; EC 1.14.13.70 (sterol 14alpha-demethylase) inhibitor	low
2-(2-chlorophenyl)-9-(3-methylphenyl)-8-oxo-7H-purine-6-carboxamide	imidazoles		low
N-[(3-methyl-6-imidazo[2,1-b]thiazolyl)methyl]-1-propanesulfonamide	imidazoles		low
oxiconazole	conazole antifungal drug; dichlorobenzene; imidazole antifungal drug; imidazoles; oxime O-ether	antiinfective agent	low
3-[(1S)-1-phenylethyl]-4-imidazolecarboxylic acid ethyl ester	imidazoles		low
d 4476	imidazoles		low
azanidazole	C-nitro compound; imidazoles		low
4-[4-(4-fluorophenyl)-2-(4-methylsulfonylphenyl)-1H-imidazol-5-yl]pyridine	imidazoles		low
N-[5-(2-imidazo[1,2-a]pyrimidinyl)-2-methoxyphenyl]-2-methylpropanamide	imidazoles		low
4-[3-(3-methylanilino)-2-imidazo[1,2-a]pyrimidinyl]phenol	imidazoles		low
2-[4-(dimethylamino)phenyl]-N-(4-methylphenyl)-3-imidazo[1,2-a]pyrimidinamine	imidazoles		low
N-(1,3-benzodioxol-5-yl)-2-(4-methylphenyl)-3-imidazo[1,2-a]pyrazinamine	imidazoles		low
sb-505124	benzodioxole; imidazoles; methylpyridines	TGFbeta receptor antagonist	low
cyazofamid	imidazole fungicide; imidazoles; nitrile; organochlorine compound; sulfamides; sulfonamide fungicide	antifungal agrochemical; mitochondrial cytochrome-bc1 complex inhibitor	low
npi 2358	2,5-diketopiperazines; benzenes; imidazoles; olefinic compound	angiogenesis inhibitor; antineoplastic agent; apoptosis inducer; microtubule-destabilising agent	low
l-779,450	imidazoles		low
chir 99021	aminopyridine; aminopyrimidine; cyanopyridine; diamine; dichlorobenzene; imidazoles; secondary amino compound	EC 2.7.11.26 (tau-protein kinase) inhibitor	low
4-(6-iodo-2-imidazo[1,2-a]pyridinyl)-N,N-dimethylaniline	imidazoles		low
eluxadoline	amino acid amide; benzamides; imidazoles; L-phenylalanine derivative; methoxybenzoic acid	delta-opioid receptor antagonist; gastrointestinal drug; kappa-opioid receptor agonist; mu-opioid receptor agonist	low
cenicriviroc	aromatic ether; benzazocine; diether; imidazoles; secondary carboxamide; sulfoxide	anti-HIV agent; anti-inflammatory agent; antirheumatic drug; chemokine receptor 2 antagonist; chemokine receptor 5 antagonist	low
4-(3-cyclohexyl-5-(4-fluoro-phenyl)-3h-imidazol-4-yl)pyrimidin-2-ylamine	aminopyrimidine; imidazoles; monofluorobenzenes	EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor	low
imidazoleacetic acid ribotide	imidazoles; monocarboxylic acid; N-glycosyl compound; ribose monophosphate		low
cefpodoxime	imidazoles		low
sgi 1776	imidazoles		low
bms-790052	biphenyls; carbamate ester; carboxamide; imidazoles; valine derivative	antiviral drug; nonstructural protein 5A inhibitor	low
9-(3,5-difluorophenyl)-6-(ethylamino)-2-purinecarbonitrile	imidazoles		low
chir 98014	aminopyrimidine; C-nitro compound; diaminopyridine; dichlorobenzene; imidazoles; secondary amino compound	antineoplastic agent; apoptosis inducer; EC 2.7.11.26 (tau-protein kinase) inhibitor; hypoglycemic agent; tau aggregation inhibitor; Wnt signalling activator	low
ledipasvir	azaspiro compound; benzimidazole; bridged compound; carbamate ester; carboxamide; fluorenes; imidazoles; L-valine derivative; N-acylpyrrolidine; organofluorine compound	antiviral drug; hepatitis C protease inhibitor	low
gs-5816	carbamate ester; ether; imidazoles; L-valine derivative; N-acylpyrrolidine; organic heteropentacyclic compound; ring assembly	antiviral drug; hepatitis C virus nonstructural protein 5A inhibitor	low
mk-8742	carbamate ester; imidazoles; L-valine derivative; N-acylpyrrolidine; organic heterotetracyclic compound; ring assembly	antiviral drug; hepatitis C virus nonstructural protein 5A inhibitor; hepatoprotective agent	low
sb-590885	aromatic ether; imidazoles; ketoxime; pyridines; tertiary amino compound		low
arotinolol	aromatic amide; thiophenes		low
azosemide	monochlorobenzenes; sulfonamide; tetrazoles; thiophenes	loop diuretic	low
dup 697	thiophenes		low
nocodazole	aromatic ketone; benzimidazoles; carbamate ester; thiophenes	antimitotic; antineoplastic agent; microtubule-destabilising agent; tubulin modulator	low
suprofen	aromatic ketone; monocarboxylic acid; thiophenes	antirheumatic drug; drug allergen; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug; peripheral nervous system drug	low
tiaprofenic acid	aromatic ketone; monocarboxylic acid; thiophenes	drug allergen; non-steroidal anti-inflammatory drug	low
cephalothin	azabicycloalkene; beta-lactam antibiotic allergen; carboxylic acid; cephalosporin; semisynthetic derivative; thiophenes	antibacterial drug; antimicrobial agent	low
thiophene-2-carboxaldehyde	aldehyde; thiophenes	metabolite	low
thiophenes	mancude organic heteromonocyclic parent; monocyclic heteroarene; thiophenes; volatile organic compound	non-polar solvent	low
ticrynafen	aromatic ether; aromatic ketone; dichlorobenzene; monocarboxylic acid; thiophenes	antihypertensive agent; hepatotoxic agent; loop diuretic	low
sufentanil	anilide; ether; piperidines; thiophenes	anaesthesia adjuvant; intravenous anaesthetic; mu-opioid receptor agonist; opioid analgesic	low
tiagabine	beta-amino acid; piperidinemonocarboxylic acid; tertiary amino compound; thiophenes	anticonvulsant; GABA reuptake inhibitor	low
tenocyclidine	piperidines; tertiary amino compound; thiophenes	central nervous system stimulant; hallucinogen; neuroprotective agent; NMDA receptor antagonist	low
thifensulfuron methyl	1,3,5-triazines; methyl ester; N-sulfonylurea; thiophenes	agrochemical; environmental contaminant; herbicide; xenobiotic	low
4-(2-thienyl)butyric acid	monocarboxylic acid; thiophenes	hapten	low
dimethenamid	aromatic amide; ether; organochlorine compound; thiophenes		low
2,5-bis(5-hydroxymethyl-2-thienyl)furan	thiophenes		low
teniposide	aromatic ether; beta-D-glucoside; cyclic acetal; furonaphthodioxole; gamma-lactone; monosaccharide derivative; phenols; thiophenes	antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor	low
(2-amino-5-methyl-3-thiophenyl)-thiophen-2-ylmethanone	aromatic ketone; thiophenes		low
2-[[2-[[4-(2-furanylmethyl)-5-(phenylmethyl)-1,2,4-triazol-3-yl]thio]-1-oxoethyl]amino]-5,6-dihydro-4H-cyclopenta[b]thiophene-3-carboxamide	aromatic amide; thiophenes		low
4,5-dimethyl-2-[[oxo(thiophen-2-yl)methyl]amino]-3-thiophenecarboxylic acid ethyl ester	aromatic amide; thiophenes		low
N-propyl-N-(5-pyridin-4-yl-1,3,4-thiadiazol-2-yl)-2-thiophenecarboxamide	aromatic amide; thiophenes		low
6-amino-4-(5-bromo-2-thiophenyl)-3-ethyl-2,4-dihydropyrano[2,3-c]pyrazole-5-carbonitrile	pyranopyrazole; thiophenes		low
3-amino-5-methyl-4-[[3-(4-morpholinyl)propylamino]-oxomethyl]-2-thiophenecarboxylic acid ethyl ester	aromatic amide; thiophenes		low
5-[(3-ethoxycarbonyl-4-thiophen-2-yl-2-thiophenyl)amino]-5-oxopentanoic acid	ring assembly; thiophenes		low
5-bromo-N-(2-pyridinylmethyl)-2-thiophenesulfonamide	thiophenes		low
tioxazafen	1,2,4-oxadiazole; thiophenes	agrochemical; nematicide	low
pyrantel	1,4,5,6-tetrahydropyrimidines; carboxamidine; thiophenes	antinematodal drug	low
N-(3-pyridinyl)-2,3-dihydrothieno[3,4-b][1,4]dioxin-5-carboxamide	aromatic amide; thiophenes		low
1-cyclohexyl-3-[[oxo(thiophen-2-yl)methyl]amino]thiourea	aromatic amide; thiophenes		low
5-amino-3-(4-methoxyphenyl)-7-methyl-4-oxo-1-thieno[3,4-d]pyridazinecarboxylic acid methyl ester	aromatic amine; thiophenes		low
N-[[(5-chloro-2-pyridinyl)amino]-sulfanylidenemethyl]-2-thiophenecarboxamide	aromatic amide; thiophenes		low
N-(2-tert-butyl-5-oxo-4,6-dihydrothieno[3,4-c]pyrazol-3-yl)-2-thiophenecarboxamide	aromatic amide; thiophenes		low
4-cyano-3-methyl-5-(4-methylphenyl)-2-thiophenecarbohydrazide	aromatic amide; thiophenes		low
N,4-dimethyl-5-phenyl-2-thiophenecarboxamide	aromatic amide; thiophenes		low
N-(2-pyridinyl)-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxamide	aromatic amide; thiophenes		low
2-amino-5-[diethylamino(oxo)methyl]-4-methyl-3-thiophenecarboxylic acid propan-2-yl ester	aromatic amine; isopropyl ester; tertiary carboxamide; thiophenes		low
N-(3-carbamoyl-5,6-dihydro-4H-cyclopenta[b]thiophen-2-yl)-4-chloro-2-methyl-3-pyrazolecarboxamide	aromatic amide; thiophenes		low
1-(2-methylphenyl)-3-[[(5-methyl-3-thiophenyl)-oxomethyl]amino]thiourea	aromatic amide; thiophenes		low
1-(3-methylphenyl)-3-[[(5-methyl-3-thiophenyl)-oxomethyl]amino]thiourea	aromatic amide; thiophenes		low
1-(3-methylphenyl)-3-[[oxo-(5-propyl-3-thiophenyl)methyl]amino]thiourea	aromatic amide; thiophenes		low
2-[[oxo(thiophen-2-yl)methyl]amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxylic acid propan-2-yl ester	aromatic amide; isopropyl ester; secondary carboxamide; thiophenes		low
5-bromo-N-(pyridin-4-ylmethyl)-2-thiophenesulfonamide	thiophenes		low
N-[3-[oxo-(3-pyridinylmethylamino)methyl]-4,5,6,7-tetrahydro-1-benzothiophen-2-yl]-2-furancarboxamide	aromatic amide; thiophenes		low
1,4-bis(thiophen-2-ylsulfonyl)piperazine	N-sulfonylpiperazine; thiophenes		low
N-[5-[(4-chlorophenoxy)methyl]-1,3,4-thiadiazol-2-yl]-2-thiophenecarboxamide	aromatic amide; thiophenes		low
N-[(2-fluorophenyl)methyl]-2-thiophenecarboxamide	aromatic amide; thiophenes		low
N-(3-carbamoyl-5-propyl-2-thiophenyl)-2-methyl-3-furancarboxamide	aromatic amide; thiophenes		low
N-(2-furanylmethyl)-5-methyl-4-phenyl-3-thiophenecarboxamide	aromatic amide; thiophenes		low
4-ethyl-5-methyl-N-[1-[(3-methylphenyl)methyl]-1,2,4-triazol-3-yl]-3-thiophenecarboxamide	aromatic amide; thiophenes		low
5-bromo-N-[2-(4-chlorophenyl)ethyl]-2-thiophenecarboxamide	aromatic amide; thiophenes		low
5-bromo-N-(5-cyclohexyl-1,3,4-thiadiazol-2-yl)-2-thiophenecarboxamide	aromatic amide; thiophenes		low
N-[2-(4-fluorophenyl)ethyl]-5-methyl-2-thiophenecarboxamide	aromatic amide; thiophenes		low
5-[(cyclohexylamino)-oxomethyl]-4-methyl-2-[(1-oxo-2-thiophen-2-ylethyl)amino]-3-thiophenecarboxylic acid ethyl ester	aromatic amide; thiophenes		low
[[[3-[(4-methylphenyl)methoxy]-2-thiophenyl]-oxomethyl]amino]thiourea	aromatic amide; thiophenes		low
n-(4-(n-(3-methoxypyrazin-2-yl)sulfamoyl)phenyl)-3-(5-nitrothiophene-2-yl)acrylamide	pyrazines; sulfonamide; thiophenes	necroptosis inhibitor; neuroprotective agent	low
5-[diethylamino(oxo)methyl]-4-methyl-2-(1-oxopentylamino)-3-thiophenecarboxylic acid methyl ester	aromatic amide; thiophenes		low
5-bromo-N-[[[oxo(thiophen-2-yl)methyl]hydrazo]-sulfanylidenemethyl]-2-furancarboxamide	aromatic amide; thiophenes		low
1-[(2-chlorophenyl)methyl]-3-methyl-N-(4-methyl-2-thiazolyl)-5-thieno[2,3-c]pyrazolecarboxamide	aromatic amide; thiophenes		low
N-(1,3-benzodioxol-5-ylmethyl)-2-[(3-methyl-4-oxo-5-thiophen-2-yl-2-thieno[2,3-d]pyrimidinyl)thio]acetamide	ring assembly; thiophenes		low
2-[2-[[2-[(3-carbamoyl-5,6-dihydro-4H-cyclopenta[b]thiophen-2-yl)amino]-2-oxoethyl]thio]-4-thiazolyl]acetic acid ethyl ester	aromatic amide; thiophenes		low
2-[[2-[5-(4-morpholinylsulfonyl)-2-thiophenyl]-1-oxoethyl]amino]-5-phenyl-3-thiophenecarboxamide	aromatic amide; thiophenes		low
N-[2,2-dimethyl-3-[[oxo(thiophen-2-yl)methyl]amino]propyl]-2-thiophenecarboxamide	aromatic amide; thiophenes		low
N-[5-(3-methoxyphenyl)-1,3,4-thiadiazol-2-yl]-2-thiophenecarboxamide	aromatic amide; thiophenes		low
1-[[(4-ethyl-5-methyl-3-thiophenyl)-oxomethyl]amino]-3-(2-phenylethyl)thiourea	aromatic amide; thiophenes		low
2-[[1-oxo-2-(1H-1,2,4-triazol-5-ylthio)ethyl]amino]-4-thiophen-2-yl-3-thiophenecarboxylic acid ethyl ester	ring assembly; thiophenes		low
N-[3-[(cyclopropylamino)-oxomethyl]-4,5,6,7,8,9-hexahydrocycloocta[b]thiophen-2-yl]-2-furancarboxamide	aromatic amide; thiophenes		low
[3,5-bis[(phenylmethyl)amino]-1,2,4-triazol-1-yl]-thiophen-2-ylmethanone	aromatic amide; thiophenes		low
N-(4-tert-butyl-2-thiazolyl)-5-methyl-2-thiophenecarboxamide	aromatic amide; thiophenes		low
2-chloro-N-[(5-chloro-2-thiophenyl)methyl]-N-methylacetamide	thiophenes		low
N-(6-methoxy-3-pyridinyl)-3-methyl-2-thiophenecarboxamide	aromatic amide; thiophenes		low
2-[[2-[[5-(4-ethylanilino)-1,3,4-thiadiazol-2-yl]thio]-1-oxoethyl]amino]-3-thiophenecarboxamide	aromatic amide; thiophenes		low
N,N-diethyl-5-thiophen-2-yl-2-thiophenecarboxamide	ring assembly; thiophenes		low
1-(4-chlorophenyl)-3-[4-methyl-2-(thiophen-2-yl)-1,3-thiazol-5-yl]urea	1,3-thiazoles; monochlorobenzenes; phenylureas; thiophenes		low
N-(6-methoxy-3-pyridinyl)-2-thiophenecarboxamide	aromatic amide; thiophenes		low
sc 514	ring assembly; thiophenes		low
N'-[4-(3-methoxyphenyl)-2-thiazolyl]-2-thiophenecarbohydrazide	aromatic amide; thiophenes		low
3-chloro-4-propan-2-ylsulfonyl-2-thiophenecarbohydrazide	aromatic amide; thiophenes		low
4-hydroxy-3-(methylthio)-4,5,6,7-tetrahydro-2-benzothiophene-1-carbohydrazide	aromatic amide; thiophenes		low
3-(5-Chloro-2-thienyl)-1-methyl-4,5-dihydro-1H-pyrazole	thiophenes		low
2-[[oxo(thiophen-2-yl)methyl]amino]-6-propyl-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxamide	aromatic amide; thiophenes		low
[3-methyl-4-[oxo(thiophen-2-yl)methyl]-1-piperazinyl]-thiophen-2-ylmethanone	aromatic amide; thiophenes		low
N-[(2-ethyl-1-piperidinyl)-sulfanylidenemethyl]-2-thiophenecarboxamide	aromatic amide; thiophenes		low
5-bromo-N-(2-oxolanylmethyl)-2-thiophenesulfonamide	thiophenes		low
N-[5-(2-oxolanyl)-1,3,4-thiadiazol-2-yl]-2-thiophenecarboxamide	aromatic amide; thiophenes		low
N-(3-carbamoyl-5-propyl-2-thiophenyl)-2-oxolanecarboxamide	aromatic amide; thiophenes		low
4-[5-(4-morpholinylsulfonyl)-2-thiophenyl]-3-phenyl-2H-furan-5-one	thiophenes		low
5-amino-3-[[[1-(2-furanylmethyl)-5-oxo-3-pyrrolidinyl]-oxomethoxy]methyl]thiophene-2,4-dicarboxylic acid dimethyl ester	aromatic amine; thiophenes		low
6-methyl-N-(5-methyl-1,3,4-thiadiazol-2-yl)-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxamide	aromatic amide; thiophenes		low
N-[2-(cyclohexylamino)-2-oxo-1-thiophen-2-ylethyl]-2,2,2-trifluoro-N-(4-methylphenyl)acetamide	secondary carboxamide; tertiary carboxamide; thiophenes; trifluoroacetamide		low
N-(2-furanylmethyl)-5-(4-morpholinyl)-4-phenyl-2-thiophenecarboxamide	aromatic amide; thiophenes		low
1-[(5-bromo-2-thiophenyl)sulfonyl]-3-methylpiperidine	thiophenes		low
5-nitro-2-thiophenecarboxylic acid [2-oxo-2-(1-phenylethylamino)ethyl] ester	C-nitro compound; thiophenes		low
3-(5-ethyl-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)-4-prop-2-enyl-1H-1,2,4-triazole-5-thione	thiophenes		low
N-(3-carbamoyl-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)-2-methyl-3-pyrazolecarboxamide	aromatic amide; thiophenes		low
1-butyl-3-[[(4,5-dimethyl-3-thiophenyl)-oxomethyl]amino]thiourea	aromatic amide; thiophenes		low
N-[5-(2,3-dihydro-1,4-dioxin-5-yl)-1,3,4-oxadiazol-2-yl]-5-nitro-2-thiophenecarboxamide	C-nitro compound; thiophenes		low
ML162	monochlorobenzenes; monomethoxybenzene; organochlorine compound; secondary carboxamide; tertiary carboxamide; thiophenes	EC 1.11.1.9 (glutathione peroxidase) inhibitor; ferroptosis inducer	low
3-ethyl-2-sulfanylidene-5-thiophen-2-yl-1H-thieno[2,3-d]pyrimidin-4-one	ring assembly; thiophenes		low
4-(5-bromo-2-thiophenyl)-6-methyl-2-(1-pyrrolyl)pyrimidine	thiophenes		low
N-methyl-5-phenyl-2-thiophenecarboxamide	aromatic amide; thiophenes		low
5-nitro-2-thiophenecarboxylic acid [1-[(3,5-dichloro-2-pyridinyl)amino]-1-oxopropan-2-yl] ester	C-nitro compound; thiophenes		low
1-(5-nitro-2-thiophenyl)piperidine	C-nitro compound; thiophenes		low
2,5-dichloro-N-[5-(4-fluorophenyl)-1,3,4-oxadiazol-2-yl]-3-thiophenecarboxamide	aromatic amide; thiophenes		low
5-nitro-2-thiophenecarboxylic acid [2-oxo-2-[(phenylmethyl)amino]ethyl] ester	C-nitro compound; thiophenes		low
5-bromo-N-(5-pyridin-4-yl-1,3,4-oxadiazol-2-yl)-2-thiophenecarboxamide	aromatic amide; thiophenes		low
5-nitro-2-thiophenecarboxylic acid [2-oxo-2-[[oxo-[(phenylmethyl)amino]methyl]amino]ethyl] ester	C-nitro compound; thiophenes		low
N-(3-carbamoyl-6-methyl-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)-3-(2-chlorophenyl)-5-methyl-4-isoxazolecarboxamide	aromatic amide; thiophenes		low
[3-(2-hydroxyphenyl)-5-(4-methoxyphenyl)-3,4-dihydropyrazol-2-yl]-thiophen-2-ylmethanone	aromatic amide; thiophenes		low
1-butyl-3-[[oxo-(5-propan-2-yl-3-thiophenyl)methyl]amino]thiourea	aromatic amide; thiophenes		low
N-ethyl-3-(1-pyrrolyl)-2-thiophenecarboxamide	aromatic amide; thiophenes		low
dorzolamide	sulfonamide; thiophenes	antiglaucoma drug; antihypertensive agent; EC 4.2.1.1 (carbonic anhydrase) inhibitor	low
2-[[cyclohexyl(oxo)methyl]amino]-3-thiophenecarboxamide	aromatic amide; thiophenes		low
batimastat	hydroxamic acid; L-phenylalanine derivative; organic sulfide; secondary carboxamide; thiophenes; triamide	angiogenesis inhibitor; antineoplastic agent; matrix metalloproteinase inhibitor	low
HTS 01037	ring assembly; thiophenes		low
N-[3-(3,5-dimethyl-1-piperidinyl)propyl]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxamide	aromatic amide; thiophenes		low
nifurzide	C-nitro compound; thiophenes		low
rivaroxaban	aromatic amide; lactam; monocarboxylic acid amide; morpholines; organochlorine compound; oxazolidinone; thiophenes	anticoagulant; EC 3.4.21.6 (coagulation factor Xa) inhibitor	low
2-((aminocarbonyl)amino)-5-(4-fluorophenyl)-3-thiophenecarboxamide	aromatic amide; thiophenes		low
azd 7762	aromatic amide; thiophenes		low
ethaboxam	1,3-thiazoles; aromatic amide; aromatic amine; nitrile; secondary amino compound; thiophenes		low
penthiopyrad	aromatic amide; organofluorine compound; pyrazoles; thiophenes		low
[5-hydroxy-3-(4-methoxyphenyl)-5-(trifluoromethyl)-4H-pyrazol-1-yl]-thiophen-2-ylmethanone	aromatic amide; thiophenes		low
N-(3-carbamoyl-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)-5-methyl-4-nitro-3-isoxazolecarboxamide	aromatic amide; thiophenes		low
canagliflozin	C-glycosyl compound; organofluorine compound; thiophenes	hypoglycemic agent; sodium-glucose transport protein subtype 2 inhibitor	low
EG00229	benzothiadiazole; dicarboxylic acid monoamide; L-arginine derivative; secondary carboxamide; sulfonamide; thiophenes	angiogenesis inhibitor; antineoplastic agent; neuropilin receptor antagonist	low

Substance	Classes	Roles	Relationship Strength
acebutolol	aromatic amide; ethanolamines; ether; monocarboxylic acid amide; propanolamine; secondary amino compound	anti-arrhythmia drug; antihypertensive agent; beta-adrenergic antagonist; sympathomimetic agent	low
alfuzosin	monocarboxylic acid amide; quinazolines; tetrahydrofuranol	alpha-adrenergic antagonist; antihypertensive agent; antineoplastic agent	low
alprenolol	secondary alcohol; secondary amino compound	anti-arrhythmia drug; antihypertensive agent; beta-adrenergic antagonist; sympatholytic agent	low
amlodipine	dihydropyridine; ethyl ester; methyl ester; monochlorobenzenes; primary amino compound	antihypertensive agent; calcium channel blocker; vasodilator agent	low
atenolol	ethanolamines; monocarboxylic acid amide; propanolamine	anti-arrhythmia drug; antihypertensive agent; beta-adrenergic antagonist; environmental contaminant; sympatholytic agent; xenobiotic	low
bendroflumethiazide	benzothiadiazine; sulfonamide	antihypertensive agent; diuretic	low
benzothiazide	benzothiadiazine; sulfonamide	antihypertensive agent; diuretic	low
bepridil	pyrrolidines; tertiary amine	anti-arrhythmia drug; antihypertensive agent; calcium channel blocker; vasodilator agent	low
bethanidine	guanidines	adrenergic antagonist; antihypertensive agent	low
betaxolol	propanolamine	antihypertensive agent; beta-adrenergic antagonist; sympatholytic agent	low
bevantolol	propanolamine	anti-arrhythmia drug; antihypertensive agent; beta-adrenergic antagonist; calcium channel blocker	low
bisoprolol	secondary alcohol; secondary amine	anti-arrhythmia drug; antihypertensive agent; beta-adrenergic antagonist; sympatholytic agent	low
bretylium	quaternary ammonium ion	adrenergic antagonist; anti-arrhythmia drug; antihypertensive agent	low
brimonidine	imidazoles; quinoxaline derivative; secondary amine	adrenergic agonist; alpha-adrenergic agonist; antihypertensive agent	low
camostat	benzoate ester; carboxylic ester; diester; guanidines; tertiary carboxamide	anti-inflammatory agent; anticoronaviral agent; antifibrinolytic drug; antihypertensive agent; antineoplastic agent; antiviral agent; serine protease inhibitor	low
candesartan	benzimidazolecarboxylic acid; biphenylyltetrazole	angiotensin receptor antagonist; antihypertensive agent; environmental contaminant; xenobiotic	low
carteolol	quinolone; secondary alcohol	anti-arrhythmia drug; antiglaucoma drug; antihypertensive agent; beta-adrenergic antagonist; sympatholytic agent	low
carvedilol	carbazoles; secondary alcohol; secondary amino compound	alpha-adrenergic antagonist; antihypertensive agent; beta-adrenergic antagonist; cardiovascular drug; vasodilator agent	low
chlorothiazide	benzothiadiazine	antihypertensive agent; diuretic	low
cyclothiazide	benzothiadiazine	antihypertensive agent; diuretic	low
debrisoquin	carboxamidine; isoquinolines	adrenergic agent; antihypertensive agent; human metabolite; sympatholytic agent	low
diazoxide	benzothiadiazine; organochlorine compound; sulfone	antihypertensive agent; beta-adrenergic agonist; bronchodilator agent; cardiotonic drug; diuretic; K-ATP channel agonist; sodium channel blocker; sympathomimetic agent; vasodilator agent	low
doxazosin	aromatic amine; benzodioxine; monocarboxylic acid amide; N-acylpiperazine; N-arylpiperazine; quinazolines	alpha-adrenergic antagonist; antihyperplasia drug; antihypertensive agent; antineoplastic agent; vasodilator agent	low
felodipine	dichlorobenzene; dihydropyridine; ethyl ester; methyl ester	anti-arrhythmia drug; antihypertensive agent; calcium channel blocker; vasodilator agent	low
fenoldopam	benzazepine	alpha-adrenergic agonist; antihypertensive agent; dopamine agonist; dopaminergic antagonist; vasodilator agent	low
guanethidine	azocanes; guanidines	adrenergic antagonist; antihypertensive agent; sympatholytic agent	low
fasudil	isoquinolines; N-sulfonyldiazepane	antihypertensive agent; calcium channel blocker; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; geroprotector; neuroprotective agent; nootropic agent; vasodilator agent	low
hydralazine	azaarene; hydrazines; ortho-fused heteroarene; phthalazines	antihypertensive agent; vasodilator agent	low
hydrochlorothiazide	benzothiadiazine; organochlorine compound; sulfonamide	antihypertensive agent; diuretic; environmental contaminant; xenobiotic	low
hydroflumethiazide	benzothiadiazine; thiazide	antihypertensive agent; diuretic	low
indapamide	indoles; organochlorine compound; sulfonamide	antihypertensive agent; diuretic	low
avapro	azaspiro compound; biphenylyltetrazole	angiotensin receptor antagonist; antihypertensive agent; environmental contaminant; xenobiotic	low
ketanserin	aromatic ketone; organofluorine compound; piperidines; quinazolines	alpha-adrenergic antagonist; antihypertensive agent; cardiovascular drug; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; serotonergic antagonist	low
losartan	biphenylyltetrazole; imidazoles	angiotensin receptor antagonist; anti-arrhythmia drug; antihypertensive agent; endothelin receptor antagonist	low
metolazone	organochlorine compound; quinazolines; sulfonamide	antihypertensive agent; diuretic; ion transport inhibitor	low
metoprolol	aromatic ether; propanolamine; secondary alcohol; secondary amino compound	antihypertensive agent; beta-adrenergic antagonist; environmental contaminant; geroprotector; xenobiotic	low
nimodipine	2-methoxyethyl ester; C-nitro compound; dicarboxylic acids and O-substituted derivatives; diester; dihydropyridine; isopropyl ester	antihypertensive agent; calcium channel blocker; cardiovascular drug; vasodilator agent	low
nitrendipine	C-nitro compound; dicarboxylic acids and O-substituted derivatives; diester; dihydropyridine; ethyl ester; methyl ester	antihypertensive agent; calcium channel blocker; geroprotector; vasodilator agent	low
palmidrol	endocannabinoid; N-(long-chain-acyl)ethanolamine; N-(saturated fatty acyl)ethanolamine	anti-inflammatory drug; anticonvulsant; antihypertensive agent; neuroprotective agent	low
pindolol	indoles; secondary amine	antiglaucoma drug; antihypertensive agent; beta-adrenergic antagonist; serotonergic antagonist; vasodilator agent	low
prazosin	aromatic ether; furans; monocarboxylic acid amide; piperazines; quinazolines	alpha-adrenergic antagonist; antihypertensive agent; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor	low
propranolol	naphthalenes; propanolamine; secondary amine	anti-arrhythmia drug; antihypertensive agent; anxiolytic drug; beta-adrenergic antagonist; environmental contaminant; human blood serum metabolite; vasodilator agent; xenobiotic	low
terazosin	furans; piperazines; primary amino compound; quinazolines	alpha-adrenergic antagonist; antihypertensive agent; antineoplastic agent	low
tolazoline	imidazoles	alpha-adrenergic antagonist; antihypertensive agent; vasodilator agent	low
trichlormethiazide	benzothiadiazine; sulfonamide antibiotic	antihypertensive agent; diuretic	low
reserpine	alkaloid ester; methyl ester; yohimban alkaloid	adrenergic uptake inhibitor; antihypertensive agent; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; environmental contaminant; first generation antipsychotic; plant metabolite; xenobiotic	low
spironolactone	3-oxo-Delta(4) steroid; oxaspiro compound; steroid lactone; thioester	aldosterone antagonist; antihypertensive agent; diuretic; environmental contaminant; xenobiotic	low
pentolinium tartrate	tartrate salt	antihypertensive agent	low
bretylium tosylate	organosulfonate salt; quaternary ammonium salt	adrenergic antagonist; anti-arrhythmia drug; antihypertensive agent	low
quinethazone	quinazolines	antihypertensive agent; diuretic	low
visnagin	aromatic ether; furanochromone; polyketide	anti-inflammatory agent; antihypertensive agent; EC 1.1.1.37 (malate dehydrogenase) inhibitor; phytotoxin; plant metabolite; vasodilator agent	low
isoamyl nitrite	nitrite esters	antihypertensive agent; vasodilator agent	low
scoparone	aromatic ether; coumarins	anti-allergic agent; anti-inflammatory agent; antihypertensive agent; antilipemic drug; immunosuppressive agent; plant metabolite	low
hydralazine hydrochloride	hydrochloride	antihypertensive agent; vasodilator agent	low
pentamethonium	quaternary ammonium ion	antihypertensive agent; vasodilator agent	low
vincamine	alkaloid ester; hemiaminal; methyl ester; organic heteropentacyclic compound; vinca alkaloid	antihypertensive agent; metabolite; vasodilator agent	low
trimethaphan	sulfonium compound	anaesthesia adjuvant; antihypertensive agent; nicotinic antagonist; vasodilator agent	low
lofexidine	aromatic ether; carboxamidine; dichlorobenzene; imidazoles	alpha-adrenergic agonist; antihypertensive agent	low
metipranolol	acetate ester; aromatic ether; propanolamine; secondary amino compound	anti-arrhythmia drug; antiglaucoma drug; antihypertensive agent; beta-adrenergic antagonist	low
timolol	timolol	anti-arrhythmia drug; antiglaucoma drug; antihypertensive agent; beta-adrenergic antagonist	low
ticrynafen	aromatic ether; aromatic ketone; dichlorobenzene; monocarboxylic acid; thiophenes	antihypertensive agent; hepatotoxic agent; loop diuretic	low
guanadrel	guanidines; spiroketal	adrenergic antagonist; antihypertensive agent	low
methyldopa	L-tyrosine derivative; non-proteinogenic L-alpha-amino acid	alpha-adrenergic agonist; antihypertensive agent; hapten; peripheral nervous system drug; sympatholytic agent	low
diltiazem	5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetate	antihypertensive agent; calcium channel blocker; vasodilator agent	low
carteolol hydrochloride	hydrochloride	anti-arrhythmia drug; antiglaucoma drug; antihypertensive agent; beta-adrenergic antagonist	low
torsemide	aminopyridine; N-sulfonylurea; secondary amino compound	antihypertensive agent; loop diuretic	low
captopril	alkanethiol; L-proline derivative; N-acylpyrrolidine; pyrrolidinemonocarboxylic acid	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor	low
colforsin	acetate ester; cyclic ketone; labdane diterpenoid; organic heterotricyclic compound; tertiary alpha-hydroxy ketone; triol	adenylate cyclase agonist; anti-HIV agent; antihypertensive agent; plant metabolite; platelet aggregation inhibitor; protein kinase A agonist	low
ci 906	hydrochloride	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor	low
quinapril	dicarboxylic acid monoester; ethyl ester; isoquinolines; tertiary carboxamide	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; prodrug	low
cilazapril, anhydrous	dicarboxylic acid monoester; ethyl ester; pyridazinodiazepine	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; prodrug	low
carmoxirole	indolecarboxylic acid; tertiary amino compound; tetrahydropyridine	antihypertensive agent; dopamine agonist; platelet aggregation inhibitor	low
amlodipine besylate	organosulfonate salt	antihypertensive agent; calcium channel blocker; vasodilator agent	low
valsartan	biphenylyltetrazole; monocarboxylic acid amide; monocarboxylic acid	angiotensin receptor antagonist; antihypertensive agent; environmental contaminant; xenobiotic	low
diltiazem hydrochloride	hydrochloride	antihypertensive agent; calcium channel blocker; vasodilator agent	low
fosinoprilat	L-proline derivative; phosphinic acids	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor	low
telmisartan	benzimidazoles; biphenyls; carboxybiphenyl	angiotensin receptor antagonist; antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; environmental contaminant; xenobiotic	low
guanadrel sulfate	organic sulfate salt	adrenergic antagonist; antihypertensive agent	low
perindoprilat	dicarboxylic acid; dipeptide; L-alanine derivative; organic heterobicyclic compound	antihypertensive agent; drug metabolite; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor	low
gr 117289	1-benzofurans; biaryl; imidazolyl carboxylic acid; monocarboxylic acid; organobromine compound; organochlorine compound; tetrazoles	angiotensin receptor antagonist; antihypertensive agent	low
corilagin	ellagitannin; gallate ester	antihypertensive agent; antioxidant; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; non-steroidal anti-inflammatory drug	low
droxidopa	catechols; L-tyrosine derivative	antihypertensive agent; prodrug; vasoconstrictor agent	low
bosentan anhydrous	primary alcohol; pyrimidines; sulfonamide	antihypertensive agent; endothelin receptor antagonist	low
perindopril	alpha-amino acid ester; dicarboxylic acid monoester; ethyl ester; organic heterobicyclic compound	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor	low
betaxolol hydrochloride	hydrochloride	antihypertensive agent; beta-adrenergic antagonist	low
quinaprilat	dicarboxylic acid; isoquinolines; tertiary carboxamide	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; vasodilator agent	low
1-hexadecyl-2-acetyl-glycero-3-phosphocholine	2-acetyl-1-alkyl-sn-glycero-3-phosphocholine	antihypertensive agent; beta-adrenergic antagonist; bronchoconstrictor agent; hematologic agent; vasodilator agent	low
cleistanthin b	beta-D-glucoside; cleistanthins; monosaccharide derivative	alpha-adrenergic antagonist; antihypertensive agent; diuretic	low
forasartan	benzenes; pyridines; tetrazoles; triazoles	angiotensin receptor antagonist; antihypertensive agent	low
olmesartan	biphenylyltetrazole	angiotensin receptor antagonist; antihypertensive agent	low
fasudil hydrochloride	hydrochloride	antihypertensive agent; calcium channel blocker; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; neuroprotective agent; nootropic agent; vasodilator agent	low
enrasentan	aromatic ether; benzodioxoles; indanes; monocarboxylic acid; monomethoxybenzene; primary alcohol	antihypertensive agent; endothelin receptor antagonist	low
acebutolol hydrochloride	hydrochloride	anti-arrhythmia drug; antihypertensive agent; beta-adrenergic antagonist; sympathomimetic agent	low
perindopril erbumine	addition compound	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor	low
metyrosine	L-tyrosine derivative; non-proteinogenic L-alpha-amino acid	antihypertensive agent; EC 1.14.16.2 (tyrosine 3-monooxygenase) inhibitor	low
raubasine	methyl ester; monoterpenoid indole alkaloid; organic heteropentacyclic compound	alpha-adrenergic antagonist; antihypertensive agent; vasodilator agent	low
eplerenone	3-oxo-Delta(4) steroid; epoxy steroid; gamma-lactone; methyl ester; organic heteropentacyclic compound; oxaspiro compound; steroid acid ester	aldosterone antagonist; antihypertensive agent	low
colforsin daropate	acetate ester; carboxylic ester; cyclic ketone; diol; organic heterotricyclic compound; tertiary amino compound	adenylate cyclase agonist; antihypertensive agent; cardiotonic drug; vasodilator agent	low
aurapten	coumarins; monoterpenoid	antihypertensive agent; antineoplastic agent; antioxidant; apoptosis inducer; dopaminergic agent; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; gamma-secretase modulator; gastrointestinal drug; hepatoprotective agent; matrix metalloproteinase inhibitor; neuroprotective agent; plant metabolite; PPARalpha agonist; vulnerary	low
1-0-octadecyl 2-0-acetyl sn-glycero-3-phosphorylcholine	2-acetyl-1-alkyl-sn-glycero-3-phosphocholine	antihypertensive agent; beta-adrenergic antagonist; bronchoconstrictor agent; hematologic agent; vasodilator agent	low
spiraprilat	azaspiro compound; dicarboxylic acid; dipeptide; dithioketal; pyrrolidinecarboxylic acid; secondary amino compound; tertiary carboxamide	antihypertensive agent; drug metabolite; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor	low
rescinnamine	indole alkaloid; methyl ester; organic heteropentacyclic compound	antihypertensive agent	low
timolol maleate	maleate salt	anti-arrhythmia drug; antiglaucoma drug; antihypertensive agent; beta-adrenergic antagonist	low
cassaine	enoate ester; organic hydroxy compound; tertiary amino compound; tricyclic diterpenoid	antihypertensive agent; cardiotonic drug; EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor; local anaesthetic; plant metabolite; poison	low
oleuropein	beta-D-glucoside; catechols; diester; methyl ester; pyrans; secoiridoid glycoside	anti-inflammatory agent; antihypertensive agent; antineoplastic agent; antioxidant; apoptosis inducer; NF-kappaB inhibitor; nutraceutical; plant metabolite; radical scavenger	low
kaempferide	7-hydroxyflavonol; monomethoxyflavone; trihydroxyflavone	antihypertensive agent; metabolite	low
morin	7-hydroxyflavonol; pentahydroxyflavone	angiogenesis modulating agent; anti-inflammatory agent; antibacterial agent; antihypertensive agent; antineoplastic agent; antioxidant; EC 5.99.1.2 (DNA topoisomerase) inhibitor; hepatoprotective agent; metabolite; neuroprotective agent	low
rottlerin	aromatic ketone; benzenetriol; chromenol; enone; methyl ketone	anti-allergic agent; antihypertensive agent; antineoplastic agent; apoptosis inducer; K-ATP channel agonist; metabolite	low
cilnidipine	2-methoxyethyl ester; C-nitro compound; dihydropyridine	antihypertensive agent; calcium channel blocker; cardiovascular drug	low
uf 021	isopropyl ester; ketone; prostaglandins Falpha	antiglaucoma drug; antihypertensive agent; prodrug	low
travoprost	(trifluoromethyl)benzenes; isopropyl ester; prostaglandins Falpha	antiglaucoma drug; antihypertensive agent; ophthalmology drug; prodrug; prostaglandin receptor agonist	low
4-hydroxychalcone	chalcones; phenols	antihypertensive agent; plant metabolite	low
eprosartan mesylate dihydrate	methanesulfonate salt	antihypertensive agent	low
camostat mesylate	methanesulfonate salt	anti-inflammatory agent; anticoronaviral agent; antifibrinolytic drug; antihypertensive agent; antineoplastic agent; antiviral agent; serine protease inhibitor	low
dorzolamide	sulfonamide; thiophenes	antiglaucoma drug; antihypertensive agent; EC 4.2.1.1 (carbonic anhydrase) inhibitor	low
bimatoprost	monocarboxylic acid amide	antiglaucoma drug; antihypertensive agent	low
fluprostenol	(trifluoromethyl)benzenes; hydroxy monocarboxylic acid; prostaglandins Falpha	abortifacient; antiglaucoma drug; antihypertensive agent; female contraceptive drug; prostaglandin receptor agonist	low
latanoprost	isopropyl ester; prostaglandins Falpha; triol	antiglaucoma drug; antihypertensive agent; EC 4.2.1.1 (carbonic anhydrase) inhibitor; prodrug	low
spirapril	azaspiro compound; dicarboxylic acid monoester; dipeptide; dithioketal; ethyl ester; pyrrolidinecarboxylic acid; secondary amino compound; tertiary carboxamide	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; prodrug	low
lisinopril	hydrate	antihypertensive agent	low
enalapril maleate	maleate salt	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; prodrug	low
enalapril	dicarboxylic acid monoester; dipeptide	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; geroprotector; prodrug	low
enalaprilat anhydrous	dicarboxylic acid; dipeptide	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor	low
trandolaprilat	dicarboxylic acid; dipeptide; organic heterobicyclic compound; secondary amino compound; tertiary carboxamide	antihypertensive agent; drug metabolite; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; human xenobiotic metabolite	low
imidapril	dicarboxylic acid monoester; dipeptide; ethyl ester; imidazolidines; N-acylurea; secondary amino compound	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; prodrug	low
imidaprilat	dicarboxylic acid; dipeptide; imidazolidines; N-acylurea; secondary amino compound	antihypertensive agent; drug metabolite; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor	low
trandolapril	dicarboxylic acid monoester; dipeptide; ethyl ester; organic heterobicyclic compound; secondary amino compound; tertiary carboxamide	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; prodrug	low
aliskiren	monocarboxylic acid amide; monomethoxybenzene	antihypertensive agent	low
ro 42-5892	cyclopropanes; diol; L-histidine derivative; secondary carboxamide; sulfone	antihypertensive agent; EC 3.4.23.15 (renin) inhibitor; peptidomimetic; vasodilator agent	low
phxa 85	hydroxy monocarboxylic acid; prostaglandins Falpha	antiglaucoma drug; antihypertensive agent; EC 4.2.1.1 (carbonic anhydrase) inhibitor	low
beraprost	enyne; monocarboxylic acid; organic heterotricyclic compound; secondary alcohol; secondary allylic alcohol	anti-inflammatory agent; antihypertensive agent; platelet aggregation inhibitor; prostaglandin receptor agonist; vasodilator agent	low
l 671152	hydrochloride; organoammonium salt	antiglaucoma drug; antihypertensive agent; EC 4.2.1.1 (carbonic anhydrase) inhibitor	low
u 62840	carbotricyclic compound; carboxylic acid	antihypertensive agent; cardiovascular drug; human blood serum metabolite; platelet aggregation inhibitor; vasodilator agent; vitamin K antagonist	low
tekturna	fumarate salt	antihypertensive agent	low
grayanotoxin i	acetate ester; pentol; secondary alcohol; tertiary alcohol; tetracyclic diterpenoid	antihypertensive agent; metabolite; neuromuscular agent; phytotoxin	low
2-hydroxy-9-cis-octadecenoic acid	2-hydroxy fatty acid; hydroxy monounsaturated fatty acid; long-chain fatty acid	antihypertensive agent; antineoplastic agent; apoptosis inducer	low
pratosartan	biphenylyltetrazole	antihypertensive agent	low
bay 58-2667	aromatic ether; benzoic acids; dicarboxylic acid; tertiary amino compound	antihypertensive agent; soluble guanylate cyclase activator; vasodilator agent	low
bay 63-2521	aminopyrimidine; carbamate ester; organofluorine compound; pyrazolopyridine	antihypertensive agent; soluble guanylate cyclase activator	low
hu 308	aromatic ether; bridged compound; carbobicyclic compound; primary allylic alcohol; synthetic cannabinoid	anti-inflammatory agent; antihypertensive agent; apoptosis inhibitor; bone density conservation agent; CB2 receptor agonist	low
bay 60-4552	aminopyrimidine; carbamate ester; monofluorobenzenes; pyrazolopyridine	antihypertensive agent; drug metabolite; soluble guanylate cyclase activator; vasodilator agent	low
macitentan	aromatic ether; organobromine compound; pyrimidines; ring assembly; sulfamides	antihypertensive agent; endothelin receptor antagonist; orphan drug	low
beraprost sodium	organic sodium salt	anti-inflammatory agent; antihypertensive agent; platelet aggregation inhibitor; prostaglandin receptor agonist; vasodilator agent	low
sodium nitrite	inorganic sodium salt; nitrite salt	antidote to cyanide poisoning; antihypertensive agent; antimicrobial food preservative; food antioxidant; poison	low
apelin-13 peptide	oligopeptide	antihypertensive agent; autophagy inhibitor; biomarker; human metabolite; neuroprotective agent	low
act-132577	aromatic ether; organobromine compound; pyrimidines; sulfamides	antihypertensive agent; drug metabolite; endothelin receptor antagonist; xenobiotic metabolite	low
cleistanthin	cleistanthins; xylose derivative	alpha-adrenergic antagonist; antihypertensive agent; diuretic	low
vericiguat	aminopyrimidine; carbamate ester; organofluorine compound; pyrazolopyridine	antihypertensive agent; soluble guanylate cyclase activator; vasodilator agent	low
angiotensin i	angiotensin; peptide zwitterion	antihypertensive agent; cardioprotective agent; human metabolite; rat metabolite	low
praliciguat	aminopyrimidine; isoxazoles; monofluorobenzenes; organofluorine compound; pyrazoles; secondary amino compound; tertiary alcohol	anti-inflammatory agent; antihypertensive agent; soluble guanylate cyclase activator; vasodilator agent	low
tak 491	1,2,4-oxadiazole; aromatic ether; benzimidazoles; carboxylic ester; cyclic carbonate ester; dioxolane	angiotensin receptor antagonist; antihypertensive agent; prodrug	low
azilsartan	1,2,4-oxadiazole; aromatic ether; benzimidazolecarboxylic acid	angiotensin receptor antagonist; antihypertensive agent	low
pd 123319	imidazopyridine	angiotensin receptor antagonist; endothelin receptor antagonist; vasoconstrictor agent	low
octane	alkane	xenobiotic	low
2-nitropropane	secondary nitroalkane	carcinogenic agent; hepatotoxic agent; polar aprotic solvent; xenobiotic	low
bupropion	aromatic ketone; monochlorobenzenes; secondary amino compound	antidepressant; environmental contaminant; xenobiotic	low
dibenzofuran	dibenzofurans; mancude organic heterotricyclic parent; polycyclic heteroarene	xenobiotic	low
1-(3-chlorophenyl)piperazine	monochlorobenzenes; N-arylpiperazine	drug metabolite; environmental contaminant; serotonergic agonist; xenobiotic	low
acetaminophen	acetamides; phenols	antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; cyclooxygenase 3 inhibitor; environmental contaminant; ferroptosis inducer; geroprotector; hepatotoxic agent; human blood serum metabolite; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic	low
acetochlor	aromatic amide; monocarboxylic acid amide; organochlorine compound	environmental contaminant; herbicide; xenobiotic	low
alachlor	aromatic amide; monocarboxylic acid amide; organochlorine compound	environmental contaminant; herbicide; xenobiotic	low
albuterol	phenols; phenylethanolamines; secondary amino compound	beta-adrenergic agonist; bronchodilator agent; environmental contaminant; xenobiotic	low
alprazolam	organochlorine compound; triazolobenzodiazepine	anticonvulsant; anxiolytic drug; GABA agonist; muscle relaxant; sedative; xenobiotic	low
diatrizoic acid	acetamides; benzoic acids; organoiodine compound	environmental contaminant; radioopaque medium; xenobiotic	low
dan 2163	aromatic amide; aromatic amine; benzamides; pyrrolidines; sulfone	environmental contaminant; second generation antipsychotic; xenobiotic	low
amitriptyline	carbotricyclic compound; tertiary amine	adrenergic uptake inhibitor; antidepressant; environmental contaminant; tropomyosin-related kinase B receptor agonist; xenobiotic	low
antazoline	aromatic amine; imidazolines; tertiary amino compound	cholinergic antagonist; H1-receptor antagonist; xenobiotic	low
antipyrine	pyrazolone	antipyretic; cyclooxygenase 3 inhibitor; environmental contaminant; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic	low
atrazine	chloro-1,3,5-triazine; diamino-1,3,5-triazine	environmental contaminant; herbicide; xenobiotic	low
bentazone	benzothiadiazine	environmental contaminant; herbicide; xenobiotic	low
caffeine	purine alkaloid; trimethylxanthine	adenosine A2A receptor antagonist; adenosine receptor antagonist; adjuvant; central nervous system stimulant; diuretic; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; environmental contaminant; food additive; fungal metabolite; geroprotector; human blood serum metabolite; mouse metabolite; mutagen; plant metabolite; psychotropic drug; ryanodine receptor agonist; xenobiotic	low
carbamazepine	dibenzoazepine; ureas	analgesic; anticonvulsant; antimanic drug; drug allergen; EC 3.5.1.98 (histone deacetylase) inhibitor; environmental contaminant; glutamate transporter activator; mitogen; non-narcotic analgesic; sodium channel blocker; xenobiotic	low
cetirizine	ether; monocarboxylic acid; monochlorobenzenes; piperazines	anti-allergic agent; environmental contaminant; H1-receptor antagonist; xenobiotic	low
chloral hydrate	aldehyde hydrate; ethanediol; organochlorine compound	general anaesthetic; mouse metabolite; sedative; xenobiotic	low
chlorpyrifos	chloropyridine; organic thiophosphate	acaricide; agrochemical; EC 3.1.1.7 (acetylcholinesterase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; environmental contaminant; insecticide; xenobiotic	low
ciprofloxacin	aminoquinoline; cyclopropanes; fluoroquinolone antibiotic; N-arylpiperazine; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone; zwitterion	antibacterial drug; antiinfective agent; antimicrobial agent; DNA synthesis inhibitor; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; environmental contaminant; topoisomerase IV inhibitor; xenobiotic	low
clotrimazole	conazole antifungal drug; imidazole antifungal drug; imidazoles; monochlorobenzenes	antiinfective agent; environmental contaminant; xenobiotic	low
diazepam	1,4-benzodiazepinone; organochlorine compound	anticonvulsant; anxiolytic drug; environmental contaminant; sedative; xenobiotic	low
diazinon	organic thiophosphate; pyrimidines	acaricide; agrochemical; EC 3.1.1.7 (acetylcholinesterase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; environmental contaminant; nematicide; xenobiotic	low
dicamba	dichlorobenzene; methoxybenzoic acid	agrochemical; environmental contaminant; herbicide; synthetic auxin; xenobiotic	low
dichlobanil	dichlorobenzene; nitrile	agrochemical; cellulose synthesis inhibitor; environmental contaminant; herbicide; xenobiotic	low
diclofenac	amino acid; aromatic amine; dichlorobenzene; monocarboxylic acid; secondary amino compound	antipyretic; drug allergen; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic	low
dimethoate	monocarboxylic acid amide; organic thiophosphate	acaricide; agrochemical; EC 3.1.1.7 (acetylcholinesterase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; environmental contaminant; insecticide; xenobiotic	low
diuron	3-(3,4-substituted-phenyl)-1,1-dimethylurea; dichlorobenzene	environmental contaminant; mitochondrial respiratory-chain inhibitor; photosystem-II inhibitor; urea herbicide; xenobiotic	low
fenofibrate	aromatic ether; chlorobenzophenone; isopropyl ester; monochlorobenzenes	antilipemic drug; environmental contaminant; geroprotector; xenobiotic	low
fluconazole	conazole antifungal drug; difluorobenzene; tertiary alcohol; triazole antifungal drug	environmental contaminant; P450 inhibitor; xenobiotic	low
fluorouracil	nucleobase analogue; organofluorine compound	antimetabolite; antineoplastic agent; environmental contaminant; immunosuppressive agent; radiosensitizing agent; xenobiotic	low
furosemide	chlorobenzoic acid; furans; sulfonamide	environmental contaminant; loop diuretic; xenobiotic	low
gabapentin	gamma-amino acid	anticonvulsant; calcium channel blocker; environmental contaminant; xenobiotic	low
ibuprofen	monocarboxylic acid	antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; drug allergen; environmental contaminant; geroprotector; non-narcotic analgesic; non-steroidal anti-inflammatory drug; radical scavenger; xenobiotic	low
lidocaine	benzenes; monocarboxylic acid amide; tertiary amino compound	anti-arrhythmia drug; drug allergen; environmental contaminant; local anaesthetic; xenobiotic	low
ifosfamide	ifosfamides	alkylating agent; antineoplastic agent; environmental contaminant; immunosuppressive agent; xenobiotic	low
indomethacin	aromatic ether; indole-3-acetic acids; monochlorobenzenes; N-acylindole	analgesic; drug metabolite; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; gout suppressant; non-steroidal anti-inflammatory drug; xenobiotic metabolite; xenobiotic	low
iohexol	benzenedicarboxamide; organoiodine compound	environmental contaminant; radioopaque medium; xenobiotic	low
iomeprol	benzenedicarboxamide; organoiodine compound	environmental contaminant; radioopaque medium; xenobiotic	low
iopromide	dicarboxylic acid diamide; organoiodine compound	environmental contaminant; nephrotoxic agent; radioopaque medium; xenobiotic	low
ketamine	cyclohexanones; monochlorobenzenes; secondary amino compound	analgesic; environmental contaminant; intravenous anaesthetic; neurotoxin; NMDA receptor antagonist; xenobiotic	low
ketoprofen	benzophenones; oxo monocarboxylic acid	antipyretic; drug allergen; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; non-steroidal anti-inflammatory drug; xenobiotic	low
lamotrigine	1,2,4-triazines; dichlorobenzene; primary arylamine	anticonvulsant; antidepressant; antimanic drug; calcium channel blocker; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; environmental contaminant; excitatory amino acid antagonist; geroprotector; non-narcotic analgesic; xenobiotic	low
tetramisole	imidazothiazole	environmental contaminant; xenobiotic	low
mefenamic acid	aminobenzoic acid; secondary amino compound	analgesic; antipyretic; antirheumatic drug; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; non-steroidal anti-inflammatory drug; xenobiotic	low
metformin	guanidines	environmental contaminant; geroprotector; hypoglycemic agent; xenobiotic	low
methomyl	aliphatic sulfide; carbamate ester	acaricide; agrochemical; EC 3.1.1.7 (acetylcholinesterase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; environmental contaminant; insecticide; nematicide; xenobiotic	low
metoclopramide	benzamides; monochlorobenzenes; substituted aniline; tertiary amino compound	antiemetic; dopaminergic antagonist; environmental contaminant; gastrointestinal drug; xenobiotic	low
metronidazole	C-nitro compound; imidazoles; primary alcohol	antiamoebic agent; antibacterial drug; antimicrobial agent; antiparasitic agent; antitrichomonal drug; environmental contaminant; prodrug; radiosensitizing agent; xenobiotic	low
moclobemide	benzamides; monochlorobenzenes; morpholines	antidepressant; environmental contaminant; xenobiotic	low
deet	benzamides; monocarboxylic acid amide	environmental contaminant; insect repellent; xenobiotic	low
1-(3-trifluoromethylphenyl)piperazine	(trifluoromethyl)benzenes; N-arylpiperazine	environmental contaminant; psychotropic drug; serotonergic agonist; xenobiotic	low
nitroglycerin	nitroglycerol	explosive; muscle relaxant; nitric oxide donor; prodrug; tocolytic agent; vasodilator agent; xenobiotic	low
norfloxacin	fluoroquinolone antibiotic; N-arylpiperazine; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone	antibacterial drug; DNA synthesis inhibitor; environmental contaminant; xenobiotic	low
oxazepam	1,4-benzodiazepinone; organochlorine compound	anxiolytic drug; environmental contaminant; xenobiotic	low
oxybenzone	hydroxybenzophenone; monomethoxybenzene	dermatologic drug; environmental contaminant; protective agent; ultraviolet filter; xenobiotic	low
pantoprazole	aromatic ether; benzimidazoles; organofluorine compound; pyridines; sulfoxide	anti-ulcer drug; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor; environmental contaminant; xenobiotic	low
pentamidine	aromatic ether; carboxamidine; diether	anti-inflammatory agent; antifungal agent; calmodulin antagonist; chemokine receptor 5 antagonist; EC 2.3.1.48 (histone acetyltransferase) inhibitor; NMDA receptor antagonist; S100 calcium-binding protein B inhibitor; trypanocidal drug; xenobiotic	low
pioglitazone	aromatic ether; pyridines; thiazolidinediones	antidepressant; cardioprotective agent; EC 2.7.1.33 (pantothenate kinase) inhibitor; EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor; ferroptosis inhibitor; geroprotector; hypoglycemic agent; insulin-sensitizing drug; PPARgamma agonist; xenobiotic	low
primidone	pyrimidone	anticonvulsant; environmental contaminant; xenobiotic	low
prometone	diamino-1,3,5-triazine; methoxy-1,3,5-triazine	environmental contaminant; herbicide; xenobiotic	low
prometryne	diamino-1,3,5-triazine; methylthio-1,3,5-triazine	environmental contaminant; herbicide; xenobiotic	low
propachlor	anilide; monocarboxylic acid amide; organochlorine compound	environmental contaminant; herbicide; xenobiotic	low
propazine	chloro-1,3,5-triazine; diamino-1,3,5-triazine	environmental contaminant; herbicide; xenobiotic	low
saccharin	1,2-benzisothiazole; N-sulfonylcarboxamide	environmental contaminant; sweetening agent; xenobiotic	low
sulfadiazine	pyrimidines; substituted aniline; sulfonamide antibiotic; sulfonamide	antiinfective agent; antimicrobial agent; antiprotozoal drug; coccidiostat; drug allergen; EC 1.1.1.153 [sepiapterin reductase (L-erythro-7,8-dihydrobiopterin forming)] inhibitor; EC 2.5.1.15 (dihydropteroate synthase) inhibitor; environmental contaminant; xenobiotic	low
simazine	chloro-1,3,5-triazine; diamino-1,3,5-triazine	environmental contaminant; herbicide; xenobiotic	low
sotalol	ethanolamines; secondary alcohol; secondary amino compound; sulfonamide	anti-arrhythmia drug; beta-adrenergic antagonist; environmental contaminant; xenobiotic	low
sulfadimethoxine	aromatic ether; pyrimidines; substituted aniline; sulfonamide antibiotic; sulfonamide	antiinfective agent; antimicrobial agent; drug allergen; environmental contaminant; xenobiotic	low
sulfamethazine	pyrimidines; sulfonamide antibiotic; sulfonamide	antibacterial drug; antiinfective agent; antimicrobial agent; carcinogenic agent; drug allergen; EC 2.5.1.15 (dihydropteroate synthase) inhibitor; environmental contaminant; ligand; xenobiotic	low
sulfamethoxazole	isoxazoles; substituted aniline; sulfonamide antibiotic; sulfonamide	antibacterial agent; antiinfective agent; antimicrobial agent; drug allergen; EC 1.1.1.153 [sepiapterin reductase (L-erythro-7,8-dihydrobiopterin forming)] inhibitor; EC 2.5.1.15 (dihydropteroate synthase) inhibitor; environmental contaminant; epitope; P450 inhibitor; xenobiotic	low
sulfapyridine	pyridines; substituted aniline; sulfonamide antibiotic; sulfonamide	antiinfective agent; dermatologic drug; drug allergen; environmental contaminant; xenobiotic	low
sulfathiazole	1,3-thiazoles; substituted aniline; sulfonamide antibiotic; sulfonamide	antiinfective agent; drug allergen; EC 2.5.1.15 (dihydropteroate synthase) inhibitor; environmental contaminant; xenobiotic	low
triclosan	aromatic ether; dichlorobenzene; monochlorobenzenes; phenols	antibacterial agent; antimalarial; drug allergen; EC 1.3.1.9 [enoyl-[acyl-carrier-protein] reductase (NADH)] inhibitor; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; fungicide; persistent organic pollutant; xenobiotic	low
trifluralin	(trifluoromethyl)benzenes; C-nitro compound; substituted aniline	agrochemical; environmental contaminant; herbicide; xenobiotic	low
trimethoprim	aminopyrimidine; methoxybenzenes	antibacterial drug; diuretic; drug allergen; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; environmental contaminant; xenobiotic	low
trimipramine	dibenzoazepine; tertiary amino compound	antidepressant; environmental contaminant; xenobiotic	low
venlafaxine	cyclohexanols; monomethoxybenzene; tertiary alcohol; tertiary amino compound	adrenergic uptake inhibitor; analgesic; antidepressant; dopamine uptake inhibitor; environmental contaminant; serotonin uptake inhibitor; xenobiotic	low
prednisolone	11beta-hydroxy steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; C21-steroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	adrenergic agent; anti-inflammatory drug; antineoplastic agent; drug metabolite; environmental contaminant; immunosuppressive agent; xenobiotic	low
aminopyrine	pyrazolone; tertiary amino compound	antipyretic; environmental contaminant; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic	low
barbituric acid	barbiturates	allergen; xenobiotic	low
bisphenol a	bisphenol	endocrine disruptor; environmental contaminant; xenobiotic; xenoestrogen	low
methylprednisolone	6-methylprednisolone; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	adrenergic agent; anti-inflammatory drug; antiemetic; environmental contaminant; neuroprotective agent; xenobiotic	low
pseudoephedrine	phenylethanolamines; secondary alcohol; secondary amino compound	anti-asthmatic drug; bronchodilator agent; central nervous system drug; nasal decongestant; plant metabolite; sympathomimetic agent; vasoconstrictor agent; xenobiotic	low
2-methyl-4-chlorophenoxy gamma-butyric acid	aromatic ether; monocarboxylic acid; monochlorobenzenes	environmental contaminant; phenoxy herbicide; xenobiotic	low
benzotriazole	benzotriazoles	environmental contaminant; xenobiotic	low
benzothiazole	benzothiazoles	environmental contaminant; plant metabolite; xenobiotic	low
3,4-dichloroaniline	dichloroaniline	epitope; xenobiotic	low
acetophenone	acetophenones	animal metabolite; photosensitizing agent; xenobiotic	low
phenylhydrazine	phenylhydrazines	xenobiotic	low
triclocarban	dichlorobenzene; monochlorobenzenes; phenylureas	antimicrobial agent; antiseptic drug; disinfectant; environmental contaminant; xenobiotic	low
fenuron	3-(3,4-substituted-phenyl)-1,1-dimethylurea	agrochemical; environmental contaminant; herbicide; photosystem-II inhibitor; xenobiotic	low
cyanuric acid	1,3,5-triazinanes; 1,3,5-triazines; heteroaryl hydroxy compound	xenobiotic	low
diglyme	polyether	environmental contaminant; solvent; xenobiotic	low
propylene	alkene; gas molecular entity	refrigerant; xenobiotic	low
2-naphthalenesulfonic acid	naphthalenesulfonic acid	environmental contaminant; xenobiotic	low
4-sulfanilic acid	aminobenzenesulfonic acid	allergen; environmental contaminant; xenobiotic metabolite; xenobiotic	low
5-tolyltriazole	benzotriazoles	environmental contaminant; xenobiotic	low
monuron	3-(3,4-substituted-phenyl)-1,1-dimethylurea; monochlorobenzenes	environmental contaminant; herbicide; xenobiotic	low
ephedrine	phenethylamine alkaloid; phenylethanolamines	bacterial metabolite; environmental contaminant; nasal decongestant; plant metabolite; sympathomimetic agent; vasoconstrictor agent; xenobiotic	low
linuron	dichlorobenzene; phenylureas	agrochemical; environmental contaminant; herbicide; xenobiotic	low
perfluorooctanoic acid	fluoroalkanoic acid	carcinogenic agent; endocrine disruptor; environmental contaminant; surfactant; xenobiotic	low
perfluorodecanoic acid	fluoroalkanoic acid	environmental contaminant; xenobiotic	low
perfluorobutyric acid	fluoroalkanoic acid	chromatographic reagent; environmental contaminant; xenobiotic	low
triphenylmethane	triarylmethane	environmental contaminant; xenobiotic	low
methamphetamine	amphetamines; secondary amine	central nervous system stimulant; environmental contaminant; neurotoxin; psychotropic drug; xenobiotic	low
3-methylquinoline	methylquinoline	xenobiotic	low
terbutryne	diamino-1,3,5-triazine; methylthio-1,3,5-triazine	environmental contaminant; herbicide; xenobiotic	low
ethambutol	ethanolamines; ethylenediamine derivative	antitubercular agent; environmental contaminant; xenobiotic	low
metformin hydrochloride	hydrochloride	environmental contaminant; hypoglycemic agent; xenobiotic	low
ioxynil	iodophenol; nitrile	environmental contaminant; herbicide; xenobiotic	low
bromoxynil	dibromobenzene; hydroxynitrile; phenols	environmental contaminant; herbicide; xenobiotic	low
pyrazon	benzenes; organochlorine compound; primary amino compound; pyridazinone	environmental contaminant; herbicide; xenobiotic	low
methiocarb	aryl sulfide; carbamate ester; methyl sulfide	acaricide; agrochemical; avicide; EC 3.1.1.7 (acetylcholinesterase) inhibitor; environmental contaminant; insecticide; molluscicide; xenobiotic	low
lenacil	cyclopentapyrimidine	agrochemical; environmental contaminant; herbicide; xenobiotic	low
fluometuron	(trifluoromethyl)benzenes; 3-(3,4-substituted-phenyl)-1,1-dimethylurea	agrochemical; environmental contaminant; herbicide; photosystem-II inhibitor; xenobiotic	low
1,2-benzisothiazoline-3-one	organic heterobicyclic compound; organonitrogen heterocyclic compound	disinfectant; drug allergen; environmental contaminant; platelet aggregation inhibitor; sensitiser; xenobiotic	low
asulam	carbamate ester; primary amino compound; substituted aniline; sulfonamide	agrochemical; EC 2.5.1.15 (dihydropteroate synthase) inhibitor; environmental contaminant; herbicide; xenobiotic	low
chlorpyrifos-methyl	chloropyridine; organic thiophosphate	acaricide; agrochemical; EC 3.1.1.7 (acetylcholinesterase) inhibitor; environmental contaminant; insecticide; xenobiotic	low
terbutylazine	chloro-1,3,5-triazine; diamino-1,3,5-triazine	environmental contaminant; herbicide; xenobiotic	low
1-indanol	aromatic alcohol; indanes; secondary alcohol	xenobiotic	low
desmedipham	carbamate ester	agrochemical; environmental contaminant; herbicide; xenobiotic	low
phenmedipham	carbamate ester	environmental contaminant; herbicide; xenobiotic	low
chlortoluron	monochlorobenzenes; phenylureas	agrochemical; environmental contaminant; herbicide; xenobiotic	low
methoxuron	3-(3,4-substituted-phenyl)-1,1-dimethylurea; monochlorobenzenes; monomethoxybenzene	agrochemical; environmental contaminant; herbicide; photosystem-II inhibitor; plant growth regulator; xenobiotic	low
neohesperidin dihydrochalcone	dihydrochalcones; disaccharide derivative; neohesperidoside	environmental contaminant; plant metabolite; sweetening agent; xenobiotic	low
metribuzin	1,2,4-triazines; cyclic ketone; organic sulfide	agrochemical; environmental contaminant; herbicide; xenobiotic	low
cyanazine	1,3,5-triazinylamino nitrile; chloro-1,3,5-triazine	environmental contaminant; herbicide; xenobiotic	low
pirimicarb	aminopyrimidine; carbamate ester; tertiary amino compound	agrochemical; carbamate insecticide; EC 3.1.1.7 (acetylcholinesterase) inhibitor; environmental contaminant; insecticide; xenobiotic	low
butachlor	aromatic amide; organochlorine compound; tertiary carboxamide	environmental contaminant; herbicide; xenobiotic	low
propamocarb	carbamate ester; carbamate fungicide; tertiary amino compound	antifungal agrochemical; environmental contaminant; xenobiotic	low
5-chloro-2-methyl-4-isothiazolin-3-one	1,2-thiazoles; organochlorine compound	antimicrobial agent; environmental contaminant; xenobiotic	low
2-n-octyl-4-isothiazolin-3-one	1,2-thiazoles	antibacterial agent; antifungal agrochemical; environmental contaminant; xenobiotic	low
ioxitalamic acid	acetamides; benzoic acids; dicarboxylic acid monoamide; organoiodine compound	environmental contaminant; radioopaque medium; xenobiotic	low
amitraz	formamidines; tertiary amino compound	acaricide; environmental contaminant; insecticide; xenobiotic	low
acetosulfame	organic heteromonocyclic compound; organonitrogen heterocyclic compound; oxacycle; sulfamate ester	environmental contaminant; sweetening agent; xenobiotic	low
isoproturon	3-(3,4-substituted-phenyl)-1,1-dimethylurea	agrochemical; environmental contaminant; herbicide; xenobiotic	low
metamitron	1,2,4-triazines	environmental contaminant; herbicide; xenobiotic	low
bezafibrate	aromatic ether; monocarboxylic acid amide; monocarboxylic acid; monochlorobenzenes	antilipemic drug; environmental contaminant; geroprotector; xenobiotic	low
triclopyr	aromatic ether; chloropyridine; monocarboxylic acid	agrochemical; environmental contaminant; herbicide; xenobiotic	low
propiconazole	conazole fungicide; cyclic ketal; dichlorobenzene; triazole fungicide; triazoles	antifungal agrochemical; EC 1.14.13.70 (sterol 14alpha-demethylase) inhibitor; environmental contaminant; xenobiotic	low
metazachlor	aromatic amide; organochlorine compound; pyrazoles	environmental contaminant; herbicide; xenobiotic	low
4,5-amino-3,5-dichloro-6-fluoro-2-pyridinyloxyacetic acid	aminopyridine; aromatic ether; monocarboxylic acid; organochlorine compound; organofluorine compound	environmental contaminant; herbicide; xenobiotic	low
fenoxycarb	aromatic ether; carbamate ester	environmental contaminant; insecticide; juvenile hormone mimic; xenobiotic	low
metsulfuron methyl	1,3,5-triazines; benzoate ester; N-sulfonylurea	environmental contaminant; herbicide; xenobiotic	low
pravastatin	3-hydroxy carboxylic acid; carbobicyclic compound; carboxylic ester; hydroxy monocarboxylic acid; secondary alcohol; statin (semi-synthetic)	anticholesteremic drug; environmental contaminant; metabolite; xenobiotic	low
clomazone	isoxazolidinone; monochlorobenzenes	agrochemical; carotenoid biosynthesis inhibitor; environmental contaminant; herbicide; xenobiotic	low
atomoxetine	aromatic ether; secondary amino compound; toluenes	adrenergic uptake inhibitor; antidepressant; environmental contaminant; xenobiotic	low
aromasil	17-oxo steroid; 3-oxo-Delta(1),Delta(4)-steroid	antineoplastic agent; EC 1.14.14.14 (aromatase) inhibitor; environmental contaminant; xenobiotic	low
gemcitabine	organofluorine compound; pyrimidine 2'-deoxyribonucleoside	antimetabolite; antineoplastic agent; antiviral drug; DNA synthesis inhibitor; EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor; environmental contaminant; immunosuppressive agent; photosensitizing agent; prodrug; radiosensitizing agent; xenobiotic	low
atorvastatin	aromatic amide; dihydroxy monocarboxylic acid; monofluorobenzenes; pyrroles; statin (synthetic)	environmental contaminant; xenobiotic	low
prosulfocarb	benzenes; monothiocarbamic ester	environmental contaminant; herbicide; xenobiotic	low
3-iodo-2-propynylbutylcarbamate	acetylenic compound; carbamate ester; carbamate fungicide; organoiodine compound	antifungal agrochemical; environmental contaminant; xenobiotic	low
oseltamivir	acetamides; amino acid ester; cyclohexenecarboxylate ester; primary amino compound	antiviral drug; EC 3.2.1.18 (exo-alpha-sialidase) inhibitor; environmental contaminant; prodrug; xenobiotic	low
iopamidol	benzenedicarboxamide; organoiodine compound; pentol	environmental contaminant; radioopaque medium; xenobiotic	low
iobitridol	benzenedicarboxamide; hexol; organoiodine compound	environmental contaminant; radioopaque medium; xenobiotic	low
perfluorohexanoic acid	fluoroalkanoic acid	environmental contaminant; xenobiotic	low
perfluoro-n-heptanoic acid	fluoroalkanoic acid	environmental contaminant; xenobiotic	low
perfluoro-n-nonanoic acid	fluoroalkanoic acid	persistent organic pollutant; surfactant; xenobiotic	low
acamprosate	acetamides; organosulfonic acid	environmental contaminant; neurotransmitter agent; xenobiotic	low
trichlorosucrose	disaccharide derivative; organochlorine compound	environmental contaminant; sweetening agent; xenobiotic	low
nicosulfuron	N-sulfonylurea; pyridines; pyrimidines	environmental contaminant; herbicide; xenobiotic	low
prochloraz	amide fungicide; aromatic ether; conazole fungicide; imidazole fungicide; imidazoles; trichlorobenzene; ureas	antifungal agrochemical; EC 1.14.13.70 (sterol 14alpha-demethylase) inhibitor; environmental contaminant; xenobiotic	low
thifensulfuron methyl	1,3,5-triazines; methyl ester; N-sulfonylurea; thiophenes	agrochemical; environmental contaminant; herbicide; xenobiotic	low
flusilazole	conazole fungicide; monofluorobenzenes; organosilicon compound; triazole fungicide; triazoles	antifungal agrochemical; EC 1.14.13.70 (sterol 14alpha-demethylase) inhibitor; environmental contaminant; xenobiotic	low
perfluoropentanoic acid	fluoroalkanoic acid	environmental contaminant; xenobiotic	low
1-benzylpiperazine	N-alkylpiperazine	environmental contaminant; psychotropic drug; serotonergic agonist; xenobiotic	low
perfluoroundecanoic acid	fluoroalkanoic acid	environmental contaminant; xenobiotic	low
sulfluramid	sulfonamide	acaricide; environmental contaminant; insecticide; xenobiotic	low
clarithromycin	macrolide antibiotic	antibacterial drug; environmental contaminant; protein synthesis inhibitor; xenobiotic	low
spiroxamine	dioxolane; spiroketal; tertiary amino compound	antifungal agrochemical; environmental contaminant; sterol biosynthesis inhibitor; xenobiotic	low
difenoconazole	aromatic ether; conazole fungicide; cyclic ketal; dioxolane; triazole fungicide; triazoles	antifungal agrochemical; EC 1.14.13.70 (sterol 14alpha-demethylase) inhibitor; environmental contaminant; xenobiotic	low
dimethomorph	mixture; morpholine fungicide	antifungal agrochemical; environmental contaminant; xenobiotic	low
cyprodinil	aminopyrimidine; anilinopyrimidine fungicide; cyclopropanes; secondary amino compound	antifungal agrochemical; aryl hydrocarbon receptor agonist; environmental contaminant; xenobiotic	low
imidacloprid	imidacloprid; imidazolidines; monochloropyridine	environmental contaminant; genotoxin; neonicotinoid insectide; nicotinic acetylcholine receptor agonist; xenobiotic	low
foe 5043	aromatic amide; monofluorobenzenes; thiadiazoles	environmental contaminant; herbicide; xenobiotic	low
nicotine	3-(1-methylpyrrolidin-2-yl)pyridine	anxiolytic drug; biomarker; immunomodulator; mitogen; neurotoxin; nicotinic acetylcholine receptor agonist; peripheral nervous system drug; phytogenic insecticide; plant metabolite; psychotropic drug; teratogenic agent; xenobiotic	low
irgarol 1051	aryl sulfide; cyclopropanes; diamino-1,3,5-triazine	antifouling biocide; environmental contaminant; xenobiotic	low
pyrimethanil	aminopyrimidine; anilinopyrimidine fungicide; secondary amino compound	antifungal agrochemical; aryl hydrocarbon receptor agonist; environmental contaminant; xenobiotic	low
kathon 930	1,2-thiazoles; organochlorine compound	environmental contaminant; fungicide; xenobiotic	low
fluazinam	(trifluoromethyl)benzenes; aminopyridine; C-nitro compound; chloropyridine; monochlorobenzenes; secondary amino compound	allergen; antifungal agrochemical; apoptosis inducer; environmental contaminant; xenobiotic	low
teflubenzuron	dichlorobenzene; difluorobenzene; N-acylurea	environmental contaminant; insecticide; xenobiotic	low
diflufenican	(trifluoromethyl)benzenes; aromatic ether; pyridinecarboxamide	carotenoid biosynthesis inhibitor; environmental contaminant; herbicide; xenobiotic	low
sulcotrione	aromatic ketone; beta-triketone; cyclohexanones; sulfone	carotenoid biosynthesis inhibitor; environmental contaminant; herbicide; xenobiotic	low
tebufenozide	carbohydrazide	ecdysone agonist; environmental contaminant; xenobiotic	low
dpx e9636	aromatic ether; N-sulfonylurea; pyridines; pyrimidines; sulfone	environmental contaminant; herbicide; xenobiotic	low
arsenocholine	arsonium ion; organoarsenic compound	human urinary metabolite; marine metabolite; xenobiotic	low
methoxyfenozide	carbohydrazide; monomethoxybenzene	environmental contaminant; insecticide; xenobiotic	low
thiamethoxam	1,3-thiazoles; 2-nitroguanidine derivative; organochlorine compound; oxadiazane	antifeedant; carcinogenic agent; environmental contaminant; neonicotinoid insectide; xenobiotic	low
thiacloprid	monochloropyridine; nitrile; thiazolidines	environmental contaminant; neonicotinoid insectide; xenobiotic	low
aspartame	carboxylic acid; dipeptide zwitterion; dipeptide; methyl ester	apoptosis inhibitor; EC 3.1.3.1 (alkaline phosphatase) inhibitor; environmental contaminant; micronutrient; nutraceutical; sweetening agent; xenobiotic	low
2-ethyl-5-carboxypentyl phthalate	phthalic acid monoester	xenobiotic	low
carpropamid	amide fungicide; cyclopropylcarboxamide; monochlorobenzenes	antifungal agrochemical; EC 4.2.1.94 (scytalone dehydratase) inhibitor; melanin synthesis inhibitor; xenobiotic	low
naproxen	methoxynaphthalene; monocarboxylic acid	antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; drug allergen; environmental contaminant; gout suppressant; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic	low
mesotrione	aromatic ketone; beta-triketone; C-nitro compound; sulfone	carotenoid biosynthesis inhibitor; EC 1.13.11.27 (4-hydroxyphenylpyruvate dioxygenase) inhibitor; environmental contaminant; herbicide; xenobiotic	low
troleandomycin	acetate ester; epoxide; macrolide antibiotic; monosaccharide derivative; polyketide; semisynthetic derivative	EC 1.14.13.97 (taurochenodeoxycholate 6alpha-hydroxylase) inhibitor; xenobiotic	low
dronedarone	1-benzofurans; aromatic ether; aromatic ketone; sulfonamide; tertiary amino compound	anti-arrhythmia drug; environmental contaminant; xenobiotic	low
pinoxaden	pivalate ester; pyrazolooxadiazepine	agrochemical; EC 6.4.1.2 (acetyl-CoA carboxylase) inhibitor; environmental contaminant; proherbicide; xenobiotic	low
2-chloro-n-(4-chlorobiphenyl-2-yl)nicotinamide	anilide fungicide; biphenyls; monochlorobenzenes; pyridinecarboxamide	antifungal agrochemical; EC 1.3.5.1 [succinate dehydrogenase (quinone)] inhibitor; environmental contaminant; xenobiotic	low
prizes	carboxamidine; monochloropyridine; nitrile	environmental contaminant; neonicotinoid insectide; xenobiotic	low
ritonavir	1,3-thiazoles; carbamate ester; carboxamide; L-valine derivative; ureas	antiviral drug; environmental contaminant; HIV protease inhibitor; xenobiotic	low
lenticin	amino-acid betaine; indole alkaloid; L-tryptophan derivative	fungal metabolite; plant metabolite; xenobiotic	low
cyanoginosin lr	microcystin	bacterial metabolite; EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor; environmental contaminant; xenobiotic	low
rosuvastatin	dihydroxy monocarboxylic acid; monofluorobenzenes; pyrimidines; statin (synthetic); sulfonamide	anti-inflammatory agent; antilipemic drug; cardioprotective agent; CETP inhibitor; environmental contaminant; xenobiotic	low
cocaine	benzoate ester; methyl ester; tertiary amino compound; tropane alkaloid	adrenergic uptake inhibitor; central nervous system stimulant; dopamine uptake inhibitor; environmental contaminant; local anaesthetic; mouse metabolite; plant metabolite; serotonin uptake inhibitor; sodium channel blocker; sympathomimetic agent; vasoconstrictor agent; xenobiotic	low
mycophenolic acid	2-benzofurans; gamma-lactone; monocarboxylic acid; phenols	anticoronaviral agent; antimicrobial agent; antineoplastic agent; EC 1.1.1.205 (IMP dehydrogenase) inhibitor; environmental contaminant; immunosuppressive agent; mycotoxin; Penicillium metabolite; xenobiotic	low
zithromax	macrolide antibiotic	antibacterial drug; environmental contaminant; xenobiotic	low
dieldrin	epoxide; organochlorine compound; organochlorine insecticide	carcinogenic agent; xenobiotic	low
thiopental	barbiturates	anticonvulsant; drug allergen; environmental contaminant; intravenous anaesthetic; sedative; xenobiotic	low
ranitidine	C-nitro compound; furans; organic sulfide; tertiary amino compound	anti-ulcer drug; drug allergen; environmental contaminant; H2-receptor antagonist; xenobiotic	low
azoxystrobin	aryloxypyrimidine; enoate ester; enol ether; methoxyacrylate strobilurin antifungal agent; methyl ester; nitrile	antifungal agrochemical; environmental contaminant; mitochondrial cytochrome-bc1 complex inhibitor; quinone outside inhibitor; xenobiotic	low
sitagliptin	triazolopyrazine; trifluorobenzene	EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor; environmental contaminant; hypoglycemic agent; serine proteinase inhibitor; xenobiotic	low
tylosin	aldehyde; disaccharide derivative; enone; leucomycin; macrolide antibiotic; monosaccharide derivative	allergen; bacterial metabolite; environmental contaminant; xenobiotic	low
codeine	morphinane alkaloid; organic heteropentacyclic compound	antitussive; drug allergen; environmental contaminant; opioid analgesic; opioid receptor agonist; prodrug; xenobiotic	low
levetiracetam	pyrrolidin-2-ones	anticonvulsant; environmental contaminant; xenobiotic	low
morphine	morphinane alkaloid; organic heteropentacyclic compound; tertiary amino compound	anaesthetic; drug allergen; environmental contaminant; geroprotector; mu-opioid receptor agonist; opioid analgesic; plant metabolite; vasodilator agent; xenobiotic	low
naltrexone	cyclopropanes; morphinane-like compound; organic heteropentacyclic compound	antidote to opioid poisoning; central nervous system depressant; environmental contaminant; mu-opioid receptor antagonist; xenobiotic	low
dextromethorphan	6-methoxy-11-methyl-1,3,4,9,10,10a-hexahydro-2H-10,4a-(epiminoethano)phenanthrene	antitussive; environmental contaminant; neurotoxin; NMDA receptor antagonist; oneirogen; prodrug; xenobiotic	low
kresoxim-methyl	aromatic ether; methoxyiminoacetate strobilurin antifungal agent; methyl ester; oxime O-ether	antifungal agrochemical; environmental contaminant; mitochondrial cytochrome-bc1 complex inhibitor; xenobiotic	low
pyrachlostrobin	aromatic ether; carbamate ester; carbanilate fungicide; methoxycarbanilate strobilurin antifungal agent; monochlorobenzenes; pyrazoles	antifungal agrochemical; environmental contaminant; mitochondrial cytochrome-bc1 complex inhibitor; xenobiotic	low
cilastatin	carboxamide; L-cysteine derivative; non-proteinogenic L-alpha-amino acid; organic sulfide	EC 3.4.13.19 (membrane dipeptidase) inhibitor; environmental contaminant; protease inhibitor; xenobiotic	low
microcystin rr	microcystin; organic molecular entity	bacterial metabolite; environmental contaminant; xenobiotic	low
roxithromycin	roxithromycin	environmental contaminant; xenobiotic	low
yunaconitine	acetate ester; aromatic ether; benzoate ester; bridged compound; diterpene alkaloid; organic heteropolycyclic compound; polyether; secondary alcohol; tertiary alcohol; tertiary amino compound	antifeedant; human urinary metabolite; phytotoxin; plant metabolite; xenobiotic	low
pymetrozine	1,2,4-triazines; pyridines	antifeedant; environmental contaminant; TRPV channel modulator; xenobiotic	low
neotame	dipeptide	environmental contaminant; sweetening agent; xenobiotic	low
flonicamid	nitrile; organofluorine compound; pyridinecarboxamide	environmental contaminant; insecticide; xenobiotic	low
microcystin-lf	microcystin	bacterial metabolite; environmental contaminant; xenobiotic	low
decarbamylsaxitoxin	alkaloid; guanidines; ketone hydrate; paralytic shellfish toxin; primary alcohol; pyrrolopurine	bacterial metabolite; marine metabolite; neurotoxin; toxin; xenobiotic	low
mephedrone	amphetamines; aromatic ketone; secondary amino compound	environmental contaminant; xenobiotic	low
imidacloprid	imidacloprid; imidazolidines; monochloropyridine	environmental contaminant; genotoxin; neonicotinoid insectide; nicotinic acetylcholine receptor agonist; xenobiotic	low
clothianidin	1,3-thiazoles; 2-nitroguanidine derivative; clothianidin; organochlorine compound	environmental contaminant; neonicotinoid insectide; nicotinic acetylcholine receptor agonist; xenobiotic	low
clozapine	benzodiazepine; N-arylpiperazine; N-methylpiperazine; organochlorine compound	adrenergic antagonist; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; environmental contaminant; GABA antagonist; histamine antagonist; muscarinic antagonist; second generation antipsychotic; serotonergic antagonist; xenobiotic	low
imidacloprid	imidacloprid; imidazolidines; monochloropyridine	environmental contaminant; genotoxin; neonicotinoid insectide; nicotinic acetylcholine receptor agonist; xenobiotic	low
clothianidin	1,3-thiazoles; 2-nitroguanidine derivative; clothianidin; organochlorine compound	environmental contaminant; neonicotinoid insectide; nicotinic acetylcholine receptor agonist; xenobiotic	low
benzene	aromatic annulene; benzenes; volatile organic compound	carcinogenic agent; environmental contaminant; non-polar solvent	low
formaldehyde	aldehyde; one-carbon compound	allergen; carcinogenic agent; disinfectant; EC 3.5.1.4 (amidase) inhibitor; environmental contaminant; Escherichia coli metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite	low
naphthalene	naphthalenes; ortho-fused bicyclic arene	apoptosis inhibitor; carcinogenic agent; environmental contaminant; mouse metabolite; plant metabolite; volatile oil component	low
phenanthrene	ortho-fused polycyclic arene; ortho-fused tricyclic hydrocarbon; phenanthrenes	environmental contaminant; mouse metabolite	low
pyridine	azaarene; mancude organic heteromonocyclic parent; monocyclic heteroarene; pyridines	environmental contaminant; NMR chemical shift reference compound	low
2,4,6-tribromophenol	bromophenol	environmental contaminant; fungicide; marine metabolite	low
2,4-dichlorophenoxyacetic acid	chlorophenoxyacetic acid; dichlorobenzene	agrochemical; defoliant; EC 1.1.1.25 (shikimate dehydrogenase) inhibitor; environmental contaminant; phenoxy herbicide; synthetic auxin	low
4-nonylphenol	phenols	environmental contaminant	low
dibutyl phthalate	diester; phthalate ester	EC 3.2.1.20 (alpha-glucosidase) inhibitor; environmental contaminant; metabolite; plasticiser; teratogenic agent	low
ethion	organic thiophosphate	acaricide; agrochemical; EC 3.1.1.7 (acetylcholinesterase) inhibitor; environmental contaminant; insecticide	low
methyl parathion	C-nitro compound; organic thiophosphate; organothiophosphate insecticide	acaricide; agrochemical; antifungal agent; EC 3.1.1.7 (acetylcholinesterase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; environmental contaminant; genotoxin	low
bromodichloromethane	halomethane	environmental contaminant; reagent	low
trichlorofluoromethane	chlorofluorocarbon; halomethane	environmental contaminant; NMR chemical shift reference compound; NMR solvent; refrigerant	low
tris(2-butoxyethyl) phosphate	trialkyl phosphate	environmental contaminant; flame retardant	low
cumene hydroperoxide	peroxol	environmental contaminant; Mycoplasma genitalium metabolite; oxidising agent	low
1-nitronaphthalene	mononitronaphthalene	environmental contaminant; mouse metabolite	low
2-nitrotoluene	mononitrotoluene	carcinogenic agent; environmental contaminant	low
2-methyl-4-chlorophenoxyacetic acid	chlorophenoxyacetic acid; monochlorobenzenes	environmental contaminant; phenoxy herbicide; synthetic auxin	low
benzotrifluoride	(trifluoromethyl)benzenes; fluorohydrocarbon	environmental contaminant; NMR chemical shift reference compound; solvent	low
n-nitrosopiperidine	nitrosamine; piperidine	apoptosis inducer; carcinogenic agent; environmental contaminant; mutagen	low
cyclamic acid	sulfamic acids	environmental contaminant; human xenobiotic metabolite	low
1,3-dichloropropane	chloroalkane; chlorohydrocarbon	environmental contaminant; nematicide	low
malachite green	organic chloride salt	antibacterial agent; antifungal drug; carcinogenic agent; environmental contaminant; fluorochrome; histological dye; teratogenic agent	low
2,6-dimethylnaphthalene	dimethylnaphthalene	environmental contaminant	low
brilliant green	organic hydrogensulfate salt	antibacterial agent; antiseptic drug; environmental contaminant; fluorochrome; histological dye; poison	low
ametryne	diamino-1,3,5-triazine; methylthio-1,3,5-triazine	environmental contaminant; herbicide	low
3-methylfuran	furans; volatile organic compound	Aspergillus metabolite; environmental contaminant; fungal metabolite; Penicillium metabolite; plant metabolite	low
bpmc	carbamate ester	agrochemical; EC 3.1.1.7 (acetylcholinesterase) inhibitor; environmental contaminant; herbicide; insecticide	low
pirimiphos methyl	aminopyrimidine; organic thiophosphate	acaricide; agrochemical; EC 3.1.1.7 (acetylcholinesterase) inhibitor; environmental contaminant; insecticide	low
pendimethalin	C-nitro compound; secondary amino compound; substituted aniline	agrochemical; environmental contaminant; herbicide	low
isoprothiolane	dithiolanes; isopropyl ester; malonate ester	antifungal agrochemical; environmental contaminant; insecticide; phospholipid biosynthesis inhibitor	low
perfluorododecanoic acid	fluoroalkanoic acid	environmental contaminant	low
t-2 toxin	acetate ester; organic heterotetracyclic compound; trichothecene	apoptosis inducer; cardiotoxic agent; DNA synthesis inhibitor; environmental contaminant; fungal metabolite; mycotoxin; neurotoxin	low

Substance	Classes	Roles	Relationship Strength
brimonidine	imidazoles; quinoxaline derivative; secondary amine	adrenergic agonist; alpha-adrenergic agonist; antihypertensive agent	low
losartan	biphenylyltetrazole; imidazoles	angiotensin receptor antagonist; anti-arrhythmia drug; antihypertensive agent; endothelin receptor antagonist	low
tolazoline	imidazoles	alpha-adrenergic antagonist; antihypertensive agent; vasodilator agent	low
lofexidine	aromatic ether; carboxamidine; dichlorobenzene; imidazoles	alpha-adrenergic agonist; antihypertensive agent	low
ticrynafen	aromatic ether; aromatic ketone; dichlorobenzene; monocarboxylic acid; thiophenes	antihypertensive agent; hepatotoxic agent; loop diuretic	low
perindoprilat	dicarboxylic acid; dipeptide; L-alanine derivative; organic heterobicyclic compound	antihypertensive agent; drug metabolite; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor	low
quinaprilat	dicarboxylic acid; isoquinolines; tertiary carboxamide	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; vasodilator agent	low
spiraprilat	azaspiro compound; dicarboxylic acid; dipeptide; dithioketal; pyrrolidinecarboxylic acid; secondary amino compound; tertiary carboxamide	antihypertensive agent; drug metabolite; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor	low
dorzolamide	sulfonamide; thiophenes	antiglaucoma drug; antihypertensive agent; EC 4.2.1.1 (carbonic anhydrase) inhibitor	low
enalaprilat anhydrous	dicarboxylic acid; dipeptide	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor	low
trandolaprilat	dicarboxylic acid; dipeptide; organic heterobicyclic compound; secondary amino compound; tertiary carboxamide	antihypertensive agent; drug metabolite; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; human xenobiotic metabolite	low
imidaprilat	dicarboxylic acid; dipeptide; imidazolidines; N-acylurea; secondary amino compound	antihypertensive agent; drug metabolite; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor	low
bay 58-2667	aromatic ether; benzoic acids; dicarboxylic acid; tertiary amino compound	antihypertensive agent; soluble guanylate cyclase activator; vasodilator agent	low
clotrimazole	conazole antifungal drug; imidazole antifungal drug; imidazoles; monochlorobenzenes	antiinfective agent; environmental contaminant; xenobiotic	low
metronidazole	C-nitro compound; imidazoles; primary alcohol	antiamoebic agent; antibacterial drug; antimicrobial agent; antiparasitic agent; antitrichomonal drug; environmental contaminant; prodrug; radiosensitizing agent; xenobiotic	low
prochloraz	amide fungicide; aromatic ether; conazole fungicide; imidazole fungicide; imidazoles; trichlorobenzene; ureas	antifungal agrochemical; EC 1.14.13.70 (sterol 14alpha-demethylase) inhibitor; environmental contaminant; xenobiotic	low
thifensulfuron methyl	1,3,5-triazines; methyl ester; N-sulfonylurea; thiophenes	agrochemical; environmental contaminant; herbicide; xenobiotic	low

Substance	Studies	Classes	Roles	First Year	Last Year	Average Age	Relationship Strength	1990's	2000's	2010's	post-2020
ethylene dichloride	2	chloroethanes	hepatotoxic agent; mutagen; non-polar solvent	2010	2010	14.0	low	0	2	0	0
aminolevulinic acid	1	4-oxo monocarboxylic acid; amino acid zwitterion; delta-amino acid	antineoplastic agent; dermatologic drug; Escherichia coli metabolite; human metabolite; mouse metabolite; photosensitizing agent; plant metabolite; prodrug; Saccharomyces cerevisiae metabolite	2023	2023	1.0	low	0	0	0	1
ethylene glycol	2	ethanediol; glycol	metabolite; mouse metabolite; solvent; toxin	2010	2010	14.0	low	0	2	0	0
adenine	1	6-aminopurines; purine nucleobase	Daphnia magna metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite	2008	2008	16.0	low	0	1	0	0
quinacrine	2	acridines; aromatic ether; organochlorine compound; tertiary amino compound	antimalarial; EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor	2008	2008	16.0	low	0	2	0	0
benzyl alcohol	1	benzyl alcohols	antioxidant; fragrance; metabolite; solvent	2008	2008	16.0	low	0	1	0	0
betaine	2	amino-acid betaine; glycine derivative	fundamental metabolite	2008	2016	12.0	low	0	1	1	0
coumarin	1	coumarins	fluorescent dye; human metabolite; plant metabolite	2023	2023	1.0	low	0	0	0	1
salicylic acid	1	monohydroxybenzoic acid	algal metabolite; antifungal agent; antiinfective agent; EC 1.11.1.11 (L-ascorbate peroxidase) inhibitor; keratolytic drug; plant hormone; plant metabolite	2023	2023	1.0	low	0	0	0	1
4-aminophenol	1	aminophenol	allergen; metabolite	2010	2010	14.0	low	0	1	0	0
bupropion	1	aromatic ketone; monochlorobenzenes; secondary amino compound	antidepressant; environmental contaminant; xenobiotic	2016	2016	8.0	low	0	0	1	0
aminocaproic acid	4	amino acid zwitterion; epsilon-amino acid; omega-amino fatty acid	antifibrinolytic drug; hematologic agent; metabolite	2008	2016	13.0	low	0	3	1	0
lactic acid	1	2-hydroxy monocarboxylic acid	algal metabolite; Daphnia magna metabolite	2008	2008	16.0	low	0	1	0	0
hexachlorocyclohexane	2	chlorocyclohexane		2010	2010	14.0	low	0	2	0	0
glycine	1	alpha-amino acid; amino acid zwitterion; proteinogenic amino acid; serine family amino acid	EC 2.1.2.1 (glycine hydroxymethyltransferase) inhibitor; fundamental metabolite; hepatoprotective agent; micronutrient; neurotransmitter; NMDA receptor agonist; nutraceutical	2008	2008	16.0	low	0	1	0	0
glycerol	1	alditol; triol	algal metabolite; detergent; Escherichia coli metabolite; geroprotector; human metabolite; mouse metabolite; osmolyte; Saccharomyces cerevisiae metabolite; solvent	2008	2008	16.0	low	0	1	0	0
alpha-glycerophosphoric acid	1	glycerol monophosphate	algal metabolite; human metabolite	2008	2008	16.0	low	0	1	0	0
histamine	1	aralkylamino compound; imidazoles	human metabolite; mouse metabolite; neurotransmitter	2008	2008	16.0	low	0	1	0	0
thioctic acid	1	dithiolanes; heterocyclic fatty acid; thia fatty acid	fundamental metabolite; geroprotector	2023	2023	1.0	low	0	0	0	1
inositol	3	cyclitol; hexol		2008	2010	14.7	low	0	3	0	0
melatonin	3	acetamides; tryptamines	anticonvulsant; central nervous system depressant; geroprotector; hormone; human metabolite; immunological adjuvant; mouse metabolite; radical scavenger	2010	2013	13.0	low	0	2	1	0
niacin	4	pyridine alkaloid; pyridinemonocarboxylic acid; vitamin B3	antidote; antilipemic drug; EC 3.5.1.19 (nicotinamidase) inhibitor; Escherichia coli metabolite; human urinary metabolite; metabolite; mouse metabolite; plant metabolite; vasodilator agent	2008	2016	13.0	low	0	3	1	0
picolinic acid	1	pyridinemonocarboxylic acid	human metabolite; MALDI matrix material	2023	2023	1.0	low	0	0	0	1
pyrazinamide	4	monocarboxylic acid amide; N-acylammonia; pyrazines	antitubercular agent; prodrug	2010	2016	11.8	low	0	2	2	0
pyridoxine	3	hydroxymethylpyridine; methylpyridines; monohydroxypyridine; vitamin B6	cofactor; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite	2010	2016	12.0	low	0	2	1	0
succinic acid	1	alpha,omega-dicarboxylic acid; C4-dicarboxylic acid	anti-ulcer drug; fundamental metabolite; micronutrient; nutraceutical; radiation protective agent	2008	2008	16.0	low	0	1	0	0
thiamine	4	primary alcohol; vitamin B1	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite	2010	2023	9.2	low	0	2	1	1
1-(3-chlorophenyl)piperazine	2	monochlorobenzenes; N-arylpiperazine	drug metabolite; environmental contaminant; serotonergic agonist; xenobiotic	2008	2013	13.5	low	0	1	1	0
2,4-dinitrophenol	2	dinitrophenol	allergen; antiseptic drug; bacterial xenobiotic metabolite; geroprotector; oxidative phosphorylation inhibitor	2010	2010	14.0	low	0	2	0	0
3-aminobenzamide	1	benzamides; substituted aniline	EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor	2023	2023	1.0	low	0	0	0	1
3-methylcholanthrene	1	ortho- and peri-fused polycyclic arene	aryl hydrocarbon receptor agonist; carcinogenic agent	2010	2010	14.0	low	0	1	0	0
enprofylline	2	oxopurine	anti-arrhythmia drug; anti-asthmatic drug; bronchodilator agent; non-steroidal anti-inflammatory drug	2008	2009	15.5	low	0	2	0	0
pleconaril	1			2023	2023	1.0	low	0	0	0	1
4-(2-aminoethyl)benzenesulfonylfluoride	1			2023	2023	1.0	low	0	0	0	1
phenytoin	5	imidazolidine-2,4-dione	anticonvulsant; drug allergen; sodium channel blocker; teratogenic agent	2010	2023	10.2	low	0	3	1	1
tacrine	6	acridines; aromatic amine	EC 3.1.1.7 (acetylcholinesterase) inhibitor	2008	2013	14.0	low	0	5	1	0
acebutolol	4	aromatic amide; ethanolamines; ether; monocarboxylic acid amide; propanolamine; secondary amino compound	anti-arrhythmia drug; antihypertensive agent; beta-adrenergic antagonist; sympathomimetic agent	2008	2016	13.2	low	0	3	1	0
acetaminophen	9	acetamides; phenols	antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; cyclooxygenase 3 inhibitor; environmental contaminant; ferroptosis inducer; geroprotector; hepatotoxic agent; human blood serum metabolite; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic	2008	2016	13.6	low	0	7	2	0
acetazolamide	8	monocarboxylic acid amide; sulfonamide; thiadiazoles	anticonvulsant; diuretic; EC 4.2.1.1 (carbonic anhydrase) inhibitor	2008	2023	11.6	low	0	5	2	1
acetohexamide	2	acetophenones; N-sulfonylurea	hypoglycemic agent; insulin secretagogue	2010	2010	14.0	low	0	2	0	0
acetohydroxamic acid	1	acetohydroxamic acids; carbohydroximic acid	algal metabolite; EC 3.5.1.5 (urease) inhibitor	2016	2016	8.0	low	0	0	1	0
methacholine	1	acetate ester; quaternary ammonium ion	bronchoconstrictor agent; cholinergic agonist; epitope; muscarinic agonist; vasodilator agent	2008	2008	16.0	low	0	1	0	0
alaproclate	1	alpha-amino acid ester		2016	2016	8.0	low	0	0	1	0
albendazole	5	aryl sulfide; benzimidazoles; benzimidazolylcarbamate fungicide; carbamate ester	anthelminthic drug; microtubule-destabilising agent; tubulin modulator	2008	2016	12.6	low	0	3	2	0
albuterol	5	phenols; phenylethanolamines; secondary amino compound	beta-adrenergic agonist; bronchodilator agent; environmental contaminant; xenobiotic	2008	2016	12.8	low	0	3	2	0
alendronate	1	1,1-bis(phosphonic acid); primary amino compound	bone density conservation agent; EC 2.5.1.1 (dimethylallyltranstransferase) inhibitor	2016	2016	8.0	low	0	0	1	0
alfuzosin	2	monocarboxylic acid amide; quinazolines; tetrahydrofuranol	alpha-adrenergic antagonist; antihypertensive agent; antineoplastic agent	2008	2016	12.0	low	0	1	1	0
alosetron	2	imidazoles; pyridoindole	antiemetic; gastrointestinal drug; serotonergic antagonist	2008	2016	12.0	low	0	1	1	0
alprazolam	4	organochlorine compound; triazolobenzodiazepine	anticonvulsant; anxiolytic drug; GABA agonist; muscle relaxant; sedative; xenobiotic	2008	2016	13.2	low	0	3	1	0
alprenolol	6	secondary alcohol; secondary amino compound	anti-arrhythmia drug; antihypertensive agent; beta-adrenergic antagonist; sympatholytic agent	2008	2023	11.8	low	0	4	1	1
altretamine	1	triamino-1,3,5-triazine		2016	2016	8.0	low	0	0	1	0
amantadine	6	adamantanes; primary aliphatic amine	analgesic; antiparkinson drug; antiviral drug; dopaminergic agent; NMDA receptor antagonist; non-narcotic analgesic	2008	2023	11.7	low	0	4	1	1
ambenonium	1	quaternary ammonium ion	EC 3.1.1.8 (cholinesterase) inhibitor	2016	2016	8.0	medium	0	0	1	0
ambroxol	1	aromatic amine		2008	2008	16.0	low	0	1	0	0
diatrizoic acid	3	acetamides; benzoic acids; organoiodine compound	environmental contaminant; radioopaque medium; xenobiotic	2008	2016	11.7	low	0	1	2	0
amifostine anhydrous	1	diamine; organic thiophosphate	antioxidant; prodrug; radiation protective agent	2016	2016	8.0	low	0	0	1	0
aminoglutethimide	4	dicarboximide; piperidones; substituted aniline	adrenergic agent; anticonvulsant; antineoplastic agent; EC 1.14.14.14 (aromatase) inhibitor	2008	2013	13.8	low	0	3	1	0
p-aminohippuric acid	1	N-acylglycine	Daphnia magna metabolite	2016	2016	8.0	low	0	0	1	0
theophylline	8	dimethylxanthine	adenosine receptor antagonist; anti-asthmatic drug; anti-inflammatory agent; bronchodilator agent; drug metabolite; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; fungal metabolite; human blood serum metabolite; immunomodulator; muscle relaxant; vasodilator agent	2008	2016	13.2	low	0	6	2	0
2-aminothiazole	1	1,3-thiazoles; primary amino compound		2023	2023	1.0	low	0	0	0	1
amiodarone	9	1-benzofurans; aromatic ketone; organoiodine compound; tertiary amino compound	cardiovascular drug	2008	2016	13.6	low	0	7	2	0
dan 2163	3	aromatic amide; aromatic amine; benzamides; pyrrolidines; sulfone	environmental contaminant; second generation antipsychotic; xenobiotic	2009	2013	13.3	low	0	2	1	0
amitriptyline	7	carbotricyclic compound; tertiary amine	adrenergic uptake inhibitor; antidepressant; environmental contaminant; tropomyosin-related kinase B receptor agonist; xenobiotic	2008	2016	13.4	low	0	5	2	0
amlexanox	1	monocarboxylic acid; pyridochromene	anti-allergic agent; anti-ulcer drug; non-steroidal anti-inflammatory drug	2013	2013	11.0	low	0	0	1	0
amlodipine	5	dihydropyridine; ethyl ester; methyl ester; monochlorobenzenes; primary amino compound	antihypertensive agent; calcium channel blocker; vasodilator agent	2008	2016	12.8	low	0	3	2	0
amodiaquine	1	aminoquinoline; organochlorine compound; phenols; secondary amino compound; tertiary amino compound	anticoronaviral agent; antimalarial; drug allergen; EC 2.1.1.8 (histamine N-methyltransferase) inhibitor; non-steroidal anti-inflammatory drug; prodrug	2023	2023	1.0	low	0	0	0	1
amoxapine	4	dibenzooxazepine	adrenergic uptake inhibitor; antidepressant; dopaminergic antagonist; geroprotector; serotonin uptake inhibitor	2010	2016	11.8	low	0	2	2	0
amsacrine	2	acridines; aromatic ether; sulfonamide	antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor	2008	2013	13.5	low	0	1	1	0
anastrozole	2	nitrile; triazoles	antineoplastic agent; EC 1.14.14.14 (aromatase) inhibitor	2013	2016	9.5	low	0	0	2	0
antazoline	1	aromatic amine; imidazolines; tertiary amino compound	cholinergic antagonist; H1-receptor antagonist; xenobiotic	2008	2008	16.0	low	0	1	0	0
anthralin	1	anthracenes	antipsoriatic	2013	2013	11.0	low	0	0	1	0
antipyrine	5	pyrazolone	antipyretic; cyclooxygenase 3 inhibitor; environmental contaminant; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic	2008	2013	14.0	low	0	4	1	0
aspirin	7	benzoic acids; phenyl acetates; salicylates	anticoagulant; antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; drug allergen; EC 1.1.1.188 (prostaglandin-F synthase) inhibitor; geroprotector; non-narcotic analgesic; non-steroidal anti-inflammatory drug; plant activator; platelet aggregation inhibitor; prostaglandin antagonist; teratogenic agent	2008	2023	11.3	low	0	4	2	1
astemizole	3	benzimidazoles; piperidines	anti-allergic agent; anticoronaviral agent; H1-receptor antagonist	2010	2013	13.0	low	0	2	1	0
atenolol	7	ethanolamines; monocarboxylic acid amide; propanolamine	anti-arrhythmia drug; antihypertensive agent; beta-adrenergic antagonist; environmental contaminant; sympatholytic agent; xenobiotic	2008	2016	13.1	low	0	5	2	0
azathioprine	5	aryl sulfide; C-nitro compound; imidazoles; thiopurine	antimetabolite; antineoplastic agent; carcinogenic agent; DNA synthesis inhibitor; hepatotoxic agent; immunosuppressive agent; prodrug	2010	2016	12.2	low	0	3	2	0
azelastine	2	monochlorobenzenes; phthalazines; tertiary amino compound	anti-allergic agent; anti-asthmatic drug; bronchodilator agent; EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor; H1-receptor antagonist; platelet aggregation inhibitor	2008	2009	15.5	low	0	2	0	0
baclofen	3	amino acid zwitterion; gamma-amino acid; monocarboxylic acid; monochlorobenzenes; primary amino compound	central nervous system depressant; GABA agonist; muscle relaxant	2013	2023	6.7	low	0	0	2	1
barbital	1	barbiturates	drug allergen	2008	2008	16.0	low	0	1	0	0
bendazac	1	indazoles; monocarboxylic acid	non-steroidal anti-inflammatory drug; radical scavenger	2016	2016	8.0	low	0	0	1	0
bendroflumethiazide	2	benzothiadiazine; sulfonamide	antihypertensive agent; diuretic	2008	2016	12.0	low	0	1	1	0
benzamide	2	benzamides		2008	2023	8.5	low	0	1	0	1
benzbromarone	6	1-benzofurans; aromatic ketone	uricosuric drug	2010	2016	12.3	low	0	3	3	0
benzocaine	1	benzoate ester; substituted aniline	allergen; antipruritic drug; sensitiser; topical anaesthetic	2013	2013	11.0	low	0	0	1	0
benzquinamide	1	monocarboxylic acid amide	antiemetic; antipsychotic agent; H1-receptor antagonist; muscarinic antagonist; sedative	2008	2008	16.0	low	0	1	0	0
bepridil	1	pyrrolidines; tertiary amine	anti-arrhythmia drug; antihypertensive agent; calcium channel blocker; vasodilator agent	2008	2008	16.0	low	0	1	0	0
bethanidine	1	guanidines	adrenergic antagonist; antihypertensive agent	2008	2008	16.0	low	0	1	0	0
betaxolol	5	propanolamine	antihypertensive agent; beta-adrenergic antagonist; sympatholytic agent	2008	2016	13.8	low	0	4	1	0
bethanechol	1	carbamate ester; quaternary ammonium ion	muscarinic agonist	2016	2016	8.0	low	0	0	1	0
bevantolol	2	propanolamine	anti-arrhythmia drug; antihypertensive agent; beta-adrenergic antagonist; calcium channel blocker	2008	2009	15.5	low	0	2	0	0
bicalutamide	4	(trifluoromethyl)benzenes; monocarboxylic acid amide; monofluorobenzenes; nitrile; sulfone; tertiary alcohol		2010	2016	11.8	low	0	2	2	0
bay h 4502	1	biphenyls; imidazoles		2013	2013	11.0	low	0	0	1	0
biperiden	3	piperidines; tertiary alcohol; tertiary amino compound	antidote to sarin poisoning; antidyskinesia agent; antiparkinson drug; muscarinic antagonist; parasympatholytic	2008	2016	12.7	low	0	2	1	0
bisacodyl	3	diarylmethane		2008	2016	11.7	low	0	1	2	0
bisoprolol	4	secondary alcohol; secondary amine	anti-arrhythmia drug; antihypertensive agent; beta-adrenergic antagonist; sympatholytic agent	2008	2016	13.2	low	0	3	1	0
bithionol	2	aryl sulfide; bridged diphenyl antifungal drug; bridged diphenyl fungicide; dichlorobenzene; organochlorine pesticide; polyphenol	antifungal agrochemical; antiplatyhelmintic drug	2010	2010	14.0	low	0	2	0	0
bromazepam	3	organic molecular entity		2008	2010	15.0	low	0	3	0	0
bromhexine	1	organobromine compound; substituted aniline; tertiary amino compound	mucolytic	2008	2008	16.0	low	0	1	0	0
bromopride	3	benzamides		2008	2013	14.0	low	0	2	1	0
bronopol	1	nitro compound		2013	2013	11.0	low	0	0	1	0
brotizolam	1	organic molecular entity		2008	2008	16.0	low	0	1	0	0
buflomedil	3	aromatic ketone		2008	2010	15.0	low	0	3	0	0
bumetanide	8	amino acid; benzoic acids; sulfonamide	diuretic; EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor	2008	2016	13.2	low	0	6	2	0
bunazosin	1	quinazolines		2008	2008	16.0	low	0	1	0	0
bunitrolol	1	aromatic ether		2008	2008	16.0	low	0	1	0	0
bupivacaine	5	aromatic amide; piperidinecarboxamide; tertiary amino compound		2008	2010	14.6	low	0	5	0	0
bupranolol	1	aromatic ether		2008	2008	16.0	low	0	1	0	0
buspirone	4	azaspiro compound; N-alkylpiperazine; N-arylpiperazine; organic heteropolycyclic compound; piperidones; pyrimidines	anxiolytic drug; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; sedative; serotonergic agonist	2008	2016	13.0	low	0	3	1	0
busulfan	8	methanesulfonate ester	alkylating agent; antineoplastic agent; carcinogenic agent; insect sterilant; teratogenic agent	2008	2016	13.2	low	0	6	2	0
secbutabarbital	1	barbiturates		2016	2016	8.0	low	0	0	1	0
butalbital	1	barbiturates	analgesic; sedative	2008	2008	16.0	low	0	1	0	0
caffeine	9	purine alkaloid; trimethylxanthine	adenosine A2A receptor antagonist; adenosine receptor antagonist; adjuvant; central nervous system stimulant; diuretic; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; environmental contaminant; food additive; fungal metabolite; geroprotector; human blood serum metabolite; mouse metabolite; mutagen; plant metabolite; psychotropic drug; ryanodine receptor agonist; xenobiotic	2008	2016	13.6	low	0	7	2	0
verapamil	6	aromatic ether; nitrile; polyether; tertiary amino compound		2008	2016	13.0	low	0	4	2	0
metrizoate	3	monocarboxylic acid	radioopaque medium	2008	2009	15.7	low	0	3	0	0
camostat	1	benzoate ester; carboxylic ester; diester; guanidines; tertiary carboxamide	anti-inflammatory agent; anticoronaviral agent; antifibrinolytic drug; antihypertensive agent; antineoplastic agent; antiviral agent; serine protease inhibitor	2023	2023	1.0	low	0	0	0	1
camphor, (+-)-isomer	1	bornane monoterpenoid; cyclic monoterpene ketone	plant metabolite	2023	2023	1.0	low	0	0	0	1
candesartan cilexetil	3	biphenyls		1996	2010	21.0	low	1	2	0	0
candesartan	9	benzimidazolecarboxylic acid; biphenylyltetrazole	angiotensin receptor antagonist; antihypertensive agent; environmental contaminant; xenobiotic	1996	2023	14.7	low	1	5	2	1
carbamazepine	5	dibenzoazepine; ureas	analgesic; anticonvulsant; antimanic drug; drug allergen; EC 3.5.1.98 (histone deacetylase) inhibitor; environmental contaminant; glutamate transporter activator; mitogen; non-narcotic analgesic; sodium channel blocker; xenobiotic	2008	2016	12.6	low	0	3	2	0
carbazochrome	1			2008	2008	16.0	low	0	1	0	0
carbinoxamine	2	monochlorobenzenes; pyridines; tertiary amino compound	anti-allergic agent; antiparkinson drug; H1-receptor antagonist; muscarinic antagonist	2008	2016	12.0	low	0	1	1	0
carisoprodol	1	carbamate ester	muscle relaxant	2016	2016	8.0	low	0	0	1	0
carmustine	3	N-nitrosoureas; organochlorine compound	alkylating agent; antineoplastic agent	2008	2013	14.3	low	0	2	1	0
carprofen	1	carbazoles; organochlorine compound	EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-steroidal anti-inflammatory drug; photosensitizing agent	2013	2013	11.0	low	0	0	1	0
carvedilol	5	carbazoles; secondary alcohol; secondary amino compound	alpha-adrenergic antagonist; antihypertensive agent; beta-adrenergic antagonist; cardiovascular drug; vasodilator agent	2008	2016	12.8	low	0	3	2	0
celecoxib	3	organofluorine compound; pyrazoles; sulfonamide; toluenes	cyclooxygenase 2 inhibitor; geroprotector; non-narcotic analgesic; non-steroidal anti-inflammatory drug	2010	2016	11.0	low	0	1	2	0
cetirizine	1	ether; monocarboxylic acid; monochlorobenzenes; piperazines	anti-allergic agent; environmental contaminant; H1-receptor antagonist; xenobiotic	2016	2016	8.0	low	0	0	1	0
cetylpyridinium	1	pyridinium ion		2023	2023	1.0	low	0	0	0	1
chlorambucil	6	aromatic amine; monocarboxylic acid; nitrogen mustard; organochlorine compound; tertiary amino compound	alkylating agent; antineoplastic agent; carcinogenic agent; drug allergen; immunosuppressive agent	2008	2016	13.0	low	0	4	2	0
chlorcyclizine	2	diarylmethane		2008	2016	12.0	low	0	1	1	0
chlordiazepoxide	6	benzodiazepine		2008	2016	13.0	low	0	4	2	0
chlormezanone	1	1,3-thiazine; lactam; monochlorobenzenes; sulfone	antipsychotic agent; anxiolytic drug; muscle relaxant	2016	2016	8.0	low	0	0	1	0
chloroquine	7	aminoquinoline; organochlorine compound; secondary amino compound; tertiary amino compound	anticoronaviral agent; antimalarial; antirheumatic drug; autophagy inhibitor; dermatologic drug	2008	2016	13.4	low	0	5	2	0
chlorothiazide	2	benzothiadiazine	antihypertensive agent; diuretic	2008	2016	12.0	low	0	1	1	0
chloroxine	1	monohydroxyquinoline; organochlorine compound	antibacterial agent; antifungal drug; antiseborrheic	2008	2008	16.0	low	0	1	0	0
chloroxylenol	1	monochlorobenzenes; phenols	antiseptic drug; disinfectant; molluscicide	2023	2023	1.0	low	0	0	0	1
chlorpheniramine	6	monochlorobenzenes; pyridines; tertiary amino compound	anti-allergic agent; antidepressant; antipruritic drug; H1-receptor antagonist; histamine antagonist; serotonin uptake inhibitor	2008	2016	13.0	low	0	4	2	0
chlorpromazine	10	organochlorine compound; phenothiazines; tertiary amine	anticoronaviral agent; antiemetic; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; phenothiazine antipsychotic drug	2008	2023	12.3	low	0	7	2	1
chlorpropamide	9	monochlorobenzenes; N-sulfonylurea	hypoglycemic agent; insulin secretagogue	2008	2016	13.6	low	0	7	2	0
chlorthalidone	5	isoindoles; monochlorobenzenes; sulfonamide		2008	2016	12.8	low	0	3	2	0
chlorzoxazone	4	1,3-benzoxazoles; heteroaryl hydroxy compound; organochlorine compound	muscle relaxant; sedative	2010	2016	11.8	low	0	2	2	0
cifenline	4	diarylmethane		2008	2013	14.0	low	0	3	1	0
ciclopirox	3	cyclic hydroxamic acid; hydroxypyridone antifungal drug; pyridone	antibacterial agent; antiseborrheic	2010	2013	13.0	low	0	2	1	0
ciglitazone	4	aromatic ether; thiazolidinone	antineoplastic agent; insulin-sensitizing drug	2010	2013	13.2	low	0	3	1	0
cilostazol	2	lactam; tetrazoles	anticoagulant; bronchodilator agent; EC 3.1.4.17 (3',5'-cyclic-nucleotide phosphodiesterase) inhibitor; fibrin modulating drug; neuroprotective agent; platelet aggregation inhibitor; vasodilator agent	2013	2016	9.5	low	0	0	2	0
cimetidine	9	aliphatic sulfide; guanidines; imidazoles; nitrile	adjuvant; analgesic; anti-ulcer drug; H2-receptor antagonist; P450 inhibitor	2008	2016	13.6	low	0	7	2	0
ciprofibrate	6	cyclopropanes; monocarboxylic acid; organochlorine compound	antilipemic drug	2008	2023	11.7	low	0	4	1	1
ciprofloxacin	6	aminoquinoline; cyclopropanes; fluoroquinolone antibiotic; N-arylpiperazine; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone; zwitterion	antibacterial drug; antiinfective agent; antimicrobial agent; DNA synthesis inhibitor; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; environmental contaminant; topoisomerase IV inhibitor; xenobiotic	2008	2016	13.0	low	0	4	2	0
cisapride	2	benzamides		2010	2010	14.0	low	0	2	0	0
citalopram	8	2-benzofurans; cyclic ether; nitrile; organofluorine compound; tertiary amino compound		2008	2016	13.5	low	0	6	2	0
clioquinol	2	monohydroxyquinoline; organochlorine compound; organoiodine compound	antibacterial agent; antifungal agent; antimicrobial agent; antineoplastic agent; antiprotozoal drug; chelator; copper chelator	2008	2013	13.5	low	0	1	1	0
clobazam	1	1,4-benzodiazepinone; organochlorine compound	anticonvulsant; anxiolytic drug; GABA modulator	2013	2013	11.0	low	0	0	1	0
clofazimine	3	monochlorobenzenes; phenazines	dye; leprostatic drug; non-steroidal anti-inflammatory drug	2008	2013	13.7	low	0	2	1	0
clofibrate	5	aromatic ether; ethyl ester; monochlorobenzenes	anticholesteremic drug; antilipemic drug; geroprotector; PPARalpha agonist	2010	2016	12.2	low	0	3	2	0
clomiphene	3	tertiary amine	estrogen antagonist; estrogen receptor modulator	2010	2016	11.0	medium	0	1	2	0
clomipramine	8	dibenzoazepine	anticoronaviral agent; antidepressant; EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor; serotonergic antagonist; serotonergic drug; serotonin uptake inhibitor	2008	2023	11.8	low	0	5	2	1
clonazepam	4	1,4-benzodiazepinone; monochlorobenzenes	anticonvulsant; anxiolytic drug; GABA modulator	2008	2016	13.2	low	0	3	1	0
clonidine	4	clonidine; imidazoline		2008	2016	13.8	low	0	3	1	0
4-chloro-N-(2,6-dimethyl-1-piperidinyl)-3-sulfamoylbenzamide	2	sulfonamide		2010	2013	12.5	medium	0	1	1	0
chlorazepate	2	1,4-benzodiazepinone	anticonvulsant; anxiolytic drug; GABA modulator; prodrug	2008	2016	12.0	high	0	1	1	0
clotrimazole	3	conazole antifungal drug; imidazole antifungal drug; imidazoles; monochlorobenzenes	antiinfective agent; environmental contaminant; xenobiotic	2010	2016	12.0	low	0	2	1	0
cromolyn	2	chromones; dicarboxylic acid	anti-asthmatic drug; calcium channel blocker	2010	2010	14.0	medium	0	2	0	0
cyclandelate	1	carboxylic ester; secondary alcohol	vasodilator agent	2008	2008	16.0	low	0	1	0	0
cyclobenzaprine	1	carbotricyclic compound	antidepressant; muscle relaxant; tranquilizing drug	2016	2016	8.0	low	0	0	1	0
cyclofenil	2	organic molecular entity		2008	2016	12.0	low	0	1	1	0
cyproheptadine	1	piperidines; tertiary amine	anti-allergic agent; antipruritic drug; gastrointestinal drug; H1-receptor antagonist; serotonergic antagonist	2016	2016	8.0	low	0	0	1	0
danthron	1	dihydroxyanthraquinone	apoptosis inducer; plant metabolite	2023	2023	1.0	low	0	0	0	1
dapsone	8	substituted aniline; sulfone	anti-inflammatory drug; antiinfective agent; antimalarial; leprostatic drug	2008	2016	13.2	low	0	6	2	0
debrisoquin	1	carboxamidine; isoquinolines	adrenergic agent; antihypertensive agent; human metabolite; sympatholytic agent	2008	2008	16.0	low	0	1	0	0
deferiprone	1	4-pyridones	iron chelator; protective agent	2023	2023	1.0	low	0	0	0	1
deferoxamine	1	acyclic desferrioxamine	bacterial metabolite; ferroptosis inhibitor; iron chelator; siderophore	2016	2016	8.0	low	0	0	1	0
desipramine	9	dibenzoazepine; secondary amino compound	adrenergic uptake inhibitor; alpha-adrenergic antagonist; antidepressant; cholinergic antagonist; drug allergen; EC 3.1.4.12 (sphingomyelin phosphodiesterase) inhibitor; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; H1-receptor antagonist; serotonin uptake inhibitor	2008	2016	13.6	low	0	7	2	0
nordazepam	1	1,4-benzodiazepinone; organochlorine compound	anticonvulsant; anxiolytic drug; GABA modulator; human metabolite; sedative	2008	2008	16.0	low	0	1	0	0
amphetamine	3	primary amine		2008	2016	13.3	low	0	2	1	0
diazepam	7	1,4-benzodiazepinone; organochlorine compound	anticonvulsant; anxiolytic drug; environmental contaminant; sedative; xenobiotic	2008	2016	13.4	low	0	5	2	0
diazoxide	6	benzothiadiazine; organochlorine compound; sulfone	antihypertensive agent; beta-adrenergic agonist; bronchodilator agent; cardiotonic drug; diuretic; K-ATP channel agonist; sodium channel blocker; sympathomimetic agent; vasodilator agent	2008	2016	13.0	low	0	4	2	0
diclofenac	6	amino acid; aromatic amine; dichlorobenzene; monocarboxylic acid; secondary amino compound	antipyretic; drug allergen; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic	2008	2016	13.5	low	0	5	1	0
dichlorphenamide	2	dichlorobenzene; sulfonamide	antiglaucoma drug; EC 4.2.1.1 (carbonic anhydrase) inhibitor; ophthalmology drug	2008	2016	12.0	low	0	1	1	0
dicyclomine	1	carboxylic ester; tertiary amine	antispasmodic drug; muscarinic antagonist; parasympatholytic	2016	2016	8.0	low	0	0	1	0
diethylcarbamazine	2	N-carbamoylpiperazine; N-methylpiperazine		2010	2010	14.0	low	0	2	0	0
pentetic acid	1	pentacarboxylic acid	copper chelator	2016	2016	8.0	low	0	0	1	0
diphenidol	1	benzenes; piperidines; tertiary alcohol	antiemetic	2008	2008	16.0	low	0	1	0	0
diflunisal	4	monohydroxybenzoic acid; organofluorine compound	non-narcotic analgesic; non-steroidal anti-inflammatory drug	2008	2016	13.0	low	0	3	1	0
dimercaprol	3	dithiol; primary alcohol	chelator	2010	2016	12.0	low	0	2	1	0
diphenhydramine	4	ether; tertiary amino compound	anti-allergic agent; antidyskinesia agent; antiemetic; antiparkinson drug; antipruritic drug; antitussive; H1-receptor antagonist; local anaesthetic; muscarinic antagonist; oneirogen; sedative	2008	2016	13.2	low	0	3	1	0
dipyridamole	5	piperidines; pyrimidopyrimidine; tertiary amino compound; tetrol	adenosine phosphodiesterase inhibitor; EC 3.5.4.4 (adenosine deaminase) inhibitor; platelet aggregation inhibitor; vasodilator agent	2010	2023	9.6	low	0	2	2	1
disopyramide	7	monocarboxylic acid amide; pyridines; tertiary amino compound	anti-arrhythmia drug	2008	2016	13.4	low	0	5	2	0
disulfiram	4	organic disulfide; organosulfur acaricide	angiogenesis inhibitor; antineoplastic agent; apoptosis inducer; EC 1.2.1.3 [aldehyde dehydrogenase (NAD(+))] inhibitor; EC 3.1.1.1 (carboxylesterase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; EC 5.99.1.2 (DNA topoisomerase) inhibitor; ferroptosis inducer; fungicide; NF-kappaB inhibitor	2010	2023	8.5	low	0	1	2	1
valproic acid	9	branched-chain fatty acid; branched-chain saturated fatty acid	anticonvulsant; antimanic drug; EC 3.5.1.98 (histone deacetylase) inhibitor; GABA agent; neuroprotective agent; psychotropic drug; teratogenic agent	2008	2023	12.3	low	0	6	2	1
domperidone	4	benzimidazoles; heteroarylpiperidine	antiemetic; dopaminergic antagonist	2008	2013	14.0	low	0	3	1	0
donepezil	4	aromatic ether; indanones; piperidines; racemate	EC 3.1.1.7 (acetylcholinesterase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; nootropic agent	2010	2016	11.8	low	0	2	2	0
doxapram	3	morpholines; pyrrolidin-2-ones	central nervous system stimulant	2008	2016	12.7	low	0	2	1	0
doxazosin	3	aromatic amine; benzodioxine; monocarboxylic acid amide; N-acylpiperazine; N-arylpiperazine; quinazolines	alpha-adrenergic antagonist; antihyperplasia drug; antihypertensive agent; antineoplastic agent; vasodilator agent	2008	2023	8.3	low	0	1	1	1
doxepin	5	dibenzooxepine; tertiary amino compound	antidepressant	2008	2016	12.8	low	0	3	2	0
doxylamine	2	pyridines; tertiary amine	anti-allergic agent; antiemetic; antitussive; cholinergic antagonist; H1-receptor antagonist; histamine antagonist; sedative	2008	2016	12.0	low	0	1	1	0
droperidol	1	aromatic ketone; benzimidazoles; organofluorine compound	anaesthesia adjuvant; antiemetic; dopaminergic antagonist; first generation antipsychotic	2016	2016	8.0	low	0	0	1	0
dyphylline	4	oxopurine; propane-1,2-diols	bronchodilator agent; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; muscle relaxant; vasodilator agent	2008	2016	13.5	low	0	3	1	0
ebastine	1	organic molecular entity		2013	2013	11.0	low	0	0	1	0
ebselen	1	benzoselenazole	anti-inflammatory drug; antibacterial agent; anticoronaviral agent; antifungal agent; antineoplastic agent; antioxidant; apoptosis inducer; EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor; EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor; EC 1.3.1.8 [acyl-CoA dehydrogenase (NADP(+))] inhibitor; EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor; EC 2.5.1.7 (UDP-N-acetylglucosamine 1-carboxyvinyltransferase) inhibitor; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; EC 3.1.3.25 (inositol-phosphate phosphatase) inhibitor; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor; EC 3.5.4.1 (cytosine deaminase) inhibitor; EC 5.1.3.2 (UDP-glucose 4-epimerase) inhibitor; enzyme mimic; ferroptosis inhibitor; genotoxin; hepatoprotective agent; neuroprotective agent; radical scavenger	2023	2023	1.0	low	0	0	0	1
edrophonium	1	phenols; quaternary ammonium ion	antidote; diagnostic agent; EC 3.1.1.8 (cholinesterase) inhibitor	2016	2016	8.0	low	0	0	1	0
enoxacin	2	1,8-naphthyridine derivative; amino acid; fluoroquinolone antibiotic; monocarboxylic acid; N-arylpiperazine; quinolone antibiotic	antibacterial drug; DNA synthesis inhibitor	2008	2013	13.5	low	0	1	1	0
estazolam	1	triazoles; triazolobenzodiazepine	anticonvulsant; anxiolytic drug; GABA modulator	2016	2016	8.0	low	0	0	1	0
ethacrynic acid	3	aromatic ether; aromatic ketone; dichlorobenzene; monocarboxylic acid	EC 2.5.1.18 (glutathione transferase) inhibitor; ion transport inhibitor; loop diuretic	2008	2016	11.7	low	0	1	2	0
profenamine	1	phenothiazines; tertiary amino compound	adrenergic antagonist; antidyskinesia agent; antiparkinson drug; histamine antagonist; muscarinic antagonist	2008	2008	16.0	low	0	1	0	0
ethosuximide	4	dicarboximide; pyrrolidinone	anticonvulsant; geroprotector; T-type calcium channel blocker	2010	2016	11.8	low	0	2	2	0
ethotoin	1	imidazolidine-2,4-dione	anticonvulsant	2016	2016	8.0	low	0	0	1	0
ethyl loflazepate	1	organic molecular entity		2008	2008	16.0	low	0	1	0	0
etidronate	2	1,1-bis(phosphonic acid)	antineoplastic agent; bone density conservation agent; chelator	2016	2023	4.5	low	0	0	1	1
etilefrine	3	phenols		2008	2010	15.0	low	0	3	0	0
etizolam	1	organic molecular entity		2008	2008	16.0	low	0	1	0	0
etodolac	1	monocarboxylic acid; organic heterotricyclic compound	antipyretic; cyclooxygenase 2 inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug	2016	2016	8.0	low	0	0	1	0
2-hexyloxybenzamide	1	aromatic ether; benzamides	antifungal agent	2023	2023	1.0	low	0	0	0	1
brl 42810	4	2-aminopurines; acetate ester	antiviral drug; prodrug	2008	2023	9.0	low	0	1	2	1
carbonyl cyanide p-trifluoromethoxyphenylhydrazone	2	aromatic ether; hydrazone; nitrile; organofluorine compound	ATP synthase inhibitor; geroprotector; ionophore	2010	2010	14.0	low	0	2	0	0
felbamate	3	carbamate ester	anticonvulsant; neuroprotective agent	2010	2016	12.0	low	0	2	1	0
4-biphenylylacetic acid	1	biphenyls; monocarboxylic acid	non-steroidal anti-inflammatory drug	2013	2013	11.0	low	0	0	1	0
felodipine	5	dichlorobenzene; dihydropyridine; ethyl ester; methyl ester	anti-arrhythmia drug; antihypertensive agent; calcium channel blocker; vasodilator agent	2008	2016	12.8	low	0	3	2	0
fenfluramine	1	(trifluoromethyl)benzenes; secondary amino compound	appetite depressant; serotonergic agonist; serotonin uptake inhibitor	2008	2008	16.0	low	0	1	0	0
fenofibrate	5	aromatic ether; chlorobenzophenone; isopropyl ester; monochlorobenzenes	antilipemic drug; environmental contaminant; geroprotector; xenobiotic	2010	2016	12.2	low	0	3	2	0
fenoldopam	1	benzazepine	alpha-adrenergic agonist; antihypertensive agent; dopamine agonist; dopaminergic antagonist; vasodilator agent	2016	2016	8.0	low	0	0	1	0
fenoprofen	2	monocarboxylic acid	antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; drug allergen; non-narcotic analgesic; non-steroidal anti-inflammatory drug	2008	2016	12.0	low	0	1	1	0
berotek	2	resorcinols; secondary alcohol; secondary amino compound	beta-adrenergic agonist; bronchodilator agent; sympathomimetic agent; tocolytic agent	2008	2008	16.0	low	0	2	0	0
fenspiride	2	azaspiro compound		2008	2010	15.0	low	0	2	0	0
fentanyl	2	anilide; monocarboxylic acid amide; piperidines	adjuvant; anaesthesia adjuvant; anaesthetic; intravenous anaesthetic; mu-opioid receptor agonist; opioid analgesic	2008	2009	15.5	low	0	2	0	0
fexofenadine	3	piperidines; tertiary amine	anti-allergic agent; H1-receptor antagonist	2010	2016	12.0	low	0	2	1	0
fipexide	3	benzodioxoles		2010	2016	12.0	low	0	2	1	0
flavoxate	2	carboxylic ester; flavones; piperidines; tertiary amino compound	antispasmodic drug; muscarinic antagonist; parasympatholytic	2008	2016	12.0	low	0	1	1	0
flecainide	5	aromatic ether; monocarboxylic acid amide; organofluorine compound; piperidines	anti-arrhythmia drug	2008	2016	13.8	low	0	4	1	0
fleroxacin	4	difluorobenzene; fluoroquinolone antibiotic; monocarboxylic acid; N-alkylpiperazine; quinolines	antibacterial drug; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; topoisomerase IV inhibitor	2008	2013	14.0	low	0	3	1	0
fluconazole	7	conazole antifungal drug; difluorobenzene; tertiary alcohol; triazole antifungal drug	environmental contaminant; P450 inhibitor; xenobiotic	2008	2016	13.1	low	0	5	2	0
flucytosine	8	aminopyrimidine; nucleoside analogue; organofluorine compound; pyrimidine antifungal drug; pyrimidone	prodrug	2008	2016	13.5	low	0	6	2	0
flufenamic acid	3	aromatic amino acid; organofluorine compound	antipyretic; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug	2008	2010	14.7	low	0	3	0	0
fluphenazine	2	N-alkylpiperazine; organofluorine compound; phenothiazines	anticoronaviral agent; dopaminergic antagonist; phenothiazine antipsychotic drug	2016	2023	4.5	low	0	0	1	1
flumazenil	8	ethyl ester; imidazobenzodiazepine; organofluorine compound	antidote to benzodiazepine poisoning; GABA antagonist	2008	2016	13.2	low	0	6	2	0
flunitrazepam	1	1,4-benzodiazepinone; C-nitro compound; monofluorobenzenes	anxiolytic drug; GABAA receptor agonist; sedative	2008	2008	16.0	low	0	1	0	0
fluorescite	4	benzoic acids; cyclic ketone; hydroxy monocarboxylic acid; organic heterotricyclic compound; phenols; xanthene dye	fluorescent dye; radioopaque medium	2008	2016	12.2	medium	0	2	2	0
fluorouracil	9	nucleobase analogue; organofluorine compound	antimetabolite; antineoplastic agent; environmental contaminant; immunosuppressive agent; radiosensitizing agent; xenobiotic	2008	2023	12.1	low	0	6	2	1
fluoxetine	6	(trifluoromethyl)benzenes; aromatic ether; secondary amino compound		2008	2016	12.8	low	0	4	2	0
fluphenazine depot	1	decanoate ester; N-alkylpiperazine; organofluorine compound; phenothiazines	dopaminergic antagonist; phenothiazine antipsychotic drug; prodrug	2008	2008	16.0	low	0	1	0	0
fluphenazine enanthate	1	phenothiazines		2008	2008	16.0	low	0	1	0	0
flurazepam	2	1,4-benzodiazepinone; monofluorobenzenes; organochlorine compound; tertiary amino compound	anticonvulsant; anxiolytic drug; GABAA receptor agonist; sedative	2008	2016	12.0	low	0	1	1	0
flurbiprofen	3	fluorobiphenyl; monocarboxylic acid	antipyretic; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug	2010	2016	12.0	low	0	2	1	0
fluspirilene	2	diarylmethane		2010	2010	14.0	low	0	2	0	0
flutamide	6	(trifluoromethyl)benzenes; monocarboxylic acid amide	androgen antagonist; antineoplastic agent	2010	2016	12.3	low	0	3	3	0
flutazolam	1	hemiaminal ether; organic molecular entity		2008	2008	16.0	medium	0	1	0	0
fomepizole	1	pyrazoles	antidote; EC 1.1.1.1 (alcohol dehydrogenase) inhibitor; protective agent	2016	2016	8.0	low	0	0	1	0
foscarnet	6	carboxylic acid; one-carbon compound; phosphonic acids	antiviral drug; geroprotector; HIV-1 reverse transcriptase inhibitor; sodium-dependent Pi-transporter inhibitor	2008	2016	13.5	low	0	5	1	0
furosemide	9	chlorobenzoic acid; furans; sulfonamide	environmental contaminant; loop diuretic; xenobiotic	2008	2016	13.6	low	0	7	2	0
gabapentin	6	gamma-amino acid	anticonvulsant; calcium channel blocker; environmental contaminant; xenobiotic	2008	2016	13.5	low	0	5	1	0
gabexate	1	benzoate ester		2023	2023	1.0	low	0	0	0	1
gemfibrozil	6	aromatic ether	antilipemic drug	2008	2016	12.8	low	0	4	2	0
glafenine	3	aminoquinoline; carboxylic ester; glycol; organochlorine compound; secondary amino compound	inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug	2010	2016	12.0	low	0	2	1	0
gliclazide	4	N-sulfonylurea	hypoglycemic agent; insulin secretagogue; radical scavenger	2008	2013	13.8	low	0	3	1	0
glimepiride	8	sulfonamide		2008	2016	13.2	low	0	6	2	0
glipizide	6	aromatic amide; monocarboxylic acid amide; N-sulfonylurea; pyrazines	EC 2.7.1.33 (pantothenate kinase) inhibitor; hypoglycemic agent; insulin secretagogue	2008	2016	13.0	low	0	4	2	0
glutaral	1	dialdehyde	cross-linking reagent; disinfectant; fixative	2023	2023	1.0	low	0	0	0	1
glutethimide	2	piperidines		2010	2010	14.0	low	0	2	0	0
glyburide	6	monochlorobenzenes; N-sulfonylurea	anti-arrhythmia drug; EC 2.7.1.33 (pantothenate kinase) inhibitor; EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor; hypoglycemic agent	2008	2016	13.0	low	0	4	2	0
2-cyclopentyl-2-hydroxy-2-phenylacetic acid (1,1-dimethyl-3-pyrrolidin-1-iumyl) ester	1	benzenes		2016	2016	8.0	medium	0	0	1	0
granisetron	4	aromatic amide; indazoles		2008	2016	13.2	low	0	3	1	0
guaifenesin	1	methoxybenzenes		2016	2016	8.0	low	0	0	1	0
guanethidine	2	azocanes; guanidines	adrenergic antagonist; antihypertensive agent; sympatholytic agent	2008	2016	12.0	low	0	1	1	0
guanfacine	6	acetamides		2008	2016	13.0	low	0	4	2	0
guanidine	1	carboxamidine; guanidines; one-carbon compound		2016	2016	8.0	low	0	0	1	0
fasudil	1	isoquinolines; N-sulfonyldiazepane	antihypertensive agent; calcium channel blocker; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; geroprotector; neuroprotective agent; nootropic agent; vasodilator agent	2023	2023	1.0	low	0	0	0	1
haloperidol	8	aromatic ketone; hydroxypiperidine; monochlorobenzenes; organofluorine compound; tertiary alcohol	antidyskinesia agent; antiemetic; dopaminergic antagonist; first generation antipsychotic; serotonergic antagonist	2008	2023	11.9	low	0	5	2	1
hexachlorophene	2	bridged diphenyl fungicide; polyphenol; trichlorobenzene	acaricide; antibacterial agent; antifungal agrochemical; antiseptic drug	2010	2010	14.0	low	0	2	0	0
miltefosine	1	phosphocholines; phospholipid	anti-inflammatory agent; anticoronaviral agent; antifungal agent; antineoplastic agent; antiprotozoal drug; apoptosis inducer; immunomodulator; protein kinase inhibitor	2023	2023	1.0	low	0	0	0	1
hexobarbital	2	barbiturates		2008	2009	15.5	low	0	2	0	0
hexylresorcinol	2	resorcinols		2008	2023	8.5	low	0	1	0	1
beta-thujaplicin	1	cyclic ketone; enol; monoterpenoid	antibacterial agent; antifungal agent; antineoplastic agent; antiplasmodial drug; plant metabolite	2023	2023	1.0	low	0	0	0	1
homochlorocyclizine	1	diarylmethane		2008	2008	16.0	low	0	1	0	0
hycanthone	3	thioxanthenes	mutagen; schistosomicide drug	2010	2023	9.7	low	0	2	0	1
hydralazine	4	azaarene; hydrazines; ortho-fused heteroarene; phthalazines	antihypertensive agent; vasodilator agent	2008	2016	13.8	low	0	3	1	0
hydrochlorothiazide	5	benzothiadiazine; organochlorine compound; sulfonamide	antihypertensive agent; diuretic; environmental contaminant; xenobiotic	2010	2023	9.6	low	0	2	2	1
hydroflumethiazide	5	benzothiadiazine; thiazide	antihypertensive agent; diuretic	2008	2016	13.0	low	0	3	2	0
hydroxychloroquine	2	aminoquinoline; organochlorine compound; primary alcohol; secondary amino compound; tertiary amino compound	anticoronaviral agent; antimalarial; antirheumatic drug; dermatologic drug	2008	2016	12.0	low	0	1	1	0
hydroxyurea	8	one-carbon compound; ureas	antimetabolite; antimitotic; antineoplastic agent; DNA synthesis inhibitor; EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor; genotoxin; immunomodulator; radical scavenger; teratogenic agent	2008	2023	11.6	low	0	5	2	1
hydroxyzine	2	hydroxyether; monochlorobenzenes; N-alkylpiperazine	anticoronaviral agent; antipruritic drug; anxiolytic drug; dermatologic drug; H1-receptor antagonist	2008	2016	12.0	low	0	1	1	0
hypericin	1			2008	2008	16.0	low	0	1	0	0
ibuprofen	8	monocarboxylic acid	antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; drug allergen; environmental contaminant; geroprotector; non-narcotic analgesic; non-steroidal anti-inflammatory drug; radical scavenger; xenobiotic	2008	2023	12.0	low	0	6	1	1
phenelzine	3	primary amine		2010	2016	12.0	low	0	2	1	0
lidocaine	8	benzenes; monocarboxylic acid amide; tertiary amino compound	anti-arrhythmia drug; drug allergen; environmental contaminant; local anaesthetic; xenobiotic	2008	2016	13.5	low	0	6	2	0
ifosfamide	7	ifosfamides	alkylating agent; antineoplastic agent; environmental contaminant; immunosuppressive agent; xenobiotic	2008	2016	13.1	low	0	5	2	0
imipramine	6	dibenzoazepine	adrenergic uptake inhibitor; antidepressant; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor	2008	2016	13.3	low	0	4	2	0
amrinone	8	bipyridines	EC 3.1.4.* (phosphoric diester hydrolase) inhibitor	2008	2016	13.5	low	0	6	2	0
indapamide	3	indoles; organochlorine compound; sulfonamide	antihypertensive agent; diuretic	2010	2016	11.0	low	0	1	2	0
indomethacin	9	aromatic ether; indole-3-acetic acids; monochlorobenzenes; N-acylindole	analgesic; drug metabolite; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; gout suppressant; non-steroidal anti-inflammatory drug; xenobiotic metabolite; xenobiotic	2008	2023	11.9	low	0	6	2	1
iodamide	1	benzoic acids; organoiodine compound	radioopaque medium	2008	2008	16.0	low	0	1	0	0
iohexol	2	benzenedicarboxamide; organoiodine compound	environmental contaminant; radioopaque medium; xenobiotic	2008	2013	13.5	low	0	1	1	0
iopromide	2	dicarboxylic acid diamide; organoiodine compound	environmental contaminant; nephrotoxic agent; radioopaque medium; xenobiotic	2008	2009	15.5	low	0	2	0	0
iothalamic acid	2	organic molecular entity		2008	2008	16.0	low	0	2	0	0
iodipamide	1	benzoic acids; organoiodine compound; secondary carboxamide	radioopaque medium	2008	2008	16.0	low	0	1	0	0
ioversol	1	amidobenzoic acid		2016	2016	8.0	low	0	0	1	0
iproniazid	5	carbohydrazide; pyridines		2010	2016	12.2	low	0	3	2	0
avapro	11	azaspiro compound; biphenylyltetrazole	angiotensin receptor antagonist; antihypertensive agent; environmental contaminant; xenobiotic	1996	2023	14.5	low	1	6	3	1
isocarboxazid	3	benzenes		2010	2016	12.0	low	0	2	1	0
isoniazid	7	carbohydrazide	antitubercular agent; drug allergen	2008	2016	13.3	low	0	5	2	0
isopropamide iodide	1	diarylmethane		2008	2008	16.0	low	0	1	0	0
isoproterenol	2	catechols; secondary alcohol; secondary amino compound	beta-adrenergic agonist; bronchodilator agent; cardiotonic drug; sympathomimetic agent	2008	2016	12.0	low	0	1	1	0
isoxsuprine	2	alkylbenzene		2008	2016	12.0	low	0	1	1	0
isradipine	4	benzoxadiazole; dihydropyridine; isopropyl ester; methyl ester		2008	2016	12.5	low	0	2	2	0
itraconazole	7	piperazines		2008	2023	11.3	low	0	4	2	1
ketamine	4	cyclohexanones; monochlorobenzenes; secondary amino compound	analgesic; environmental contaminant; intravenous anaesthetic; neurotoxin; NMDA receptor antagonist; xenobiotic	2008	2016	12.2	low	0	2	2	0
ketanserin	5	aromatic ketone; organofluorine compound; piperidines; quinazolines	alpha-adrenergic antagonist; antihypertensive agent; cardiovascular drug; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; serotonergic antagonist	2008	2013	14.0	low	0	4	1	0
ketoconazole	6	dichlorobenzene; dioxolane; ether; imidazoles; N-acylpiperazine; N-arylpiperazine		2008	2016	12.8	low	0	4	2	0
ketoprofen	6	benzophenones; oxo monocarboxylic acid	antipyretic; drug allergen; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; non-steroidal anti-inflammatory drug; xenobiotic	2008	2016	13.5	low	0	5	1	0
ketorolac	4	amino acid; aromatic ketone; monocarboxylic acid; pyrrolizines; racemate	analgesic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; non-steroidal anti-inflammatory drug	2008	2016	13.2	low	0	3	1	0
ketotifen	3	cyclic ketone; olefinic compound; organic heterotricyclic compound; organosulfur heterocyclic compound; piperidines; tertiary amino compound	anti-asthmatic drug; H1-receptor antagonist	2008	2010	14.7	low	0	3	0	0
kojic acid	1	4-pyranones; enol; primary alcohol	Aspergillus metabolite; EC 1.10.3.1 (catechol oxidase) inhibitor; EC 1.10.3.2 (laccase) inhibitor; EC 1.13.11.24 (quercetin 2,3-dioxygenase) inhibitor; EC 1.14.18.1 (tyrosinase) inhibitor; EC 1.4.3.3 (D-amino-acid oxidase) inhibitor; NF-kappaB inhibitor; skin lightening agent	2023	2023	1.0	low	0	0	0	1
labetalol	6	benzamides; benzenes; phenols; primary carboxamide; salicylamides; secondary alcohol; secondary amino compound		2008	2016	13.8	low	0	5	1	0
lamotrigine	3	1,2,4-triazines; dichlorobenzene; primary arylamine	anticonvulsant; antidepressant; antimanic drug; calcium channel blocker; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; environmental contaminant; excitatory amino acid antagonist; geroprotector; non-narcotic analgesic; xenobiotic	2010	2016	11.0	low	0	1	2	0
lansoprazole	6	benzimidazoles; pyridines; sulfoxide	anti-ulcer drug; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor	2008	2016	13.0	low	0	4	2	0
lapachol	1			2023	2023	1.0	low	0	0	0	1
leflunomide	5	(trifluoromethyl)benzenes; isoxazoles; monocarboxylic acid amide	antineoplastic agent; antiparasitic agent; EC 1.3.98.1 [dihydroorotate oxidase (fumarate)] inhibitor; EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor; hepatotoxic agent; immunosuppressive agent; non-steroidal anti-inflammatory drug; prodrug; pyrimidine synthesis inhibitor; tyrosine kinase inhibitor	2008	2016	12.6	low	0	3	2	0
letrozole	5	nitrile; triazoles	antineoplastic agent; EC 1.14.14.14 (aromatase) inhibitor	2008	2016	12.8	low	0	3	2	0
lofepramine	1	aromatic ketone; dibenzoazepine; monochlorobenzenes; tertiary amino compound	antidepressant	2013	2013	11.0	low	0	0	1	0
lomefloxacin	1	fluoroquinolone antibiotic; N-arylpiperazine; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone	antimicrobial agent; antitubercular agent; photosensitizing agent	2016	2016	8.0	low	0	0	1	0
lomustine	2	N-nitrosoureas; organochlorine compound	alkylating agent; antineoplastic agent	2013	2016	9.5	low	0	0	2	0
loperamide	2	monocarboxylic acid amide; monochlorobenzenes; piperidines; tertiary alcohol	anticoronaviral agent; antidiarrhoeal drug; mu-opioid receptor agonist	2016	2023	4.5	low	0	0	1	1
loratadine	4	benzocycloheptapyridine; ethyl ester; N-acylpiperidine; organochlorine compound; tertiary carboxamide	anti-allergic agent; cholinergic antagonist; geroprotector; H1-receptor antagonist	2008	2023	9.0	low	0	1	2	1
lorazepam	5	benzodiazepine		2008	2016	13.8	low	0	4	1	0
losartan	11	biphenylyltetrazole; imidazoles	angiotensin receptor antagonist; anti-arrhythmia drug; antihypertensive agent; endothelin receptor antagonist	1996	2023	14.2	low	1	7	2	1
loxapine	2	dibenzooxazepine	antipsychotic agent; dopaminergic antagonist	2008	2016	12.0	low	0	1	1	0
4-(dimethylamino)-n-(7-(hydroxyamino)-7-oxoheptyl)benzamide	1	benzamides; hydroxamic acid; secondary carboxamide; tertiary amino compound	antineoplastic agent; apoptosis inducer; EC 3.5.1.98 (histone deacetylase) inhibitor	2023	2023	1.0	low	0	0	0	1
mafenide	1	aromatic amine		2023	2023	1.0	low	0	0	0	1
maprotiline	7	anthracenes		2008	2016	13.3	low	0	5	2	0
mebendazole	7	aromatic ketone; benzimidazoles; carbamate ester	antinematodal drug; microtubule-destabilising agent; tubulin modulator	2008	2016	13.1	low	0	5	2	0
mecamylamine	1	primary aliphatic amine		2016	2016	8.0	low	0	0	1	0
mechlorethamine	1	nitrogen mustard; organochlorine compound	alkylating agent	2016	2016	8.0	low	0	0	1	0
meclizine	1	diarylmethane		2016	2016	8.0	low	0	0	1	0
meclofenamic acid	1	aminobenzoic acid; organochlorine compound; secondary amino compound	analgesic; anticonvulsant; antineoplastic agent; antipyretic; antirheumatic drug; EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-steroidal anti-inflammatory drug	2016	2016	8.0	low	0	0	1	0
meclofenamate sodium anhydrous	2	organic sodium salt		2010	2010	14.0	low	0	2	0	0
mefenamic acid	4	aminobenzoic acid; secondary amino compound	analgesic; antipyretic; antirheumatic drug; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; non-steroidal anti-inflammatory drug; xenobiotic	2010	2016	11.8	low	0	2	2	0
memantine	4	adamantanes; primary aliphatic amine	antidepressant; antiparkinson drug; dopaminergic agent; neuroprotective agent; NMDA receptor antagonist	2008	2016	13.0	low	0	3	1	0
vitamin k 3	3	1,4-naphthoquinones; vitamin K	angiogenesis inhibitor; antineoplastic agent; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor; human urinary metabolite; nutraceutical	2008	2010	14.7	low	0	3	0	0
mepenzolate	1	diarylmethane		2016	2016	8.0	low	0	0	1	0
meperidine	3	ethyl ester; piperidinecarboxylate ester; tertiary amino compound	antispasmodic drug; kappa-opioid receptor agonist; mu-opioid receptor agonist; opioid analgesic	2008	2016	13.0	low	0	2	1	0
mephenytoin	1	imidazolidine-2,4-dione	anticonvulsant	2016	2016	8.0	low	0	0	1	0
mepivacaine	2	piperidinecarboxamide	drug allergen; local anaesthetic	2008	2016	12.0	low	0	1	1	0
meprobamate	4	organic molecular entity		2008	2016	13.0	low	0	3	1	0
mesalamine	2	amino acid; aromatic amine; monocarboxylic acid; monohydroxybenzoic acid; phenols	non-steroidal anti-inflammatory drug	2008	2016	12.0	low	0	1	1	0
mesoridazine	2	phenothiazines; sulfoxide; tertiary amino compound	dopaminergic antagonist; first generation antipsychotic	2008	2016	12.0	low	0	1	1	0
metaproterenol	1	aralkylamino compound; phenylethanolamines; resorcinols; secondary alcohol; secondary amino compound		2016	2016	8.0	low	0	0	1	0
metformin	9	guanidines	environmental contaminant; geroprotector; hypoglycemic agent; xenobiotic	2008	2016	13.6	low	0	7	2	0
methadone	4	benzenes; diarylmethane; ketone; tertiary amino compound		2008	2016	13.2	low	0	3	1	0
methapyrilene	4	ethylenediamine derivative	anti-allergic agent; carcinogenic agent; H1-receptor antagonist; sedative	2008	2010	15.0	low	0	4	0	0
methazolamide	2	sulfonamide; thiadiazoles		2016	2023	4.5	low	0	0	1	1
methocarbamol	3	aromatic ether; carbamate ester; secondary alcohol		2008	2023	8.3	low	0	1	1	1
methoxsalen	1	aromatic ether; psoralens	antineoplastic agent; cross-linking reagent; dermatologic drug; photosensitizing agent; plant metabolite	2016	2016	8.0	low	0	0	1	0
methyclothiazide	1	benzothiadiazine		2016	2016	8.0	low	0	0	1	0
nocodazole	2	aromatic ketone; benzimidazoles; carbamate ester; thiophenes	antimitotic; antineoplastic agent; microtubule-destabilising agent; tubulin modulator	2010	2010	14.0	low	0	2	0	0
methylphenidate	5	beta-amino acid ester; methyl ester; piperidines		2008	2016	13.4	low	0	4	1	0
methyprylon	1	organic molecular entity		2008	2008	16.0	low	0	1	0	0
metoclopramide	6	benzamides; monochlorobenzenes; substituted aniline; tertiary amino compound	antiemetic; dopaminergic antagonist; environmental contaminant; gastrointestinal drug; xenobiotic	2008	2016	13.0	low	0	4	2	0
metolazone	6	organochlorine compound; quinazolines; sulfonamide	antihypertensive agent; diuretic; ion transport inhibitor	2008	2016	13.5	low	0	5	1	0
metoprolol	7	aromatic ether; propanolamine; secondary alcohol; secondary amino compound	antihypertensive agent; beta-adrenergic antagonist; environmental contaminant; geroprotector; xenobiotic	2008	2016	13.4	low	0	5	2	0
metronidazole	8	C-nitro compound; imidazoles; primary alcohol	antiamoebic agent; antibacterial drug; antimicrobial agent; antiparasitic agent; antitrichomonal drug; environmental contaminant; prodrug; radiosensitizing agent; xenobiotic	2008	2016	13.5	low	0	6	2	0
metyrapone	2	aromatic ketone	antimetabolite; diagnostic agent; EC 1.14.15.4 (steroid 11beta-monooxygenase) inhibitor	2008	2016	12.0	low	0	1	1	0
mexiletine	4	aromatic ether; primary amino compound	anti-arrhythmia drug	2008	2016	12.5	low	0	2	2	0
mianserin	3	dibenzoazepine	adrenergic uptake inhibitor; alpha-adrenergic antagonist; antidepressant; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; geroprotector; H1-receptor antagonist; histamine agonist; sedative; serotonergic antagonist	2008	2010	14.7	low	0	3	0	0
miconazole	2	dichlorobenzene; ether; imidazoles		2010	2010	14.0	low	0	2	0	0
midazolam	7	imidazobenzodiazepine; monofluorobenzenes; organochlorine compound	anticonvulsant; antineoplastic agent; anxiolytic drug; apoptosis inducer; central nervous system depressant; GABAA receptor agonist; general anaesthetic; muscle relaxant; sedative	2008	2016	13.4	low	0	5	2	0
midodrine	1	amino acid amide; aromatic ether; secondary alcohol	alpha-adrenergic agonist; prodrug; sympathomimetic agent; vasoconstrictor agent	2016	2016	8.0	low	0	0	1	0
milrinone	4	bipyridines; nitrile; pyridone	cardiotonic drug; EC 3.1.4.17 (3',5'-cyclic-nucleotide phosphodiesterase) inhibitor; platelet aggregation inhibitor; vasodilator agent	2008	2016	13.2	low	0	3	1	0
minoxidil	3	dialkylarylamine; tertiary amino compound		2010	2016	11.0	low	0	1	2	0
mirtazapine	5	benzazepine; tetracyclic antidepressant	alpha-adrenergic antagonist; anxiolytic drug; H1-receptor antagonist; histamine antagonist; oneirogen; serotonergic antagonist	2008	2016	12.8	low	0	3	2	0
mitotane	1	diarylmethane		2016	2016	8.0	low	0	0	1	0
mitoxantrone	4	dihydroxyanthraquinone	analgesic; antineoplastic agent	2008	2023	10.0	low	0	2	1	1
moclobemide	5	benzamides; monochlorobenzenes; morpholines	antidepressant; environmental contaminant; xenobiotic	2008	2013	14.0	low	0	4	1	0
modafinil	2	monocarboxylic acid amide; sulfoxide		2008	2016	12.0	low	0	1	1	0
moxisylyte	2	monoterpenoid		2008	2016	12.0	low	0	1	1	0
entinostat	1	benzamides; carbamate ester; primary amino compound; pyridines; substituted aniline	antineoplastic agent; apoptosis inducer; EC 3.5.1.98 (histone deacetylase) inhibitor	2023	2023	1.0	low	0	0	0	1
acecainide	4	acetamides; benzamides	anti-arrhythmia drug	2008	2013	14.0	low	0	3	1	0
ethylmaleimide	1	maleimides	anticoronaviral agent; EC 1.3.1.8 [acyl-CoA dehydrogenase (NADP(+))] inhibitor; EC 2.1.1.122 [(S)-tetrahydroprotoberberine N-methyltransferase] inhibitor; EC 2.7.1.1 (hexokinase) inhibitor	2023	2023	1.0	low	0	0	0	1
nabumetone	2	methoxynaphthalene; methyl ketone	cyclooxygenase 2 inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug; prodrug	2016	2023	4.5	low	0	0	1	1
nadolol	3	tetralins		2010	2016	11.0	medium	0	1	2	0
nafamostat	1	benzoic acids; guanidines		2023	2023	1.0	low	0	0	0	1
nalidixic acid	5	1,8-naphthyridine derivative; monocarboxylic acid; quinolone antibiotic	antibacterial drug; antimicrobial agent; DNA synthesis inhibitor	2008	2016	12.6	low	0	3	2	0
naratriptan	4	heteroarylpiperidine; sulfonamide; tryptamines	serotonergic agonist; vasoconstrictor agent	2008	2016	13.2	low	0	3	1	0
nefazodone	9	aromatic ether; monochlorobenzenes; N-alkylpiperazine; N-arylpiperazine; triazoles	alpha-adrenergic antagonist; analgesic; antidepressant; serotonergic antagonist; serotonin uptake inhibitor	2008	2016	13.6	low	0	7	2	0
nefopam	3	benzoxazocine; tertiary amino compound		2008	2013	13.7	low	0	2	1	0
neostigmine	2	quaternary ammonium ion	antidote to curare poisoning; EC 3.1.1.7 (acetylcholinesterase) inhibitor	2010	2013	12.5	low	0	1	1	0
nevirapine	7	cyclopropanes; dipyridodiazepine	antiviral drug; HIV-1 reverse transcriptase inhibitor	2008	2023	11.3	low	0	4	2	1
nialamide	1	organonitrogen compound; organooxygen compound		2016	2016	8.0	low	0	0	1	0
nicardipine	6	benzenes; C-nitro compound; diester; dihydropyridine; methyl ester; tertiary amino compound		2008	2016	13.0	low	0	4	2	0
nifedipine	7	C-nitro compound; dihydropyridine; methyl ester	calcium channel blocker; human metabolite; tocolytic agent; vasodilator agent	2008	2016	13.1	low	0	5	2	0
nilutamide	1	(trifluoromethyl)benzenes; C-nitro compound; imidazolidinone	androgen antagonist; antineoplastic agent	2016	2016	8.0	low	0	0	1	0
nimesulide	4	aromatic ether; C-nitro compound; sulfonamide	cyclooxygenase 2 inhibitor; non-steroidal anti-inflammatory drug	2010	2016	11.8	low	0	2	2	0
nimetazepam	1	1,4-benzodiazepinone; C-nitro compound	anticonvulsant; antispasmodic drug; GABA modulator; sedative	2008	2008	16.0	low	0	1	0	0
nimodipine	9	2-methoxyethyl ester; C-nitro compound; dicarboxylic acids and O-substituted derivatives; diester; dihydropyridine; isopropyl ester	antihypertensive agent; calcium channel blocker; cardiovascular drug; vasodilator agent	2008	2016	13.6	low	0	7	2	0
nisoldipine	7	C-nitro compound; dicarboxylic acids and O-substituted derivatives; diester; dihydropyridine; methyl ester		2008	2016	13.1	low	0	5	2	0
nitrazepam	6	1,4-benzodiazepinone; C-nitro compound	anticonvulsant; antispasmodic drug; drug metabolite; GABA modulator; sedative	2008	2013	14.3	low	0	5	1	0
nitrendipine	5	C-nitro compound; dicarboxylic acids and O-substituted derivatives; diester; dihydropyridine; ethyl ester; methyl ester	antihypertensive agent; calcium channel blocker; geroprotector; vasodilator agent	2008	2013	14.4	low	0	4	1	0
nitroglycerin	1	nitroglycerol	explosive; muscle relaxant; nitric oxide donor; prodrug; tocolytic agent; vasodilator agent; xenobiotic	2016	2016	8.0	low	0	0	1	0
nizatidine	4	1,3-thiazoles; C-nitro compound; carboxamidine; organic sulfide; tertiary amino compound	anti-ulcer drug; cholinergic drug; H2-receptor antagonist	2008	2016	13.2	medium	0	3	1	0
nomifensine	7	isoquinolines	dopamine uptake inhibitor	2008	2016	13.9	low	0	6	1	0
norfloxacin	2	fluoroquinolone antibiotic; N-arylpiperazine; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone	antibacterial drug; DNA synthesis inhibitor; environmental contaminant; xenobiotic	2013	2016	9.5	low	0	0	2	0
nortriptyline	7	organic tricyclic compound; secondary amine	adrenergic uptake inhibitor; analgesic; antidepressant; antineoplastic agent; apoptosis inducer; drug metabolite	2008	2016	13.4	low	0	5	2	0
ofloxacin	6	3-oxo monocarboxylic acid; N-arylpiperazine; N-methylpiperazine; organofluorine compound; oxazinoquinoline		2008	2016	13.3	low	0	4	2	0
omeprazole	8	aromatic ether; benzimidazoles; pyridines; sulfoxide		2008	2023	11.9	low	0	5	2	1
ondansetron	5	carbazoles		2008	2016	12.6	low	0	3	2	0
orphenadrine	1	ether; tertiary amino compound	antidyskinesia agent; antiparkinson drug; H1-receptor antagonist; muscarinic antagonist; muscle relaxant; NMDA receptor antagonist; parasympatholytic	2016	2016	8.0	low	0	0	1	0
osalmide	1	organic molecular entity		2023	2023	1.0	low	0	0	0	1
oxamniquine	1	aromatic primary alcohol; C-nitro compound; quinolines; secondary amino compound		2008	2008	16.0	low	0	1	0	0
oxaprozin	4	1,3-oxazoles; monocarboxylic acid	analgesic; non-steroidal anti-inflammatory drug	2010	2016	11.8	low	0	2	2	0
oxazepam	4	1,4-benzodiazepinone; organochlorine compound	anxiolytic drug; environmental contaminant; xenobiotic	2008	2016	13.2	low	0	3	1	0
oxethazaine	1	amino acid amide		2023	2023	1.0	low	0	0	0	1
oxibendazole	2	benzimidazoles; carbamate ester		2010	2010	14.0	low	0	2	0	0
oxiracetam	2	organonitrogen compound; organooxygen compound		2008	2010	15.0	low	0	2	0	0
oxolinic acid	1	aromatic carboxylic acid; organic heterotricyclic compound; oxacycle; quinolinemonocarboxylic acid; quinolone antibiotic	antibacterial drug; antifungal agent; antiinfective agent; antimicrobial agent; enzyme inhibitor	2008	2008	16.0	low	0	1	0	0
oxybutynin	4	acetylenic compound; carboxylic ester; racemate; tertiary alcohol; tertiary amino compound	antispasmodic drug; calcium channel blocker; local anaesthetic; muscarinic antagonist; muscle relaxant; parasympatholytic	2008	2016	12.2	low	0	2	2	0
aminosalicylic acid	3	aminobenzoic acid; phenols	antitubercular agent	2010	2016	12.0	low	0	2	1	0
palmidrol	1	endocannabinoid; N-(long-chain-acyl)ethanolamine; N-(saturated fatty acyl)ethanolamine	anti-inflammatory drug; anticonvulsant; antihypertensive agent; neuroprotective agent	2023	2023	1.0	low	0	0	0	1
pamidronate	4	phosphonoacetic acid		2008	2016	13.0	low	0	3	1	0
pantoprazole	4	aromatic ether; benzimidazoles; organofluorine compound; pyridines; sulfoxide	anti-ulcer drug; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor; environmental contaminant; xenobiotic	2008	2016	13.2	low	0	3	1	0
papaverine	7	benzylisoquinoline alkaloid; dimethoxybenzene; isoquinolines	antispasmodic drug; vasodilator agent	2008	2023	11.3	low	0	4	2	1
4-dichlorobenzene	2	dichlorobenzene	insecticide	2010	2010	14.0	low	0	2	0	0
pargyline	3	aromatic amine		2008	2010	14.7	low	0	3	0	0
pemoline	4	1,3-oxazoles	central nervous system stimulant	2010	2016	11.8	low	0	2	2	0
pentamidine	4	aromatic ether; carboxamidine; diether	anti-inflammatory agent; antifungal agent; calmodulin antagonist; chemokine receptor 5 antagonist; EC 2.3.1.48 (histone acetyltransferase) inhibitor; NMDA receptor antagonist; S100 calcium-binding protein B inhibitor; trypanocidal drug; xenobiotic	2008	2016	12.2	low	0	2	2	0
pentobarbital	3	barbiturates	GABAA receptor agonist	2008	2016	13.3	low	0	2	1	0
pentoxifylline	6	oxopurine		2008	2023	11.0	low	0	3	2	1
perhexiline	5	piperidines	cardiovascular drug	2008	2023	10.6	low	0	3	1	1
perphenazine	6	N-(2-hydroxyethyl)piperazine; N-alkylpiperazine; organochlorine compound; phenothiazines	antiemetic; dopaminergic antagonist; phenothiazine antipsychotic drug	2008	2016	13.3	low	0	4	2	0
phenacemide	1	acetamides		2008	2008	16.0	low	0	1	0	0
phenacetin	6	acetamides; aromatic ether	cyclooxygenase 3 inhibitor; non-narcotic analgesic; peripheral nervous system drug	2008	2013	14.2	low	0	5	1	0
phenazopyridine	2	diaminopyridine; monoazo compound	anticoronaviral agent; carcinogenic agent; local anaesthetic; non-narcotic analgesic	2008	2023	8.5	low	0	1	0	1
phenindione	1	aromatic ketone; beta-diketone	anticoagulant	2008	2008	16.0	low	0	1	0	0
pheniramine	1	pyridines; tertiary amino compound		2008	2008	16.0	low	0	1	0	0
phenobarbital	6	barbiturates	anticonvulsant; drug allergen; excitatory amino acid antagonist; sedative	2008	2016	13.8	low	0	5	1	0
phenolphthalein	1	phenols		2008	2008	16.0	low	0	1	0	0
phenoxybenzamine	1	aromatic amine		2016	2016	8.0	low	0	0	1	0
phentermine	2	primary amine	adrenergic agent; appetite depressant; central nervous system drug; central nervous system stimulant; dopaminergic agent; sympathomimetic agent	2008	2016	12.0	low	0	1	1	0
4-phenylbutyric acid	2	monocarboxylic acid	antineoplastic agent; apoptosis inducer; EC 3.5.1.98 (histone deacetylase) inhibitor; prodrug	2016	2023	4.5	low	0	0	1	1
phenylbutazone	2	pyrazolidines	antirheumatic drug; EC 1.1.1.184 [carbonyl reductase (NADPH)] inhibitor; metabolite; non-narcotic analgesic; non-steroidal anti-inflammatory drug; peripheral nervous system drug	2010	2010	14.0	low	0	2	0	0
phenylmethylsulfonyl fluoride	1	acyl fluoride	serine proteinase inhibitor	2023	2023	1.0	low	0	0	0	1
moxonidine	3	organohalogen compound; pyrimidines		2008	2010	15.0	low	0	3	0	0
pimobendan	2	benzimidazoles; pyridazinone	cardiotonic drug; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; vasodilator agent	2008	2023	8.5	low	0	1	0	1
pinacidil	2	pyridines		2010	2010	14.0	low	0	2	0	0
pindolol	9	indoles; secondary amine	antiglaucoma drug; antihypertensive agent; beta-adrenergic antagonist; serotonergic antagonist; vasodilator agent	2008	2016	13.6	low	0	7	2	0
pioglitazone	5	aromatic ether; pyridines; thiazolidinediones	antidepressant; cardioprotective agent; EC 2.7.1.33 (pantothenate kinase) inhibitor; EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor; ferroptosis inhibitor; geroprotector; hypoglycemic agent; insulin-sensitizing drug; PPARgamma agonist; xenobiotic	2010	2016	12.2	low	0	3	2	0
piracetam	1	organonitrogen compound; organooxygen compound		2013	2013	11.0	low	0	0	1	0
piretanide	2	aromatic ether		2008	2009	15.5	low	0	2	0	0
piribedil	1	N-arylpiperazine		2013	2013	11.0	low	0	0	1	0
pj-34	1	phenanthridines; secondary carboxamide; tertiary amino compound	angiogenesis inhibitor; anti-inflammatory agent; antiatherosclerotic agent; antineoplastic agent; apoptosis inducer; cardioprotective agent; EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor; neuroprotective agent	2023	2023	1.0	low	0	0	0	1
polythiazide	1	benzothiadiazine		2016	2016	8.0	low	0	0	1	0
practolol	2	acetamides; ethanolamines; propanolamine; secondary alcohol; secondary amino compound	anti-arrhythmia drug; beta-adrenergic antagonist	2009	2010	14.5	low	0	2	0	0
duodote	1	pyridinium ion	antidote to organophosphate poisoning; antidote to sarin poisoning; cholinergic drug; cholinesterase reactivator	2016	2016	8.0	low	0	0	1	0
ono 1078	1	chromones		2013	2013	11.0	low	0	0	1	0
pyranoprofen	2	pyridochromene		2008	2013	13.5	low	0	1	1	0
praziquantel	5	isoquinolines		2010	2023	9.6	low	0	2	2	1
prazosin	6	aromatic ether; furans; monocarboxylic acid amide; piperazines; quinazolines	alpha-adrenergic antagonist; antihypertensive agent; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor	2008	2016	13.0	low	0	4	2	0
prilocaine	1	amino acid amide; monocarboxylic acid amide	anticonvulsant; local anaesthetic	2008	2008	16.0	low	0	1	0	0
primaquine	4	aminoquinoline; aromatic ether; N-substituted diamine	antimalarial	2008	2016	12.2	low	0	2	2	0
primidone	4	pyrimidone	anticonvulsant; environmental contaminant; xenobiotic	2010	2016	11.8	low	0	2	2	0
probenecid	9	benzoic acids; sulfonamide	uricosuric drug	2008	2023	12.1	low	0	6	2	1
probucol	3	dithioketal; polyphenol	anti-inflammatory drug; anticholesteremic drug; antilipemic drug; antioxidant; cardiovascular drug	2010	2023	9.7	low	0	2	0	1
procainamide	7	benzamides	anti-arrhythmia drug; platelet aggregation inhibitor; sodium channel blocker	2008	2016	13.4	low	0	5	2	0
procarbazine	1	benzamides; hydrazines	antineoplastic agent	2016	2016	8.0	low	0	0	1	0
prochlorperazine	4	N-alkylpiperazine; N-methylpiperazine; organochlorine compound; phenothiazines	alpha-adrenergic antagonist; antiemetic; cholinergic antagonist; dopamine receptor D2 antagonist; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; first generation antipsychotic	2008	2016	12.2	low	0	2	2	0
procyclidine	4	pyrrolidines; tertiary alcohol	antidyskinesia agent; antiparkinson drug; muscarinic antagonist	2008	2016	12.2	low	0	2	2	0
proglumide	1	benzamides; dicarboxylic acid monoamide; glutamine derivative; racemate	anti-ulcer drug; cholecystokinin antagonist; cholinergic antagonist; delta-opioid receptor agonist; drug metabolite; gastrointestinal drug; opioid analgesic; xenobiotic metabolite	2008	2008	16.0	low	0	1	0	0
promazine	3	phenothiazines; tertiary amine	antiemetic; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; H1-receptor antagonist; muscarinic antagonist; phenothiazine antipsychotic drug; serotonergic antagonist	2008	2023	11.0	low	0	2	0	1
promethazine	7	phenothiazines; tertiary amine	anti-allergic agent; anticoronaviral agent; antiemetic; antipruritic drug; H1-receptor antagonist; local anaesthetic; sedative	2008	2023	11.6	low	0	4	2	1
propafenone	3	aromatic ketone; secondary alcohol; secondary amino compound	anti-arrhythmia drug	2008	2016	11.7	low	0	1	2	0
propantheline	1	xanthenes		2016	2016	8.0	low	0	0	1	0
propiomazine	1	aromatic ketone; phenothiazines; tertiary amino compound	dopaminergic antagonist; histamine antagonist; muscarinic antagonist; phenothiazine antipsychotic drug; sedative; serotonergic antagonist	2008	2008	16.0	low	0	1	0	0
propofol	4	phenols	anticonvulsant; antiemetic; intravenous anaesthetic; radical scavenger; sedative	2008	2016	13.0	low	0	3	1	0
propranolol	10	naphthalenes; propanolamine; secondary amine	anti-arrhythmia drug; antihypertensive agent; anxiolytic drug; beta-adrenergic antagonist; environmental contaminant; human blood serum metabolite; vasodilator agent; xenobiotic	2008	2023	12.3	low	0	7	2	1
protriptyline	2	carbotricyclic compound	antidepressant	2008	2016	12.0	low	0	1	1	0
proxyphylline	1	oxopurine		2008	2008	16.0	low	0	1	0	0
pyridostigmine	4	pyridinium ion		2008	2016	13.2	medium	0	3	1	0
pyrimethamine	4	aminopyrimidine; monochlorobenzenes	antimalarial; antiprotozoal drug; EC 1.5.1.3 (dihydrofolate reductase) inhibitor	2008	2016	13.0	low	0	3	1	0
sch 16134	1	benzodiazepine		2016	2016	8.0	low	0	0	1	0
quetiapine	1	dibenzothiazepine; N-alkylpiperazine; N-arylpiperazine	adrenergic antagonist; dopaminergic antagonist; histamine antagonist; second generation antipsychotic; serotonergic antagonist	2016	2016	8.0	low	0	0	1	0
rabeprazole	4	benzimidazoles; pyridines; sulfoxide	anti-ulcer drug; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor	2008	2016	13.2	low	0	3	1	0
raloxifene	3	1-benzothiophenes; aromatic ketone; N-oxyethylpiperidine; phenols	bone density conservation agent; estrogen antagonist; estrogen receptor modulator	2010	2016	12.0	low	0	2	1	0
ranitidine	6	aralkylamine		2008	2013	14.0	low	0	5	1	0
riluzole	4	benzothiazoles		2010	2016	11.8	low	0	2	2	0
rimantadine	2	alkylamine		2016	2023	4.5	low	0	0	1	1
risperidone	8	1,2-benzoxazoles; heteroarylpiperidine; organofluorine compound; pyridopyrimidine	alpha-adrenergic antagonist; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; H1-receptor antagonist; psychotropic drug; second generation antipsychotic; serotonergic antagonist	2008	2016	13.2	low	0	6	2	0
rizatriptan	4	tryptamines	anti-inflammatory drug; serotonergic agonist; vasoconstrictor agent	2008	2016	13.8	low	0	3	1	0
rofecoxib	3	butenolide; sulfone	analgesic; cyclooxygenase 2 inhibitor; non-steroidal anti-inflammatory drug	2008	2013	13.7	low	0	2	1	0
rolipram	1	pyrrolidin-2-ones	antidepressant; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor	2023	2023	1.0	low	0	0	0	1
ropinirole	1	indolones; tertiary amine	antidyskinesia agent; antiparkinson drug; central nervous system drug; dopamine agonist	2016	2016	8.0	low	0	0	1	0
salicylsalicylic acid	2	benzoate ester; benzoic acids; phenols; salicylates	antineoplastic agent; antirheumatic drug; EC 3.5.2.6 (beta-lactamase) inhibitor; hypoglycemic agent; non-narcotic analgesic; non-steroidal anti-inflammatory drug; prodrug	2008	2016	12.0	low	0	1	1	0
scriptaid	1	isoquinolines		2023	2023	1.0	low	0	0	0	1
sebacic acid	1	alpha,omega-dicarboxylic acid; dicarboxylic fatty acid	human metabolite; plant metabolite	2023	2023	1.0	low	0	0	0	1
secobarbital	2	barbiturates	anaesthesia adjuvant; GABA modulator; sedative	2008	2016	12.0	low	0	1	1	0
sibutramine	1	organochlorine compound; tertiary amino compound	anti-obesity agent; serotonin uptake inhibitor	2016	2016	8.0	low	0	0	1	0
sulfadiazine	6	pyrimidines; substituted aniline; sulfonamide antibiotic; sulfonamide	antiinfective agent; antimicrobial agent; antiprotozoal drug; coccidiostat; drug allergen; EC 1.1.1.153 [sepiapterin reductase (L-erythro-7,8-dihydrobiopterin forming)] inhibitor; EC 2.5.1.15 (dihydropteroate synthase) inhibitor; environmental contaminant; xenobiotic	2008	2016	13.0	low	0	4	2	0
ipodate	1			2008	2008	16.0	low	0	1	0	0
risedronic acid	4	pyridines		2008	2016	13.2	low	0	3	1	0
sotalol	7	ethanolamines; secondary alcohol; secondary amino compound; sulfonamide	anti-arrhythmia drug; beta-adrenergic antagonist; environmental contaminant; xenobiotic	2008	2016	13.4	low	0	5	2	0
fenofibrate	1	benzochromenone; delta-lactone; naphtho-alpha-pyrone	platelet aggregation inhibitor; Sir2 inhibitor	2023	2023	1.0	low	0	0	0	1
imatinib	6	aromatic amine; benzamides; N-methylpiperazine; pyridines; pyrimidines	antineoplastic agent; apoptosis inducer; tyrosine kinase inhibitor	2008	2023	10.8	low	0	3	2	1
vorinostat	3	dicarboxylic acid diamide; hydroxamic acid	antineoplastic agent; apoptosis inducer; EC 3.5.1.98 (histone deacetylase) inhibitor	2008	2016	11.7	low	0	1	2	0
succinylcholine	2	quaternary ammonium ion; succinate ester	drug allergen; muscle relaxant; neuromuscular agent	2008	2016	12.0	low	0	1	1	0
sulfabenzamide	2	benzenes; sulfonamide antibiotic; sulfonamide	antibacterial drug; antimicrobial drug	2010	2010	14.0	low	0	2	0	0

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

CYP2C9-mediated metabolic activation of losartan detected by a highly sensitive cell-based screening assay.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 39, Issue:5, 2011

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonists--a perspective.
Bioorganic & medicinal chemistry, , Dec-15, Volume: 18, Issue:24, 2010

Angiotensin II AT1 receptor antagonists. Clinical implications of active metabolites.
Journal of medicinal chemistry, , Jun-05, Volume: 46, Issue:12, 2003

Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy.
Journal of medicinal chemistry, , Feb-02, Volume: 39, Issue:3, 1996

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

CYP2C9-mediated metabolic activation of losartan detected by a highly sensitive cell-based screening assay.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 39, Issue:5, 2011

Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonists--a perspective.
Bioorganic & medicinal chemistry, , Dec-15, Volume: 18, Issue:24, 2010

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Pharmacophore, drug metabolism, and pharmacokinetics models on non-peptide AT1, AT2, and AT1/AT2 angiotensin II receptor antagonists.
Journal of medicinal chemistry, , Jun-30, Volume: 48, Issue:13, 2005

Angiotensin II AT1 receptor antagonists. Clinical implications of active metabolites.
Journal of medicinal chemistry, , Jun-05, Volume: 46, Issue:12, 2003

Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy.
Journal of medicinal chemistry, , Feb-02, Volume: 39, Issue:3, 1996

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

CYP2C9-mediated metabolic activation of losartan detected by a highly sensitive cell-based screening assay.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 39, Issue:5, 2011

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

CYP2C9-mediated metabolic activation of losartan detected by a highly sensitive cell-based screening assay.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 39, Issue:5, 2011

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

CYP2C9-mediated metabolic activation of losartan detected by a highly sensitive cell-based screening assay.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 39, Issue:5, 2011

Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonists--a perspective.
Bioorganic & medicinal chemistry, , Dec-15, Volume: 18, Issue:24, 2010

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

Pharmacophore, drug metabolism, and pharmacokinetics models on non-peptide AT1, AT2, and AT1/AT2 angiotensin II receptor antagonists.
Journal of medicinal chemistry, , Jun-30, Volume: 48, Issue:13, 2005

Angiotensin II AT1 receptor antagonists. Clinical implications of active metabolites.
Journal of medicinal chemistry, , Jun-05, Volume: 46, Issue:12, 2003

Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy.
Journal of medicinal chemistry, , Feb-02, Volume: 39, Issue:3, 1996

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

CYP2C9-mediated metabolic activation of losartan detected by a highly sensitive cell-based screening assay.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 39, Issue:5, 2011

Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonists--a perspective.
Bioorganic & medicinal chemistry, , Dec-15, Volume: 18, Issue:24, 2010

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

Pharmacophore, drug metabolism, and pharmacokinetics models on non-peptide AT1, AT2, and AT1/AT2 angiotensin II receptor antagonists.
Journal of medicinal chemistry, , Jun-30, Volume: 48, Issue:13, 2005

Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy.
Journal of medicinal chemistry, , Feb-02, Volume: 39, Issue:3, 1996

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

CYP2C9-mediated metabolic activation of losartan detected by a highly sensitive cell-based screening assay.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 39, Issue:5, 2011

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

Inhibiting the HIV integration process: past, present, and the future.
Journal of medicinal chemistry, , Feb-13, Volume: 57, Issue:3, 2014

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

CYP2C9-mediated metabolic activation of losartan detected by a highly sensitive cell-based screening assay.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 39, Issue:5, 2011

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonists--a perspective.
Bioorganic & medicinal chemistry, , Dec-15, Volume: 18, Issue:24, 2010

Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy.
Journal of medicinal chemistry, , Feb-02, Volume: 39, Issue:3, 1996

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Inhibiting the HIV integration process: past, present, and the future.
Journal of medicinal chemistry, , Feb-13, Volume: 57, Issue:3, 2014

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

CYP2C9-mediated metabolic activation of losartan detected by a highly sensitive cell-based screening assay.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 39, Issue:5, 2011

Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonists--a perspective.
Bioorganic & medicinal chemistry, , Dec-15, Volume: 18, Issue:24, 2010

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

Pharmacophore, drug metabolism, and pharmacokinetics models on non-peptide AT1, AT2, and AT1/AT2 angiotensin II receptor antagonists.
Journal of medicinal chemistry, , Jun-30, Volume: 48, Issue:13, 2005

Angiotensin II AT1 receptor antagonists. Clinical implications of active metabolites.
Journal of medicinal chemistry, , Jun-05, Volume: 46, Issue:12, 2003

Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy.
Journal of medicinal chemistry, , Feb-02, Volume: 39, Issue:3, 1996

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonists--a perspective.
Bioorganic & medicinal chemistry, , Dec-15, Volume: 18, Issue:24, 2010

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Pharmacophore, drug metabolism, and pharmacokinetics models on non-peptide AT1, AT2, and AT1/AT2 angiotensin II receptor antagonists.
Journal of medicinal chemistry, , Jun-30, Volume: 48, Issue:13, 2005

Angiotensin II AT1 receptor antagonists. Clinical implications of active metabolites.
Journal of medicinal chemistry, , Jun-05, Volume: 46, Issue:12, 2003

Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy.
Journal of medicinal chemistry, , Feb-02, Volume: 39, Issue:3, 1996

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

CYP2C9-mediated metabolic activation of losartan detected by a highly sensitive cell-based screening assay.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 39, Issue:5, 2011

Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonists--a perspective.
Bioorganic & medicinal chemistry, , Dec-15, Volume: 18, Issue:24, 2010

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

Pharmacophore, drug metabolism, and pharmacokinetics models on non-peptide AT1, AT2, and AT1/AT2 angiotensin II receptor antagonists.
Journal of medicinal chemistry, , Jun-30, Volume: 48, Issue:13, 2005

Angiotensin II AT1 receptor antagonists. Clinical implications of active metabolites.
Journal of medicinal chemistry, , Jun-05, Volume: 46, Issue:12, 2003

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonists--a perspective.
Bioorganic & medicinal chemistry, , Dec-15, Volume: 18, Issue:24, 2010

Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy.
Journal of medicinal chemistry, , Feb-02, Volume: 39, Issue:3, 1996

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

CYP2C9-mediated metabolic activation of losartan detected by a highly sensitive cell-based screening assay.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 39, Issue:5, 2011

Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonists--a perspective.
Bioorganic & medicinal chemistry, , Dec-15, Volume: 18, Issue:24, 2010

Pharmacophore, drug metabolism, and pharmacokinetics models on non-peptide AT1, AT2, and AT1/AT2 angiotensin II receptor antagonists.
Journal of medicinal chemistry, , Jun-30, Volume: 48, Issue:13, 2005

Angiotensin II AT1 receptor antagonists. Clinical implications of active metabolites.
Journal of medicinal chemistry, , Jun-05, Volume: 46, Issue:12, 2003

Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy.
Journal of medicinal chemistry, , Feb-02, Volume: 39, Issue:3, 1996

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Angiotensin II AT1 receptor antagonists. Clinical implications of active metabolites.
Journal of medicinal chemistry, , Jun-05, Volume: 46, Issue:12, 2003

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

Pharmacophore, drug metabolism, and pharmacokinetics models on non-peptide AT1, AT2, and AT1/AT2 angiotensin II receptor antagonists.
Journal of medicinal chemistry, , Jun-30, Volume: 48, Issue:13, 2005

Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy.
Journal of medicinal chemistry, , Feb-02, Volume: 39, Issue:3, 1996

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy.
Journal of medicinal chemistry, , Feb-02, Volume: 39, Issue:3, 1996

Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonists--a perspective.
Bioorganic & medicinal chemistry, , Dec-15, Volume: 18, Issue:24, 2010

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonists--a perspective.
Bioorganic & medicinal chemistry, , Dec-15, Volume: 18, Issue:24, 2010

Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy.
Journal of medicinal chemistry, , Feb-02, Volume: 39, Issue:3, 1996

Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy.
Journal of medicinal chemistry, , Feb-02, Volume: 39, Issue:3, 1996

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonists--a perspective.
Bioorganic & medicinal chemistry, , Dec-15, Volume: 18, Issue:24, 2010

Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy.
Journal of medicinal chemistry, , Feb-02, Volume: 39, Issue:3, 1996

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonists--a perspective.
Bioorganic & medicinal chemistry, , Dec-15, Volume: 18, Issue:24, 2010

Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy.
Journal of medicinal chemistry, , Feb-02, Volume: 39, Issue:3, 1996

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

CYP2C9-mediated metabolic activation of losartan detected by a highly sensitive cell-based screening assay.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 39, Issue:5, 2011

Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonists--a perspective.
Bioorganic & medicinal chemistry, , Dec-15, Volume: 18, Issue:24, 2010

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonists--a perspective.
Bioorganic & medicinal chemistry, , Dec-15, Volume: 18, Issue:24, 2010

Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy.
Journal of medicinal chemistry, , Feb-02, Volume: 39, Issue:3, 1996

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonists--a perspective.
Bioorganic & medicinal chemistry, , Dec-15, Volume: 18, Issue:24, 2010

Pharmacophore, drug metabolism, and pharmacokinetics models on non-peptide AT1, AT2, and AT1/AT2 angiotensin II receptor antagonists.
Journal of medicinal chemistry, , Jun-30, Volume: 48, Issue:13, 2005

Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy.
Journal of medicinal chemistry, , Feb-02, Volume: 39, Issue:3, 1996

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

CYP2C9-mediated metabolic activation of losartan detected by a highly sensitive cell-based screening assay.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 39, Issue:5, 2011

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonists--a perspective.
Bioorganic & medicinal chemistry, , Dec-15, Volume: 18, Issue:24, 2010

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonists--a perspective.
Bioorganic & medicinal chemistry, , Dec-15, Volume: 18, Issue:24, 2010

Selenosartans: novel selenophene analogues of milfasartan and eprosartan.
Bioorganic & medicinal chemistry letters, , Feb-01, Volume: 18, Issue:3, 2008

Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy.
Journal of medicinal chemistry, , Feb-02, Volume: 39, Issue:3, 1996

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonists--a perspective.
Bioorganic & medicinal chemistry, , Dec-15, Volume: 18, Issue:24, 2010

Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy.
Journal of medicinal chemistry, , Feb-02, Volume: 39, Issue:3, 1996

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

Inhibiting the HIV integration process: past, present, and the future.
Journal of medicinal chemistry, , Feb-13, Volume: 57, Issue:3, 2014

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy.
Journal of medicinal chemistry, , Feb-02, Volume: 39, Issue:3, 1996

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

CYP2C9-mediated metabolic activation of losartan detected by a highly sensitive cell-based screening assay.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 39, Issue:5, 2011

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy.
Journal of medicinal chemistry, , Feb-02, Volume: 39, Issue:3, 1996

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

CYP2C9-mediated metabolic activation of losartan detected by a highly sensitive cell-based screening assay.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 39, Issue:5, 2011

Angiotensin II AT1 receptor antagonists. Clinical implications of active metabolites.
Journal of medicinal chemistry, , Jun-05, Volume: 46, Issue:12, 2003

Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonists--a perspective.
Bioorganic & medicinal chemistry, , Dec-15, Volume: 18, Issue:24, 2010

Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy.
Journal of medicinal chemistry, , Feb-02, Volume: 39, Issue:3, 1996

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy.
Journal of medicinal chemistry, , Feb-02, Volume: 39, Issue:3, 1996

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy.
Journal of medicinal chemistry, , Feb-02, Volume: 39, Issue:3, 1996

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Angiotensin II AT1 receptor antagonists. Clinical implications of active metabolites.
Journal of medicinal chemistry, , Jun-05, Volume: 46, Issue:12, 2003

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Inhibiting the HIV integration process: past, present, and the future.
Journal of medicinal chemistry, , Feb-13, Volume: 57, Issue:3, 2014

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

Inhibiting the HIV integration process: past, present, and the future.
Journal of medicinal chemistry, , Feb-13, Volume: 57, Issue:3, 2014

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010

Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7, 2008

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonists--a perspective.
Bioorganic & medicinal chemistry, , Dec-15, Volume: 18, Issue:24, 2010

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Disease models & mechanisms, , 03-01, Volume: 16, Issue:3, 2023

Substance	Studies	Classes	Roles	First Year	Last Year	Average Age	Relationship Strength	Trials	1990's	2000's	2010's	post-2020
n(g),n(g')-dimethyl-l-arginine	2	alpha-amino acid		2002	2008	19.0	low	1	0	2	0	0
glycine	1	alpha-amino acid; amino acid zwitterion; proteinogenic amino acid; serine family amino acid	EC 2.1.2.1 (glycine hydroxymethyltransferase) inhibitor; fundamental metabolite; hepatoprotective agent; micronutrient; neurotransmitter; NMDA receptor agonist; nutraceutical	1992	1992	32.0	low	0	1	0	0	0
melatonin	2	acetamides; tryptamines	anticonvulsant; central nervous system depressant; geroprotector; hormone; human metabolite; immunological adjuvant; mouse metabolite; radical scavenger	2009	2012	13.5	low	0	0	1	1	0
nitrates	1	monovalent inorganic anion; nitrogen oxoanion; reactive nitrogen species		2015	2015	9.0	low	0	0	0	1	0
nitrites	1	monovalent inorganic anion; nitrogen oxoanion; reactive nitrogen species	human metabolite	2015	2015	9.0	low	0	0	0	1	0
uric acid	5	uric acid	Escherichia coli metabolite; human metabolite; mouse metabolite	1996	2021	20.8	low	4	3	1	0	1
amlodipine	3	dihydropyridine; ethyl ester; methyl ester; monochlorobenzenes; primary amino compound	antihypertensive agent; calcium channel blocker; vasodilator agent	2006	2009	16.3	low	2	0	3	0	0
atenolol	2	ethanolamines; monocarboxylic acid amide; propanolamine	anti-arrhythmia drug; antihypertensive agent; beta-adrenergic antagonist; environmental contaminant; sympatholytic agent; xenobiotic	2002	2006	20.0	low	1	0	2	0	0
bisoprolol	1	secondary alcohol; secondary amine	anti-arrhythmia drug; antihypertensive agent; beta-adrenergic antagonist; sympatholytic agent	2016	2016	8.0	low	0	0	0	1	0
candesartan cilexetil	4	biphenyls		1995	2020	18.0	low	0	2	1	1	0
candesartan	19	benzimidazolecarboxylic acid; biphenylyltetrazole	angiotensin receptor antagonist; antihypertensive agent; environmental contaminant; xenobiotic	2000	2014	21.1	low	1	2	16	1	0
carvedilol	1	carbazoles; secondary alcohol; secondary amino compound	alpha-adrenergic antagonist; antihypertensive agent; beta-adrenergic antagonist; cardiovascular drug; vasodilator agent	2008	2008	16.0	low	1	0	1	0	0
chlorthalidone	1	isoindoles; monochlorobenzenes; sulfonamide		2020	2020	4.0	low	0	0	0	1	0
desipramine	1	dibenzoazepine; secondary amino compound	adrenergic uptake inhibitor; alpha-adrenergic antagonist; antidepressant; cholinergic antagonist; drug allergen; EC 3.1.4.12 (sphingomyelin phosphodiesterase) inhibitor; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; H1-receptor antagonist; serotonin uptake inhibitor	2004	2004	20.0	low	0	0	1	0	0
doxazosin	1	aromatic amine; benzodioxine; monocarboxylic acid amide; N-acylpiperazine; N-arylpiperazine; quinazolines	alpha-adrenergic antagonist; antihyperplasia drug; antihypertensive agent; antineoplastic agent; vasodilator agent	2002	2002	22.0	low	0	0	1	0	0
erythrosine	1			2010	2010	14.0	low	0	0	1	0	0
fluconazole	1	conazole antifungal drug; difluorobenzene; tertiary alcohol; triazole antifungal drug	environmental contaminant; P450 inhibitor; xenobiotic	1997	1997	27.0	low	1	1	0	0	0
glyburide	1	monochlorobenzenes; N-sulfonylurea	anti-arrhythmia drug; EC 2.7.1.33 (pantothenate kinase) inhibitor; EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor; hypoglycemic agent	1997	1997	27.0	low	1	1	0	0	0
hydralazine	1	azaarene; hydrazines; ortho-fused heteroarene; phthalazines	antihypertensive agent; vasodilator agent	2004	2004	20.0	low	0	0	1	0	0
hydrochlorothiazide	13	benzothiadiazine; organochlorine compound; sulfonamide	antihypertensive agent; diuretic; environmental contaminant; xenobiotic	1999	2020	18.3	low	8	2	9	2	0
indapamide	1	indoles; organochlorine compound; sulfonamide	antihypertensive agent; diuretic	2016	2016	8.0	low	0	0	0	1	0
indomethacin	1	aromatic ether; indole-3-acetic acids; monochlorobenzenes; N-acylindole	analgesic; drug metabolite; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; gout suppressant; non-steroidal anti-inflammatory drug; xenobiotic metabolite; xenobiotic	1995	1995	29.0	low	0	1	0	0	0
avapro	25	azaspiro compound; biphenylyltetrazole	angiotensin receptor antagonist; antihypertensive agent; environmental contaminant; xenobiotic	1995	2020	20.1	low	0	6	16	3	0
losartan	45	biphenylyltetrazole; imidazoles	angiotensin receptor antagonist; anti-arrhythmia drug; antihypertensive agent; endothelin receptor antagonist	1992	2022	21.5	low	9	15	26	2	2
nifedipine	1	C-nitro compound; dihydropyridine; methyl ester	calcium channel blocker; human metabolite; tocolytic agent; vasodilator agent	2009	2009	15.0	low	0	0	1	0	0
nitrendipine	11	C-nitro compound; dicarboxylic acids and O-substituted derivatives; diester; dihydropyridine; ethyl ester; methyl ester	antihypertensive agent; calcium channel blocker; geroprotector; vasodilator agent	2005	2009	17.4	low	3	0	11	0	0
pd 98059	1	aromatic amine; monomethoxyflavone	EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; geroprotector	2015	2015	9.0	low	0	0	0	1	0
moxonidine	3	organohalogen compound; pyrimidines		2002	2009	19.0	low	1	0	3	0	0
pioglitazone	2	aromatic ether; pyridines; thiazolidinediones	antidepressant; cardioprotective agent; EC 2.7.1.33 (pantothenate kinase) inhibitor; EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor; ferroptosis inhibitor; geroprotector; hypoglycemic agent; insulin-sensitizing drug; PPARgamma agonist; xenobiotic	2005	2021	11.0	low	0	0	1	0	1
potassium chloride	1	inorganic chloride; inorganic potassium salt; potassium salt	fertilizer	2008	2008	16.0	low	0	0	1	0	0
rofecoxib	1	butenolide; sulfone	analgesic; cyclooxygenase 2 inhibitor; non-steroidal anti-inflammatory drug	2003	2003	21.0	low	0	0	1	0	0
carbachol	1	ammonium salt; carbamate ester	cardiotonic drug; miotic; muscarinic agonist; nicotinic acetylcholine receptor agonist; non-narcotic analgesic	2002	2002	22.0	low	0	0	1	0	0
spironolactone	1	3-oxo-Delta(4) steroid; oxaspiro compound; steroid lactone; thioester	aldosterone antagonist; antihypertensive agent; diuretic; environmental contaminant; xenobiotic	2005	2005	19.0	low	0	0	1	0	0
aldosterone	5	11beta-hydroxy steroid; 18-oxo steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; C21-steroid hormone; mineralocorticoid; primary alpha-hydroxy ketone; steroid aldehyde	human metabolite; mouse metabolite	1997	2010	23.2	low	3	4	1	0	0
lysine	1	aspartate family amino acid; L-alpha-amino acid zwitterion; L-alpha-amino acid; lysine; organic molecular entity; proteinogenic amino acid	algal metabolite; anticonvulsant; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; plant metabolite; Saccharomyces cerevisiae metabolite	2010	2010	14.0	low	1	0	1	0	0
histidine	1	amino acid zwitterion; histidine; L-alpha-amino acid; polar amino acid zwitterion; proteinogenic amino acid	algal metabolite; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; Saccharomyces cerevisiae metabolite	1995	1995	29.0	low	0	1	0	0	0
valine	19	L-alpha-amino acid zwitterion; L-alpha-amino acid; proteinogenic amino acid; pyruvate family amino acid; valine	algal metabolite; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; Saccharomyces cerevisiae metabolite	1995	2014	21.2	low	2	4	14	1	0
arginine	3	arginine; glutamine family amino acid; L-alpha-amino acid; proteinogenic amino acid	biomarker; Escherichia coli metabolite; micronutrient; mouse metabolite; nutraceutical	1995	2008	22.3	low	1	1	2	0	0
acetonitrile	1	aliphatic nitrile; volatile organic compound	EC 3.5.1.4 (amidase) inhibitor; NMR chemical shift reference compound; polar aprotic solvent	2014	2014	10.0	low	0	0	0	1	0
tert-butylhydroperoxide	1	alkyl hydroperoxide	antibacterial agent; oxidising agent	2008	2008	16.0	low	1	0	1	0	0
isosorbide dinitrate	1	glucitol derivative; nitrate ester	nitric oxide donor; vasodilator agent	2003	2003	21.0	low	1	0	1	0	0
thiophenes	257	mancude organic heteromonocyclic parent; monocyclic heteroarene; thiophenes; volatile organic compound	non-polar solvent	1991	2022	20.0	low	77	72	150	29	6
pyrazolanthrone	1	anthrapyrazole; aromatic ketone; cyclic ketone	antineoplastic agent; c-Jun N-terminal kinase inhibitor; geroprotector	2015	2015	9.0	low	0	0	0	1	0
indazoles	1	indazole		2009	2009	15.0	low	0	0	1	0	0
malondialdehyde	1	dialdehyde	biomarker	2015	2015	9.0	low	0	0	0	1	0
dithiothreitol	1	1,4-dimercaptobutane-2,3-diol; butanediols; dithiol; glycol; thiol	chelator; human metabolite; reducing agent	1992	1992	32.0	low	0	1	0	0	0
platinum	1	elemental platinum; nickel group element atom; platinum group metal atom		2008	2008	16.0	low	0	0	1	0	0
cerium	1	f-block element atom; lanthanoid atom		2008	2008	16.0	low	0	0	1	0	0
isosorbide-5-mononitrate	1	glucitol derivative; nitrate ester	nitric oxide donor; vasodilator agent	2003	2003	21.0	low	1	0	1	0	0
ribavirin	1	1-ribosyltriazole; aromatic amide; monocarboxylic acid amide; primary carboxamide	anticoronaviral agent; antiinfective agent; antimetabolite; antiviral agent; EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor	2020	2020	4.0	low	0	0	0	1	0
ng-nitroarginine methyl ester	1	alpha-amino acid ester; L-arginine derivative; methyl ester; N-nitro compound	EC 1.14.13.39 (nitric oxide synthase) inhibitor	1999	1999	25.0	low	0	1	0	0	0
captopril	7	alkanethiol; L-proline derivative; N-acylpyrrolidine; pyrrolidinemonocarboxylic acid	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor	1992	2005	26.1	low	1	4	3	0	0
moxalactam	1	cephalosporin; oxacephem	antibacterial drug	2023	2023	1.0	low	0	0	0	0	1
dup 532	1			1995	1995	29.0	low	0	1	0	0	0
valsartan	21	biphenylyltetrazole; monocarboxylic acid amide; monocarboxylic acid	angiotensin receptor antagonist; antihypertensive agent; environmental contaminant; xenobiotic	1995	2020	19.7	low	2	4	14	3	0
fluorexon	1	xanthene dye	fluorochrome	2010	2010	14.0	low	0	0	1	0	0
glutathione disulfide	1	glutathione derivative; organic disulfide	Escherichia coli metabolite; mouse metabolite	2022	2022	2.0	low	0	0	0	0	1
telmisartan	19	benzimidazoles; biphenyls; carboxybiphenyl	angiotensin receptor antagonist; antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; environmental contaminant; xenobiotic	1995	2009	20.6	low	3	3	16	0	0
fibrinogen	1	iditol	fungal metabolite	2004	2004	20.0	low	1	0	1	0	0
perindopril	3	alpha-amino acid ester; dicarboxylic acid monoester; ethyl ester; organic heterobicyclic compound	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor	1999	2005	22.0	low	1	1	2	0	0
exp3174	7	biphenylyltetrazole; imidazoles; organochlorine compound	metabolite	1992	2004	27.0	low	1	5	2	0	0
pd 123177	1	diarylmethane		1992	1992	32.0	low	0	1	0	0	0
cgp 42112a	2	benzyl ester; oligopeptide; pyridinecarboxamide	angiotensin receptor agonist; anti-inflammatory agent; antineoplastic agent; neuroprotective agent; vasodilator agent	1992	1993	31.5	low	0	2	0	0	0
n(6)-carboxymethyllysine	1	L-lysine derivative; non-proteinogenic L-alpha-amino acid	antigen	2010	2010	14.0	low	1	0	1	0	0
n,n-dimethylarginine	2	dimethylarginine; guanidines; L-arginine derivative; non-proteinogenic L-alpha-amino acid	EC 1.14.13.39 (nitric oxide synthase) inhibitor	2002	2008	19.0	low	1	0	2	0	0
wl 19	2			1992	1993	31.5	medium	0	2	0	0	0
exp7711	1			2003	2003	21.0	low	0	0	1	0	0
olmesartan medoxomil	3	biphenyls		2003	2010	18.7	low	0	0	3	0	0
ici d8731	1			1995	1995	29.0	low	0	1	0	0	0
forasartan	2	benzenes; pyridines; tetrazoles; triazoles	angiotensin receptor antagonist; antihypertensive agent	1995	2003	25.0	medium	0	1	1	0	0
omega-n-methylarginine	1	amino acid zwitterion; arginine derivative; guanidines; L-arginine derivative; non-proteinogenic L-alpha-amino acid		2002	2002	22.0	low	1	0	1	0	0
embusartan	1			2001	2001	23.0	medium	0	0	1	0	0
olmesartan	2	biphenylyltetrazole	angiotensin receptor antagonist; antihypertensive agent	2010	2014	12.0	low	0	0	1	1	0
angiotensin ii	63	amino acid zwitterion; angiotensin II	human metabolite	1991	2022	23.3	low	12	28	31	3	1
atropine	1			2002	2002	22.0	low	0	0	1	0	0
l 158809	1			1995	1995	29.0	low	0	1	0	0	0
darunavir	1	carbamate ester; furofuran; sulfonamide	antiviral drug; HIV protease inhibitor	2023	2023	1.0	low	0	0	0	0	1
dihydropyridines	1			2001	2001	23.0	low	0	0	1	0	0
fibrin	1	peptide		2002	2002	22.0	low	1	0	1	0	0
bradykinin	2	oligopeptide	human blood serum metabolite; vasodilator agent	1999	2005	22.0	low	1	1	1	0	0
nitroarginine	1	guanidines; L-arginine derivative; N-nitro compound; non-proteinogenic L-alpha-amino acid		1995	1995	29.0	low	0	1	0	0	0
betadex	1	cyclodextrin		2022	2022	2.0	low	0	0	0	0	1
phosphoramidon	1	deoxyaldohexose phosphate; dipeptide	bacterial metabolite; EC 3.4.24.11 (neprilysin) inhibitor; EC 3.4.24.71 (endothelin-converting enzyme 1) inhibitor	1994	1994	30.0	low	0	1	0	0	0
prostaglandin d2	1	prostaglandins D	human metabolite; mouse metabolite	2015	2015	9.0	low	0	0	0	1	0
gw9662	1	benzamides		2008	2008	16.0	low	0	0	1	0	0
D-fructopyranose	1	cyclic hemiketal; D-fructose; fructopyranose	sweetening agent	2021	2021	3.0	low	1	0	0	0	1
thioacetamide	1	thiocarboxamide	hepatotoxic agent	2022	2022	2.0	low	0	0	0	0	1
digoxin	2	cardenolide glycoside; steroid saponin	anti-arrhythmia drug; cardiotonic drug; EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor; epitope	1997	2010	20.5	low	1	1	1	0	0
ranitidine	1	C-nitro compound; furans; organic sulfide; tertiary amino compound	anti-ulcer drug; drug allergen; environmental contaminant; H2-receptor antagonist; xenobiotic	1998	1998	26.0	low	1	1	0	0	0
milfasartan	1			2008	2008	16.0	medium	0	0	1	0	0
quercetin	1	7-hydroxyflavonol; pentahydroxyflavone	antibacterial agent; antineoplastic agent; antioxidant; Aurora kinase inhibitor; chelator; EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor; geroprotector; phytoestrogen; plant metabolite; protein kinase inhibitor; radical scavenger	2022	2022	2.0	low	0	0	0	0	1
thromboxane a2	1	epoxy monocarboxylic acid; thromboxanes A	mouse metabolite	2003	2003	21.0	low	0	0	1	0	0
kallidin	1	peptide		2005	2005	19.0	low	1	0	1	0	0
lisinopril	2	dipeptide	EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor	2008	2009	15.5	low	1	0	2	0	0
ramipril	1	azabicycloalkane; cyclopentapyrrole; dicarboxylic acid monoester; dipeptide; ethyl ester	bradykinin receptor B2 agonist; cardioprotective agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; matrix metalloproteinase inhibitor; prodrug	2009	2009	15.0	low	0	0	1	0	0
sulfur	1	chalcogen; nonmetal atom	macronutrient	2008	2008	16.0	low	0	0	1	0	0
enalapril	23	dicarboxylic acid monoester; dipeptide	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; geroprotector; prodrug	1992	2009	23.7	low	12	12	11	0	0
tetrodotoxin	1	azatetracycloalkane; oxatetracycloalkane; quinazoline alkaloid	animal metabolite; bacterial metabolite; marine metabolite; neurotoxin; voltage-gated sodium channel blocker	2004	2004	20.0	low	0	0	1	0	0
eprosartan mesylate dihydrate	1			1999	1999	25.0	medium	0	1	0	0	0
abt 869	1	aromatic amine; indazoles; phenylureas	angiogenesis inhibitor; antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor	2009	2009	15.0	low	0	0	1	0	0
icatibant	1			1999	1999	25.0	low	0	1	0	0	0
atrial natriuretic factor	3	polypeptide		2001	2009	20.3	low	1	0	3	0	0
endothelin-1	1			2003	2003	21.0	low	0	0	1	0	0
15-deoxyprostaglandin j2	1			2015	2015	9.0	low	0	0	0	1	0
3h-imidazo(4,5-b)pyridine, 2-butyl-3-((2'-(1h-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-, sodium salt	1			1995	1995	29.0	medium	0	1	0	0	0
natriuretic peptide, brain	1	polypeptide		2010	2010	14.0	low	1	0	1	0	0
warfarin	1	benzenes; hydroxycoumarin; methyl ketone		1998	1998	26.0	low	1	1	0	0	0
angiotensin i	6	angiotensin; peptide zwitterion	human metabolite; neurotransmitter agent	1992	2005	25.2	low	1	3	3	0	0
chondroitin sulfates	1			2015	2015	9.0	low	0	0	0	1	0
cyclic gmp	1	3',5'-cyclic purine nucleotide; guanyl ribonucleotide	Escherichia coli metabolite; human metabolite; mouse metabolite; plant metabolite; Saccharomyces cerevisiae metabolite	1998	1998	26.0	low	0	1	0	0	0
allopurinol	1	nucleobase analogue; organic heterobicyclic compound	antimetabolite; EC 1.17.3.2 (xanthine oxidase) inhibitor; gout suppressant; radical scavenger	1995	1995	29.0	low	0	1	0	0	0
guanylyl imidodiphosphate	1	nucleoside triphosphate analogue		1992	1992	32.0	low	0	1	0	0	0

Condition	Indicated	Studies	First Year	Last Year	Average Age	Relationship Strength	Trials	1990's	2000's	2010's	post-2020
Acute Disease	0	1	2003	2003	21.0	low	1	0	1	0	0
Acute Kidney Failure	0	2	1993	2023	16.0	low	0	1	0	0	1
Acute Kidney Injury	0	2	1993	2023	16.0	low	0	1	0	0	1
Acute Liver Injury, Drug-Induced	0	7	2010	2022	10.9	low	0	0	3	3	1
Acute Onset Vascular Dementia	0	1	2007	2007	17.0	low	1	0	1	0	0
Advanced Sleep Phase Syndrome	0	1	2012	2012	12.0	low	0	0	0	1	0
Adverse Drug Event	0	2	2011	2013	12.0	low	0	0	0	2	0
Aging	0	2	1998	2004	23.0	low	0	1	1	0	0
Anemia, Sickle Cell	0	1	2022	2022	2.0	low	0	0	0	0	1
Aneurysm, Arteriovenous	0	1	2005	2005	19.0	low	0	0	1	0	0
Angiitis	0	2	2002	2004	21.0	low	0	0	2	0	0
Angioedema	0	1	2001	2001	23.0	low	0	0	1	0	0
Angiogenesis, Pathologic	0	1	2014	2014	10.0	low	0	0	0	1	0
Angioneurotic Edema	0	1	2001	2001	23.0	low	0	0	1	0	0
ANS (Autonomic Nervous System) Diseases	0	1	2001	2001	23.0	low	0	0	1	0	0
Anterior Circulation Transient Ischemic Attack	0	3	2006	2009	17.0	low	2	0	3	0	0
Apoplexy	0	19	2000	2009	18.6	low	5	1	18	0	0
Arteriosclerosis, Coronary	0	1	2002	2002	22.0	low	0	0	1	0	0
Atherogenesis	0	1	2007	2007	17.0	low	0	0	1	0	0
Atherosclerosis	0	1	2007	2007	17.0	low	0	0	1	0	0
Benign Neoplasms	0	3	2009	2023	8.3	low	0	0	1	1	1
Blood Clot	0	1	2002	2002	22.0	low	0	0	1	0	0
Blood Pressure, High	0	133	1992	2021	19.5	high	52	27	91	13	2
Body Weight	0	3	2001	2002	22.7	low	0	0	3	0	0
Brain Ischemia	0	1	2005	2005	19.0	low	0	0	1	0	0
Brain Vascular Disorders	0	3	1999	2021	15.0	low	0	1	1	0	1
Bright Disease	0	1	2007	2007	17.0	low	1	0	1	0	0
Burning Mouth Syndrome	0	1	2002	2002	22.0	low	0	0	1	0	0
Carcinoma, Epidermoid	0	1	2023	2023	1.0	low	0	0	0	0	1
Carcinoma, Squamous Cell	0	1	2023	2023	1.0	low	0	0	0	0	1
Cardiac Failure	0	11	1998	2007	21.6	low	4	3	8	0	0
Cardiac Hypertrophy	0	3	1998	2005	22.7	low	0	1	2	0	0
Cardiac Neurosis	0	1	2003	2003	21.0	low	0	0	1	0	0
Cardiac Remodeling, Ventricular	0	2	2001	2005	21.0	low	0	0	2	0	0
Cardiomegaly	0	3	1998	2005	22.7	low	0	1	2	0	0
Cardiometabolic Syndrome	0	2	2008	2021	9.5	low	1	0	1	0	1
Cardiovascular Diseases	1	14	1999	2013	17.9	low	2	1	11	2	0
Celiac Disease	0	1	2015	2015	9.0	low	0	0	0	1	0
Celiac Sprue	0	1	2015	2015	9.0	low	0	0	0	1	0
Cerebral Ischemia	0	1	2005	2005	19.0	low	0	0	1	0	0
Cerebrovascular Disorders	0	3	1999	2021	15.0	low	0	1	1	0	1
Chemical and Drug Induced Liver Injury	0	7	2010	2022	10.9	low	0	0	3	3	1
Chronic Disease	0	2	2005	2007	18.0	low	2	0	2	0	0
Chronic Illness	0	2	2005	2007	18.0	low	2	0	2	0	0
Chronic Kidney Diseases	0	1	2013	2013	11.0	low	1	0	0	1	0
Chronic Kidney Failure	0	1	2004	2004	20.0	low	1	0	1	0	0
Cirrhosis	0	1	2022	2022	2.0	low	0	0	0	0	1
Cognition Disorders	0	4	2007	2008	16.8	low	2	0	4	0	0
Complications of Diabetes Mellitus	0	2	2004	2008	18.0	low	0	0	2	0	0
Congenital Zika Syndrome	0	1	2020	2020	4.0	low	0	0	0	1	0
Coronary Artery Disease	0	1	2002	2002	22.0	low	0	0	1	0	0
Coronary Disease	0	2	2002	2014	16.0	low	0	0	1	1	0
Coronary Heart Disease	0	2	2002	2014	16.0	low	0	0	1	1	0
Cough	0	8	1993	2009	23.8	low	5	4	4	0	0
Decerebrate Posturing	0	3	1992	2001	27.3	low	0	2	1	0	0
Dementia, Vascular	0	1	2007	2007	17.0	low	1	0	1	0	0
Diabetes Mellitus	0	1	2002	2002	22.0	low	0	0	1	0	0
Diabetes Mellitus, Adult-Onset	0	4	1997	2021	17.0	low	2	1	2	0	1
Diabetes Mellitus, Type 2	0	4	1997	2021	17.0	low	2	1	2	0	1
Diabetic Angiopathies	0	1	2004	2004	20.0	low	1	0	1	0	0
Diabetic Glomerulosclerosis	0	3	2000	2015	17.7	low	0	1	1	1	0
Diabetic Nephropathies	0	3	2000	2015	17.7	low	0	1	1	1	0
Diabetic Retinopathy	0	1	2004	2004	20.0	low	0	0	1	0	0
Diffuse Parenchymal Lung Disease	0	1	2012	2012	12.0	low	0	0	0	1	0
Disease Exacerbation	0	2	2002	2003	21.5	low	0	0	2	0	0
Disease Models, Animal	0	6	1998	2020	17.5	low	0	2	2	2	0
Diseases, Occupational	0	4	2001	2009	18.5	low	1	0	4	0	0
Dizziness	0	1	2003	2003	21.0	low	0	0	1	0	0
Dizzyness	0	1	2003	2003	21.0	low	0	0	1	0	0
Drug-Related Side Effects and Adverse Reactions	0	2	2011	2013	12.0	low	0	0	0	2	0
Dysgeusia	0	1	2002	2002	22.0	low	0	0	1	0	0
Essential Hypertension	1	1	2016	2016	8.0	low	0	0	0	1	0
Fasting Hypoglycemia	0	1	2005	2005	19.0	low	1	0	1	0	0
Fibrosis	0	1	2022	2022	2.0	low	0	0	0	0	1
Focal Segmental Glomerulosclerosis	0	2	1999	2003	23.0	low	0	1	1	0	0
Glomerulonephritis	0	1	2007	2007	17.0	low	1	0	1	0	0
Glomerulosclerosis, Focal Segmental	0	2	1999	2003	23.0	low	0	1	1	0	0
HbS Disease	0	1	2022	2022	2.0	low	0	0	0	0	1
Heart Failure	0	11	1998	2007	21.6	low	4	3	8	0	0
HIV	0	1	2014	2014	10.0	low	0	0	0	1	0
HIV Coinfection	0	1	2014	2014	10.0	low	0	0	0	1	0
HIV Infections	0	1	2014	2014	10.0	low	0	0	0	1	0
Hypercoagulability	0	1	2013	2013	11.0	low	1	0	0	1	0
Hyperglycemia	0	1	2000	2000	24.0	low	0	1	0	0	0
Hyperglycemia, Postprandial	0	1	2000	2000	24.0	low	0	1	0	0	0
Hypertension	0	133	1992	2021	19.5	high	52	27	91	13	2
Hypertension, Essential	0	1	2016	2016	8.0	low	0	0	0	1	0
Hypertension, Renal	0	1	2003	2003	21.0	low	0	0	1	0	0
Hypertrophy, Left Ventricular	0	2	1999	2004	22.5	low	1	1	1	0	0
Hypoglycemia	0	1	2005	2005	19.0	low	1	0	1	0	0
Inflammation	0	4	2002	2023	11.2	low	0	0	2	0	2
Injury, Ischemia-Reperfusion	0	3	2021	2023	1.7	low	0	0	0	0	3
Injury, Myocardial Reperfusion	0	1	2014	2014	10.0	low	0	0	0	1	0
Innate Inflammatory Response	0	4	2002	2023	11.2	low	0	0	2	0	2
Insulin Resistance	0	3	1999	2006	21.0	low	0	1	2	0	0
Insulin Sensitivity	0	3	1999	2006	21.0	low	0	1	2	0	0
Interstitial Nephritis	0	1	2003	2003	21.0	low	0	0	1	0	0
Ischemia	0	1	2023	2023	1.0	low	0	0	0	0	1
Ischemic Attack, Transient	0	3	2006	2009	17.0	low	2	0	3	0	0
Kidney Diseases	1	6	2000	2008	20.5	low	0	1	5	0	0
Kidney Failure	0	2	1998	1999	25.5	low	1	2	0	0	0
Kidney Failure, Chronic	0	1	2004	2004	20.0	low	1	0	1	0	0
Left Ventricular Dysfunction	0	3	2003	2007	19.3	low	1	0	3	0	0
Left Ventricular Hypertrophy	0	2	1999	2004	22.5	low	1	1	1	0	0
Lung Diseases, Interstitial	0	1	2012	2012	12.0	low	0	0	0	1	0
Metabolic Syndrome	0	2	2008	2021	9.5	low	1	0	1	0	1
Neoplasms	0	3	2009	2023	8.3	low	0	0	1	1	1
Nephritis, Interstitial	0	1	2003	2003	21.0	low	0	0	1	0	0
Overweight	0	1	2009	2009	15.0	low	1	0	1	0	0
Proteinuria	0	4	1999	2003	23.2	low	0	2	2	0	0
Recrudescence	0	3	2003	2009	18.3	low	2	0	3	0	0
Renal Artery Obstruction	0	1	1992	1992	32.0	low	0	1	0	0	0
Renal Artery Stenosis	0	1	1992	1992	32.0	low	0	1	0	0	0
Renal Insufficiency	0	2	1998	1999	25.5	low	1	2	0	0	0
Renal Insufficiency, Chronic	0	1	2013	2013	11.0	low	1	0	0	1	0
Reperfusion Injury	0	3	2021	2023	1.7	low	0	0	0	0	3
Sensitivity and Specificity	0	3	2006	2011	16.0	low	0	0	2	1	0
Sleep Disorders, Circadian Rhythm	0	1	2012	2012	12.0	low	0	0	0	1	0
Stroke	0	19	2000	2009	18.6	low	5	1	18	0	0
Thrombophilia	0	1	2013	2013	11.0	low	1	0	0	1	0
Thrombosis	0	1	2002	2002	22.0	low	0	0	1	0	0
Vasculitis	0	2	2002	2004	21.0	low	0	0	2	0	0
Ventricular Dysfunction	0	1	2010	2010	14.0	low	1	0	1	0	0
Ventricular Dysfunction, Left	0	3	2003	2007	19.3	low	1	0	3	0	0
Zika Virus Infection	0	1	2020	2020	4.0	low	0	0	0	1	0

Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Proceedings of the National Academy of Sciences of the United States of America, , 12-08, Volume: 117, Issue:49, 2020

Acute eprosartan-induced intrarenal vasodilation in hypertensive humans is not influenced by dietary sodium intake or angiotensin II co-infusion.
Journal of hypertension, , Volume: 34, Issue:8, 2016

[Antihypertensive treatment with eprosartan mesilate of patients in acute and late periods of ischemic stroke].
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, , Volume: 103, Issue:11, 2003

Different prejunctional and postjunctional responses to angiotensin II and AT1-receptor inhibition: influence of maturation.
Journal of cardiovascular pharmacology, , Volume: 43, Issue:3, 2004

Effect of age and gender on the pharmacokinetics of eprosartan.
British journal of clinical pharmacology, , Volume: 46, Issue:3, 1998

ATR1 Angiotensin II Receptor Reduces Hemoglobin S Polymerization, Phosphatidylserine Exposure, and Increases Deformability of Sickle Cell Disease Erythrocytes.
Cell biochemistry and biophysics, , Volume: 80, Issue:4, 2022

Can angiotensin II receptor blockers be used in patients who have developed a cough or angioedema as a result of taking an ACE inhibitor?
Cleveland Clinic journal of medicine, , Volume: 68, Issue:3, 2001

Drug points: Dysgeusia and burning mouth syndrome by eprosartan.
BMJ (Clinical research ed.), , Nov-30, Volume: 325, Issue:7375, 2002

KARAPANDZIC FLAP FOR SQUAMOUS CELL CARCINOMA OF THE LOWER LIPP: POTENTIAL ROLE OF NITROSAMINES IN EPROSARTAN AS CANCER TRIGGERING FACTORS.
Georgian medical news, , Issue:334, 2023

Design and methodology of POWER, an open-label observation of the effect of primary care interventions on total cardiovascular risk in patients with hypertension.
Fundamental & clinical pharmacology, , Volume: 27, Issue:2, 2013

Effect of eprosartan-based therapy on systolic blood pressure and total cardiovascular risk in a large international population: preliminary report of the observational POWER study.
Vascular health and risk management, , Volume: 8, 2012

Cost-utility analysis of eprosartan compared to enalapril in primary prevention and nitrendipine in secondary prevention in Europe--the HEALTH model.
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, , Volume: 12, Issue:6, 2009

Eprosartan: a review of its use in hypertension.
Drugs, , Volume: 69, Issue:17, 2009

Introduction: The pharmacological profile of eprosartan--implications for cerebrovascular and cardiovascular risk reduction.
Current medical research and opinion, , Volume: 23 Suppl 5, 2007

Unique dual mechanism of action of eprosartan: effects on systolic blood pressure, pulse pressure, risk of stroke and cognitive decline.
Expert review of cardiovascular therapy, , Volume: 5, Issue:6, 2007

Morbidity and mortality after stroke--eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES).
Stroke, , Volume: 37, Issue:2, 2006

Preventing cerebrovascular and cardiovascular events after stroke: eprosartan or nitrendipine?
Nature clinical practice. Neurology, , Volume: 2, Issue:1, 2006

[Stress-associated hypertension in the work place: results of the STARLET project].
Deutsche medizinische Wochenschrift (1946), , Nov-17, Volume: 131, Issue:46, 2006

Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES).
Stroke, , Volume: 36, Issue:6, 2005

Effect of eprosartan on pulse pressure and blood pressure components in patients with isolated systolic hypertension.
Blood pressure. Supplement, , Volume: 2, 2004

Clinical profile of eprosartan.
Cardiovascular drugs and therapy, , Volume: 16, Issue:6, 2002

Expanded role for ARBs in cardiovascular and renal disease? Recent observations have far-reaching implications.
Postgraduate medicine, , Volume: 109, Issue:4, 2001

Safety and efficacy of eprosartan, a new angiotensin II receptor blocker.
American heart journal, , Volume: 138, Issue:3 Pt 2, 1999

Angiotensin receptor blockade and arterial compliance in chronic kidney disease: a pilot study.
American journal of nephrology, , Volume: 25, Issue:4

Celiac disease-like enteropathy due to antihypertensive therapy with the angiotensin-II receptor type 1 inhibitor eprosartan.
Ceskoslovenska patologie, , Volume: 51, Issue:2, 2015

[Cerebral hemodynamics and endothelium function in patients with cerebrovascular pathology treated by teveten].
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, , Issue:Suppl 13, 2005

Angiotensin receptor blockers and secondary stroke prevention: the MOSES study.
Expert review of cardiovascular therapy, , Volume: 7, Issue:5, 2009

Morbidity and mortality after stroke--eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES).
Stroke, , Volume: 37, Issue:2, 2006

MOSES raises questions.
Stroke, , Volume: 37, Issue:2, 2006

Eprosartan: A closer insight into its neuroprotective activity in rats with focal cerebral ischemia-reperfusion injury.
Journal of biochemical and molecular toxicology, , Volume: 35, Issue:7, 2021

Introduction: The pharmacological profile of eprosartan--implications for cerebrovascular and cardiovascular risk reduction.
Current medical research and opinion, , Volume: 23 Suppl 5, 2007

Pharmacology of eprosartan, an angiotensin II receptor antagonist: exploring hypotheses from clinical data.
American heart journal, , Volume: 138, Issue:3 Pt 2, 1999

Effects of different AT1-receptor antagonists in the therapy of severe heart failure pretreated with ACE inhibitors.
Acta cardiologica, , Volume: 62, Issue:4, 2007

[Effect of a combination of teveten and prestarium in patients with chronic heart failure].
Georgian medical news, , Issue:123, 2005

Angiotensin receptor blockade and arterial compliance in chronic kidney disease: a pilot study.
American journal of nephrology, , Volume: 25, Issue:4

Emerging role of angiotensin II type 1 receptor blockers for the treatment of endothelial dysfunction and vascular inflammation.
The Canadian journal of cardiology, , Volume: 18, Issue:12, 2002

Effect of eprosartan-based antihypertensive therapy on coronary heart disease risk assessed by Framingham methodology in Canadian patients: results of the POWER survey.
Vascular health and risk management, , Volume: 10, 2014

[Therapy of hypertension. Why the systolic value is decisive].
MMW Fortschritte der Medizin, , Jun-06, Volume: 144, Issue:23, 2002

Teveten (eprosartan) reduces future risk in hypertensive stroke patients.
Cardiovascular journal of South Africa : official journal for Southern Africa Cardiac Society [and] South African Society of Cardiac Practitioners, , Volume: 15, Issue:5

Eprosartan: a review of its use in hypertension.
Drugs, , Volume: 69, Issue:17, 2009

Comparison of quality of life and cough on eprosartan and enalapril in people with moderate hypertension.
Journal of human hypertension, , Volume: 15, Issue:12, 2001

Quality of life and cough on antihypertensive treatment: a randomised trial of eprosartan, enalapril and placebo.
Journal of human hypertension, , Volume: 15, Issue:12, 2001

Can angiotensin II receptor blockers be used in patients who have developed a cough or angioedema as a result of taking an ACE inhibitor?
Cleveland Clinic journal of medicine, , Volume: 68, Issue:3, 2001

Effect of eprosartan and enalapril in the treatment of elderly hypertensive patients: subgroup analysis of a 26-week, double-blind, multicentre study. Eprosartan Multinational Study Group.
Current medical research and opinion, , Volume: 15, Issue:1, 1999

Effect of eprosartan and enalapril in the treatment of black hypertensive patients: subgroup analysis of a 26-week, double-blind, multicentre study. Eprosartan Multinational Study Group.
Current medical research and opinion, , Volume: 15, Issue:1, 1999

Double-blind comparison of eprosartan and enalapril on cough and blood pressure in unselected hypertensive patients. Eprosartan Study Group.
Journal of human hypertension, , Volume: 13, Issue:6, 1999

Nonpeptide angiotensin II receptor antagonists: potential advantages over ACE inhibitors.
Proceedings of the Western Pharmacology Society, , Volume: 36, 1993

Emerging role of angiotensin II type 1 receptor blockers for the treatment of endothelial dysfunction and vascular inflammation.
The Canadian journal of cardiology, , Volume: 18, Issue:12, 2002

Formulation and design optimization of nano-transferosomes using pioglitazone and eprosartan mesylate for concomitant therapy against diabetes and hypertension.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, , Jul-01, Volume: 162, 2021

[An AT-II blocker in patients with type II diabetes and arterial hypertension].
Klinicheskaia meditsina, , Volume: 84, Issue:2, 2006

Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: a randomized, double-blind, placebo-controlled 12-month study.
Hypertension research : official journal of the Japanese Society of Hypertension, , Volume: 27, Issue:7, 2004

Eprosartan, an angiotensin II receptor antagonist, does not affect the pharmacodynamics of glyburide in patients with type II diabetes mellitus.
Journal of clinical pharmacology, , Volume: 37, Issue:2, 1997

Ameliorative effect of eprosartan on high-fat diet/streptozotocin-induced early diabetic nephropathy in rats.
European journal of pharmacology, , Mar-05, Volume: 750, 2015

[Candesartan - a novel AT(1)-angiotensin receptor blocker: peculiarities of pharmacology and experience of use in arterial hypertension].
Kardiologiia, , Volume: 44, Issue:1, 2004

Effect of angiotensin II antagonist eprosartan on hyperglycemia-induced activation of intrarenal renin-angiotensin system in healthy humans.
Hypertension (Dallas, Tex. : 1979), , Volume: 36, Issue:1, 2000

Plasma vascular endothelial growth factor, angiopoietin-2, and soluble angiopoietin receptor tie-2 in diabetic retinopathy: effects of laser photocoagulation and angiotensin receptor blockade.
The British journal of ophthalmology, , Volume: 88, Issue:12, 2004

Cardiology patient page. Angiotensin receptor blockers.
Circulation, , Jun-24, Volume: 107, Issue:24, 2003

Protective and therapeutic role of mango pulp and eprosartan drug and their anti-synergistic effects against thioacetamide-induced hepatotoxicity in male rats.
Environmental science and pollution research international, , Volume: 29, Issue:34, 2022

[The effectiveness of eprosartan in patients with chronic glomerulonephritis].
Klinicheskaia meditsina, , Volume: 85, Issue:8, 2007

Renal damage is not improved by blockade of endothelin receptors in primary renin-dependent hypertension.
Journal of hypertension, , Volume: 21, Issue:12, 2003

Effects of eprosartan on glomerular injury in rats with reduced renal mass.
Pharmacology, , Volume: 59, Issue:2, 1999

Effects of spironolactone and eprosartan on cardiac remodeling and angiotensin-converting enzyme isoforms in rats with experimental heart failure.
American journal of physiology. Heart and circulatory physiology, , Volume: 289, Issue:4, 2005

Eprosartan reduces cardiac hypertrophy, protects heart and kidney, and prevents early mortality in severely hypertensive stroke-prone rats.
Cardiovascular research, , Volume: 50, Issue:3, 2001

Effects of eprosartan on renal function and cardiac hypertrophy in rats with experimental heart failure.
Hypertension (Dallas, Tex. : 1979), , Volume: 32, Issue:4, 1998

Effects of different AT1-receptor antagonists in the therapy of severe heart failure pretreated with ACE inhibitors.
Acta cardiologica, , Volume: 62, Issue:4, 2007

[Effect of a combination of teveten and prestarium in patients with chronic heart failure].
Georgian medical news, , Issue:123, 2005

Effects of spironolactone and eprosartan on cardiac remodeling and angiotensin-converting enzyme isoforms in rats with experimental heart failure.
American journal of physiology. Heart and circulatory physiology, , Volume: 289, Issue:4, 2005

Cardiology patient page. Angiotensin receptor blockers.
Circulation, , Jun-24, Volume: 107, Issue:24, 2003

Impaired neuronal and vascular responses to angiotensin II in a rabbit congestive heart failure model.
Journal of the renin-angiotensin-aldosterone system : JRAAS, , Volume: 4, Issue:4, 2003

Effects of the AT1-receptor antagonist eprosartan on the progression of left ventricular dysfunction in dogs with heart failure.
British journal of pharmacology, , Volume: 138, Issue:2, 2003

Potential of the angiotensin II receptor 1 blocker eprosartan in the management of patients with hypertension or heart failure.
Current hypertension reports, , Volume: 3 Suppl 1, 2001

ADEPT: Addition of the AT1 receptor antagonist eprosartan to ACE inhibitor therapy in chronic heart failure trial: hemodynamic and neurohormonal effects.
American heart journal, , Volume: 141, Issue:5, 2001

Control of cardiomyocyte gene expression as drug target.
Molecular and cellular biochemistry, , Volume: 212, Issue:1-2, 2000

Improvement of cardiac output in patients with severe heart failure by use of ACE-inhibitors combined with the AT1-antagonist eprosartan.
European journal of heart failure, , Volume: 2, Issue:2, 2000

Effects of eprosartan on renal function and cardiac hypertrophy in rats with experimental heart failure.
Hypertension (Dallas, Tex. : 1979), , Volume: 32, Issue:4, 1998

Inhibiting the HIV integration process: past, present, and the future.
Journal of medicinal chemistry, , Feb-13, Volume: 57, Issue:3, 2014

Effect of angiotensin II antagonist eprosartan on hyperglycemia-induced activation of intrarenal renin-angiotensin system in healthy humans.
Hypertension (Dallas, Tex. : 1979), , Volume: 36, Issue:1, 2000

Effect of eprosartan on catecholamines and peripheral haemodynamics in subjects with insulin-induced hypoglycaemia.
Clinical science (London, England : 1979), , Volume: 108, Issue:2, 2005

PROTECTIVE EFFECT OF EPROSARTAN IN RENAL ISCHEMIA REPERFUSION INJURY BY REGULATING OXIDATIVE STRESS, INFLAMMATION, AND APOPTOTIC CASCADES IN A BILATERAL RAT MODEL.
Wiadomosci lekarskie (Warsaw, Poland : 1960), , Volume: 76, Issue:7, 2023

Protective and therapeutic role of mango pulp and eprosartan drug and their anti-synergistic effects against thioacetamide-induced hepatotoxicity in male rats.
Environmental science and pollution research international, , Volume: 29, Issue:34, 2022

Heat shock treatment protects against angiotensin II-induced hypertension and inflammation in aorta.
Cell stress & chaperones, , Volume: 9, Issue:1, 2004

Effects of eprosartan versus hydrochlorothiazide on markers of vascular oxidation and inflammation and blood pressure (renin-angiotensin system antagonists, oxidation, and inflammation).
The American journal of cardiology, , Mar-15, Volume: 89, Issue:6, 2002

[An AT-II blocker in patients with type II diabetes and arterial hypertension].
Klinicheskaia meditsina, , Volume: 84, Issue:2, 2006

Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity.
Circulation, , May-04, Volume: 109, Issue:17, 2004

ACE inhibition and glucose transport in insulinresistant muscle: roles of bradykinin and nitric oxide.
The American journal of physiology, , Volume: 277, Issue:1, 1999

Protective effect of Eprosartan against ischemic acute renal injury: Acting on NF-κB, caspase 3, and Sirtuin 1.
International immunopharmacology, , Volume: 115, 2023

Clinical profile of eprosartan: a different angiotensin II receptor blocker.
Cardiovascular & hematological agents in medicinal chemistry, , Volume: 6, Issue:4, 2008

Angiotensin blockade with eprosartan: vascular and functional implications.
Current medical research and opinion, , Volume: 23 Suppl 5, 2007

Cardiology patient page. Angiotensin receptor blockers.
Circulation, , Jun-24, Volume: 107, Issue:24, 2003

The angiotensin type 1 receptor antagonist, eprosartan, attenuates the progression of renal disease in spontaneously hypertensive stroke-prone rats with accelerated hypertension.
The Journal of pharmacology and experimental therapeutics, , Volume: 301, Issue:1, 2002

Expanded role for ARBs in cardiovascular and renal disease? Recent observations have far-reaching implications.
Postgraduate medicine, , Volume: 109, Issue:4, 2001

Gene expression in rats with renal disease treated with the angiotensin II receptor antagonist, eprosartan.
Physiological genomics, , Nov-09, Volume: 4, Issue:1, 2000

Potential renoprotective effects of the angiotensin receptor blocker eprosartan: a review of preliminary renal studies.
Cardiovascular journal of South Africa : official journal for Southern Africa Cardiac Society [and] South African Society of Cardiac Practitioners, , Volume: 15, Issue:1

Angiotensin receptor blockade and arterial compliance in chronic kidney disease: a pilot study.
American journal of nephrology, , Volume: 25, Issue:4

Moxonidine normalizes sympathetic hyperactivity in patients with eprosartan-treated chronic renal failure.
Journal of the American Society of Nephrology : JASN, , Volume: 15, Issue:11, 2004

Effect of hepatic disease on the pharmacokinetics and plasma protein binding of eprosartan.
Pharmacotherapy, , Volume: 18, Issue:1

Exploring the possibility of drug repurposing for cancer therapy targeting human lactate dehydrogenase A: a computational approach.
Journal of biomolecular structure & dynamics, , Volume: 41, Issue:19, 2023

A self-assembled system for tumor-targeted co-delivery of drug and gene.
Materials science & engineering. C, Materials for biological applications, , Nov-01, Volume: 56, 2015

Effect of the multitargeted receptor tyrosine kinase inhibitor, ABT-869 [N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N'-(2-fluoro-5-methylphenyl)urea], on blood pressure in conscious rats and mice: reversal with antihypertensive agents and effect on tumor growt
The Journal of pharmacology and experimental therapeutics, , Volume: 329, Issue:3, 2009

Renal damage is not improved by blockade of endothelin receptors in primary renin-dependent hypertension.
Journal of hypertension, , Volume: 21, Issue:12, 2003

Eprosartan dual action offers clinical benefit for elderly and overweight hypertensives.
Cardiovascular journal of South Africa : official journal for Southern Africa Cardiac Society [and] South African Society of Cardiac Practitioners, , Volume: 15, Issue:2

Renal damage is not improved by blockade of endothelin receptors in primary renin-dependent hypertension.
Journal of hypertension, , Volume: 21, Issue:12, 2003

Eprosartan reduces cardiac hypertrophy, protects heart and kidney, and prevents early mortality in severely hypertensive stroke-prone rats.
Cardiovascular research, , Volume: 50, Issue:3, 2001

Gene expression in rats with renal disease treated with the angiotensin II receptor antagonist, eprosartan.
Physiological genomics, , Nov-09, Volume: 4, Issue:1, 2000

Effects of eprosartan on glomerular injury in rats with reduced renal mass.
Pharmacology, , Volume: 59, Issue:2, 1999

Effect of captopril and the nonpeptide angiotensin II antagonists, SK&F 108566 and EXP3174, on renal function in dogs with a renal artery stenosis.
The Journal of pharmacology and experimental therapeutics, , Volume: 263, Issue:2, 1992

CYP2C9-mediated metabolic activation of losartan detected by a highly sensitive cell-based screening assay.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 39, Issue:5, 2011

Unique dual mechanism of action of eprosartan: effects on systolic blood pressure, pulse pressure, risk of stroke and cognitive decline.
Expert review of cardiovascular therapy, , Volume: 5, Issue:6, 2007

Validation of a solid phase extraction-high performance liquid chromatographic method for the determination of eprosartan in human plasma.
Journal of chromatography. A, , Jun-30, Volume: 1119, Issue:1-2, 2006

Liquid chromatographic method for the simultaneous determination of eprosartan and hydrochlorothiazide in tablets and human plasma.
Journal of AOAC International, , Volume: 94, Issue:3

The angiotensin type 1 receptor antagonist, eprosartan, attenuates the progression of renal disease in spontaneously hypertensive stroke-prone rats with accelerated hypertension.
The Journal of pharmacology and experimental therapeutics, , Volume: 301, Issue:1, 2002

Eprosartan in the primary prevention of cardiac allograft vascular disease: a double-blind prospectively randomized study using intravascular ultrasound.
The Journal of international medical research, , Volume: 36, Issue:5

Eprosartan improves cardiac performance, reduces cardiac hypertrophy and mortality and downregulates myocardial monocyte chemoattractant protein-1 and inflammation in hypertensive heart disease.
Journal of hypertension, , Volume: 22, Issue:3, 2004

Emerging role of angiotensin II type 1 receptor blockers for the treatment of endothelial dysfunction and vascular inflammation.
The Canadian journal of cardiology, , Volume: 18, Issue:12, 2002

Observational Study on Cognitive function And systolic blood pressure Reduction (OSCAR): preliminary analysis of 6-month data from > 10,000 patients and review of the literature.
Current medical research and opinion, , Volume: 23 Suppl 5, 2007

Protective effect of Eprosartan against ischemic acute renal injury: Acting on NF-κB, caspase 3, and Sirtuin 1.
International immunopharmacology, , Volume: 115, 2023

PROTECTIVE EFFECT OF EPROSARTAN IN RENAL ISCHEMIA REPERFUSION INJURY BY REGULATING OXIDATIVE STRESS, INFLAMMATION, AND APOPTOTIC CASCADES IN A BILATERAL RAT MODEL.
Wiadomosci lekarskie (Warsaw, Poland : 1960), , Volume: 76, Issue:7, 2023

Eprosartan: A closer insight into its neuroprotective activity in rats with focal cerebral ischemia-reperfusion injury.
Journal of biochemical and molecular toxicology, , Volume: 35, Issue:7, 2021

Inhibiting the HIV integration process: past, present, and the future.
Journal of medicinal chemistry, , Feb-13, Volume: 57, Issue:3, 2014

Eprosartan improves cardiac performance, reduces cardiac hypertrophy and mortality and downregulates myocardial monocyte chemoattractant protein-1 and inflammation in hypertensive heart disease.
Journal of hypertension, , Volume: 22, Issue:3, 2004

Effect of long-term eprosartan versus enalapril antihypertensive therapy on left ventricular mass and coronary flow reserve in stage I-II hypertension. Eprosartan Study Group.
Current medical research and opinion, , Volume: 15, Issue:1, 1999

Interstitial pneumonitis secondary to eprosartan.
Archivos de bronconeumologia, , Volume: 48, Issue:12, 2012

Angiotensin blockade with eprosartan: vascular and functional implications.
Current medical research and opinion, , Volume: 23 Suppl 5, 2007

[Comparison of eprosartan and captopril in left ventricular systolic dysfunction: relation of efficacy to myocardial viability].
Kardiologiia, , Volume: 44, Issue:1, 2004

Effects of the AT1-receptor antagonist eprosartan on the progression of left ventricular dysfunction in dogs with heart failure.
British journal of pharmacology, , Volume: 138, Issue:2, 2003

[Effect of eprosartan on the hemostatic system in patients with chronic kidney disease associated with hereditary thrombophilia].
Terapevticheskii arkhiv, , Volume: 85, Issue:9, 2013

[The use of melatonin for correction of sleep disturbances in assembly-line shift workers with arterial hypertension].
Klinicheskaia meditsina, , Volume: 90, Issue:3, 2012

Hemodynamic and cardiac effects of chronic eprosartan and moxonidine therapy in stroke-prone spontaneously hypertensive rats.
Hypertension (Dallas, Tex. : 1979), , Volume: 53, Issue:5, 2009

Angiotensin receptor blockers and secondary stroke prevention: the MOSES study.
Expert review of cardiovascular therapy, , Volume: 7, Issue:5, 2009

Cost-utility analysis of eprosartan compared to enalapril in primary prevention and nitrendipine in secondary prevention in Europe--the HEALTH model.
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, , Volume: 12, Issue:6, 2009

Risk reduction by preventing stroke: need for blockade of angiotensin II and catecholamines?
Current medical research and opinion, , Volume: 23 Suppl 5, 2007

Observational Study on Cognitive function And systolic blood pressure Reduction (OSCAR): preliminary analysis of 6-month data from > 10,000 patients and review of the literature.
Current medical research and opinion, , Volume: 23 Suppl 5, 2007

Unique dual mechanism of action of eprosartan: effects on systolic blood pressure, pulse pressure, risk of stroke and cognitive decline.
Expert review of cardiovascular therapy, , Volume: 5, Issue:6, 2007

Does the MOSES study provide sufficient evidence for Eprosartan against Nitrendipine?
Stroke, , Volume: 37, Issue:6, 2006

Morbidity and mortality after stroke--eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES).
Stroke, , Volume: 37, Issue:2, 2006

MOSES raises questions.
Stroke, , Volume: 37, Issue:2, 2006

Preventing cerebrovascular and cardiovascular events after stroke: eprosartan or nitrendipine?
Nature clinical practice. Neurology, , Volume: 2, Issue:1, 2006

[Not all antihypertensive agents protect equally well].
MMW Fortschritte der Medizin, , Aug-17, Volume: 148, Issue:33-34, 2006

Effects of eprosartan on target organ protection.
Vascular health and risk management, , Volume: 2, Issue:1, 2006

Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES).
Stroke, , Volume: 36, Issue:6, 2005

Analysis of recent papers in hypertension. An angiotensin receptor blocker is more effective than a calcium channel blocker in secondary stroke prevention.
Journal of clinical hypertension (Greenwich, Conn.), , Volume: 7, Issue:8, 2005

[Antihypertensive treatment with eprosartan mesilate of patients in acute and late periods of ischemic stroke].
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, , Volume: 103, Issue:11, 2003

[Therapy of hypertension. Why the systolic value is decisive].
MMW Fortschritte der Medizin, , Jun-06, Volume: 144, Issue:23, 2002

The angiotensin type 1 receptor antagonist, eprosartan, attenuates the progression of renal disease in spontaneously hypertensive stroke-prone rats with accelerated hypertension.
The Journal of pharmacology and experimental therapeutics, , Volume: 301, Issue:1, 2002

Eprosartan reduces cardiac hypertrophy, protects heart and kidney, and prevents early mortality in severely hypertensive stroke-prone rats.
Cardiovascular research, , Volume: 50, Issue:3, 2001

[Stroke prevention. Is there an added value to RAS inhibition?].
MMW Fortschritte der Medizin, , Feb-10, Volume: 142, Issue:6, 2000

Eprosartan (Teveten) offers new opportunities to prevent a second stroke.
Cardiovascular journal of South Africa : official journal for Southern Africa Cardiac Society [and] South African Society of Cardiac Practitioners, , Volume: 16, Issue:1

Teveten (eprosartan) reduces future risk in hypertensive stroke patients.
Cardiovascular journal of South Africa : official journal for Southern Africa Cardiac Society [and] South African Society of Cardiac Practitioners, , Volume: 15, Issue:5

Eprosartan in secondary prevention of stroke: the economic evidence.
Cardiovascular journal of Africa, , Volume: 18, Issue:2

Losartan and Eprosartan Induce a Similar Effect on the Acute Rise in Serum Uric Acid Concentration after an Oral Fructose Load in Patients with Metabolic Syndrome.
Journal of the renin-angiotensin-aldosterone system : JRAAS, , Volume: 2021, 2021

[Effect of eprosartan on thrombocytes aggregative capacity in patients with arterial hypertension and metabolic syndrome].
Klinicheskaia meditsina, , Volume: 86, Issue:4, 2008

Angiotensin blockade with eprosartan: vascular and functional implications.
Current medical research and opinion, , Volume: 23 Suppl 5, 2007

[Effect of eprosartan on the hemostatic system in patients with chronic kidney disease associated with hereditary thrombophilia].
Terapevticheskii arkhiv, , Volume: 85, Issue:9, 2013

Pharmacokinetics and protein binding of eprosartan in hemodialysis-dependent patients with end-stage renal disease.
Pharmacotherapy, , Volume: 19, Issue:5, 1999

Pharmacokinetics and protein binding of eprosartan in healthy volunteers and in patients with varying degrees of renal impairment.
Journal of clinical pharmacology, , Volume: 38, Issue:2, 1998

Protective and therapeutic role of mango pulp and eprosartan drug and their anti-synergistic effects against thioacetamide-induced hepatotoxicity in male rats.
Environmental science and pollution research international, , Volume: 29, Issue:34, 2022

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
PLoS computational biology, , Volume: 7, Issue:12, 2011

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Protective effect of Eprosartan against ischemic acute renal injury: Acting on NF-κB, caspase 3, and Sirtuin 1.
International immunopharmacology, , Volume: 115, 2023

Nonpeptide angiotensin II receptor antagonists: potential advantages over ACE inhibitors.
Proceedings of the Western Pharmacology Society, , Volume: 36, 1993

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
PLoS computational biology, , Volume: 7, Issue:12, 2011

Eprosartan improves cardiac performance, reduces cardiac hypertrophy and mortality and downregulates myocardial monocyte chemoattractant protein-1 and inflammation in hypertensive heart disease.
Journal of hypertension, , Volume: 22, Issue:3, 2004

Effect of long-term eprosartan versus enalapril antihypertensive therapy on left ventricular mass and coronary flow reserve in stage I-II hypertension. Eprosartan Study Group.
Current medical research and opinion, , Volume: 15, Issue:1, 1999

Interstitial pneumonitis secondary to eprosartan.
Archivos de bronconeumologia, , Volume: 48, Issue:12, 2012

Effects of the AT1-receptor antagonist eprosartan on the progression of left ventricular dysfunction in dogs with heart failure.
British journal of pharmacology, , Volume: 138, Issue:2, 2003

The angiotensin type 1 receptor antagonist, eprosartan, attenuates the progression of renal disease in spontaneously hypertensive stroke-prone rats with accelerated hypertension.
The Journal of pharmacology and experimental therapeutics, , Volume: 301, Issue:1, 2002

Angiotensin blockade with eprosartan: vascular and functional implications.
Current medical research and opinion, , Volume: 23 Suppl 5, 2007

[Comparison of eprosartan and captopril in left ventricular systolic dysfunction: relation of efficacy to myocardial viability].
Kardiologiia, , Volume: 44, Issue:1, 2004

Effects of the AT1-receptor antagonist eprosartan on the progression of left ventricular dysfunction in dogs with heart failure.
British journal of pharmacology, , Volume: 138, Issue:2, 2003

Effects of eprosartan on diastolic function and neurohormones in patients with hypertension and diastolic dysfunction.
Cardiovascular drugs and therapy, , Volume: 24, Issue:1, 2010

[Effect of eprosartan on the hemostatic system in patients with chronic kidney disease associated with hereditary thrombophilia].
Terapevticheskii arkhiv, , Volume: 85, Issue:9, 2013

[The use of melatonin for correction of sleep disturbances in assembly-line shift workers with arterial hypertension].
Klinicheskaia meditsina, , Volume: 90, Issue:3, 2012

Effects of spironolactone and eprosartan on cardiac remodeling and angiotensin-converting enzyme isoforms in rats with experimental heart failure.
American journal of physiology. Heart and circulatory physiology, , Volume: 289, Issue:4, 2005

Eprosartan reduces cardiac hypertrophy, protects heart and kidney, and prevents early mortality in severely hypertensive stroke-prone rats.
Cardiovascular research, , Volume: 50, Issue:3, 2001

Hemodynamic and cardiac effects of chronic eprosartan and moxonidine therapy in stroke-prone spontaneously hypertensive rats.
Hypertension (Dallas, Tex. : 1979), , Volume: 53, Issue:5, 2009

Angiotensin receptor blockers and secondary stroke prevention: the MOSES study.
Expert review of cardiovascular therapy, , Volume: 7, Issue:5, 2009

Cost-utility analysis of eprosartan compared to enalapril in primary prevention and nitrendipine in secondary prevention in Europe--the HEALTH model.
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, , Volume: 12, Issue:6, 2009

Observational Study on Cognitive function And systolic blood pressure Reduction (OSCAR): preliminary analysis of 6-month data from > 10,000 patients and review of the literature.
Current medical research and opinion, , Volume: 23 Suppl 5, 2007

Risk reduction by preventing stroke: need for blockade of angiotensin II and catecholamines?
Current medical research and opinion, , Volume: 23 Suppl 5, 2007

Unique dual mechanism of action of eprosartan: effects on systolic blood pressure, pulse pressure, risk of stroke and cognitive decline.
Expert review of cardiovascular therapy, , Volume: 5, Issue:6, 2007

MOSES raises questions.
Stroke, , Volume: 37, Issue:2, 2006

Effects of eprosartan on target organ protection.
Vascular health and risk management, , Volume: 2, Issue:1, 2006

Does the MOSES study provide sufficient evidence for Eprosartan against Nitrendipine?
Stroke, , Volume: 37, Issue:6, 2006

Preventing cerebrovascular and cardiovascular events after stroke: eprosartan or nitrendipine?
Nature clinical practice. Neurology, , Volume: 2, Issue:1, 2006

[Not all antihypertensive agents protect equally well].
MMW Fortschritte der Medizin, , Aug-17, Volume: 148, Issue:33-34, 2006

Morbidity and mortality after stroke--eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES).
Stroke, , Volume: 37, Issue:2, 2006

Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES).
Stroke, , Volume: 36, Issue:6, 2005

Analysis of recent papers in hypertension. An angiotensin receptor blocker is more effective than a calcium channel blocker in secondary stroke prevention.
Journal of clinical hypertension (Greenwich, Conn.), , Volume: 7, Issue:8, 2005

[Antihypertensive treatment with eprosartan mesilate of patients in acute and late periods of ischemic stroke].
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, , Volume: 103, Issue:11, 2003

[Therapy of hypertension. Why the systolic value is decisive].
MMW Fortschritte der Medizin, , Jun-06, Volume: 144, Issue:23, 2002

The angiotensin type 1 receptor antagonist, eprosartan, attenuates the progression of renal disease in spontaneously hypertensive stroke-prone rats with accelerated hypertension.
The Journal of pharmacology and experimental therapeutics, , Volume: 301, Issue:1, 2002

Eprosartan reduces cardiac hypertrophy, protects heart and kidney, and prevents early mortality in severely hypertensive stroke-prone rats.
Cardiovascular research, , Volume: 50, Issue:3, 2001

[Stroke prevention. Is there an added value to RAS inhibition?].
MMW Fortschritte der Medizin, , Feb-10, Volume: 142, Issue:6, 2000

Eprosartan (Teveten) offers new opportunities to prevent a second stroke.
Cardiovascular journal of South Africa : official journal for Southern Africa Cardiac Society [and] South African Society of Cardiac Practitioners, , Volume: 16, Issue:1

Teveten (eprosartan) reduces future risk in hypertensive stroke patients.
Cardiovascular journal of South Africa : official journal for Southern Africa Cardiac Society [and] South African Society of Cardiac Practitioners, , Volume: 15, Issue:5

Eprosartan in secondary prevention of stroke: the economic evidence.
Cardiovascular journal of Africa, , Volume: 18, Issue:2

Losartan and Eprosartan Induce a Similar Effect on the Acute Rise in Serum Uric Acid Concentration after an Oral Fructose Load in Patients with Metabolic Syndrome.
Journal of the renin-angiotensin-aldosterone system : JRAAS, , Volume: 2021, 2021

[Effect of eprosartan on thrombocytes aggregative capacity in patients with arterial hypertension and metabolic syndrome].
Klinicheskaia meditsina, , Volume: 86, Issue:4, 2008

Effectiveness of eprosartan in diabetic hypertensive patients.
European journal of internal medicine, , Volume: 19, Issue:1, 2008

[Anti-hypertensive effect of eprosartan in diabetic patients].
Anales de medicina interna (Madrid, Spain : 1984), , Volume: 21, Issue:5, 2004

Comparative effects of telmisartan and eprosartan on insulin sensitivity in the treatment of overweight hypertensive patients.
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, , Volume: 41, Issue:12, 2009

Angiotensin blockade with eprosartan: vascular and functional implications.
Current medical research and opinion, , Volume: 23 Suppl 5, 2007

[Effect of eprosartan on the hemostatic system in patients with chronic kidney disease associated with hereditary thrombophilia].
Terapevticheskii arkhiv, , Volume: 85, Issue:9, 2013

Pharmacokinetics and protein binding of eprosartan in hemodialysis-dependent patients with end-stage renal disease.
Pharmacotherapy, , Volume: 19, Issue:5, 1999

Pharmacokinetics and protein binding of eprosartan in healthy volunteers and in patients with varying degrees of renal impairment.
Journal of clinical pharmacology, , Volume: 38, Issue:2, 1998

Protective and therapeutic role of mango pulp and eprosartan drug and their anti-synergistic effects against thioacetamide-induced hepatotoxicity in male rats.
Environmental science and pollution research international, , Volume: 29, Issue:34, 2022

DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Drug discovery today, , Volume: 21, Issue:4, 2016

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
PLoS computational biology, , Volume: 7, Issue:12, 2011

Developing structure-activity relationships for the prediction of hepatotoxicity.
Chemical research in toxicology, , Jul-19, Volume: 23, Issue:7, 2010

Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 118, Issue:2, 2010

A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 38, Issue:12, 2010

Protective effect of Eprosartan against ischemic acute renal injury: Acting on NF-κB, caspase 3, and Sirtuin 1.
International immunopharmacology, , Volume: 115, 2023

Nonpeptide angiotensin II receptor antagonists: potential advantages over ACE inhibitors.
Proceedings of the Western Pharmacology Society, , Volume: 36, 1993

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013

Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
PLoS computational biology, , Volume: 7, Issue:12, 2011

Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Proceedings of the National Academy of Sciences of the United States of America, , 12-08, Volume: 117, Issue:49, 2020

Acute eprosartan-induced intrarenal vasodilation in hypertensive humans is not influenced by dietary sodium intake or angiotensin II co-infusion.
Journal of hypertension, , Volume: 34, Issue:8, 2016

ATR1 Angiotensin II Receptor Reduces Hemoglobin S Polymerization, Phosphatidylserine Exposure, and Increases Deformability of Sickle Cell Disease Erythrocytes.
Cell biochemistry and biophysics, , Volume: 80, Issue:4, 2022

Can angiotensin II receptor blockers be used in patients who have developed a cough or angioedema as a result of taking an ACE inhibitor?
Cleveland Clinic journal of medicine, , Volume: 68, Issue:3, 2001

Effects of spironolactone and eprosartan on cardiac remodeling and angiotensin-converting enzyme isoforms in rats with experimental heart failure.
American journal of physiology. Heart and circulatory physiology, , Volume: 289, Issue:4, 2005

Differentiation in the angiotensin II receptor 1 blocker class on autonomic function.
Current hypertension reports, , Volume: 3 Suppl 1, 2001

The angiotensin type 1 receptor antagonist, eprosartan, attenuates the progression of renal disease in spontaneously hypertensive stroke-prone rats with accelerated hypertension.
The Journal of pharmacology and experimental therapeutics, , Volume: 301, Issue:1, 2002

Central inhibition of AT1receptors by eprosartan--in vitro autoradiography in the brain.
Pharmacological research, , Volume: 43, Issue:3, 2001

Eprosartan reduces cardiac hypertrophy, protects heart and kidney, and prevents early mortality in severely hypertensive stroke-prone rats.
Cardiovascular research, , Volume: 50, Issue:3, 2001

KARAPANDZIC FLAP FOR SQUAMOUS CELL CARCINOMA OF THE LOWER LIPP: POTENTIAL ROLE OF NITROSAMINES IN EPROSARTAN AS CANCER TRIGGERING FACTORS.
Georgian medical news, , Issue:334, 2023

Celiac disease-like enteropathy due to antihypertensive therapy with the angiotensin-II receptor type 1 inhibitor eprosartan.
Ceskoslovenska patologie, , Volume: 51, Issue:2, 2015

[Cerebral hemodynamics and endothelium function in patients with cerebrovascular pathology treated by teveten].
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, , Issue:Suppl 13, 2005

Angiotensin receptor blockers and secondary stroke prevention: the MOSES study.
Expert review of cardiovascular therapy, , Volume: 7, Issue:5, 2009

MOSES raises questions.
Stroke, , Volume: 37, Issue:2, 2006

Morbidity and mortality after stroke--eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES).
Stroke, , Volume: 37, Issue:2, 2006

Eprosartan: A closer insight into its neuroprotective activity in rats with focal cerebral ischemia-reperfusion injury.
Journal of biochemical and molecular toxicology, , Volume: 35, Issue:7, 2021

Introduction: The pharmacological profile of eprosartan--implications for cerebrovascular and cardiovascular risk reduction.
Current medical research and opinion, , Volume: 23 Suppl 5, 2007

Pharmacology of eprosartan, an angiotensin II receptor antagonist: exploring hypotheses from clinical data.
American heart journal, , Volume: 138, Issue:3 Pt 2, 1999

Effects of different AT1-receptor antagonists in the therapy of severe heart failure pretreated with ACE inhibitors.
Acta cardiologica, , Volume: 62, Issue:4, 2007

[Effect of a combination of teveten and prestarium in patients with chronic heart failure].
Georgian medical news, , Issue:123, 2005

Angiotensin receptor blockade and arterial compliance in chronic kidney disease: a pilot study.
American journal of nephrology, , Volume: 25, Issue:4

Effects of hypertension therapy based on eprosartan on systolic arterial blood pressure and cognitive function: primary results of the Observational Study on Cognitive function And Systolic Blood Pressure Reduction open-label study.
Journal of hypertension, , Volume: 26, Issue:8, 2008

Observational Study on Cognitive function And systolic blood pressure Reduction (OSCAR): preliminary analysis of 6-month data from > 10,000 patients and review of the literature.
Current medical research and opinion, , Volume: 23 Suppl 5, 2007

Unique dual mechanism of action of eprosartan: effects on systolic blood pressure, pulse pressure, risk of stroke and cognitive decline.
Expert review of cardiovascular therapy, , Volume: 5, Issue:6, 2007

Rationale, design and methods of the OSCAR study: observational study on cognitive function and systolic blood pressure reduction in hypertensive patients.
Fundamental & clinical pharmacology, , Volume: 21, Issue:2, 2007

Emerging role of angiotensin II type 1 receptor blockers for the treatment of endothelial dysfunction and vascular inflammation.
The Canadian journal of cardiology, , Volume: 18, Issue:12, 2002

Effect of eprosartan-based antihypertensive therapy on coronary heart disease risk assessed by Framingham methodology in Canadian patients: results of the POWER survey.
Vascular health and risk management, , Volume: 10, 2014

[Therapy of hypertension. Why the systolic value is decisive].
MMW Fortschritte der Medizin, , Jun-06, Volume: 144, Issue:23, 2002

Teveten (eprosartan) reduces future risk in hypertensive stroke patients.
Cardiovascular journal of South Africa : official journal for Southern Africa Cardiac Society [and] South African Society of Cardiac Practitioners, , Volume: 15, Issue:5

Inhibition of facilitation of sympathetic neurotransmission and angiotensin II-induced pressor effects in the pithed rat: comparison between valsartan, candesartan, eprosartan and embusartan.
Journal of hypertension, , Volume: 19, Issue:12, 2001

Inhibition of sympathetic outflow by the angiotensin II receptor antagonist, eprosartan, but not by losartan, valsartan or irbesartan: relationship to differences in prejunctional angiotensin II receptor blockade.
Pharmacology, , Volume: 55, Issue:5, 1997

The antihypertensive effect of the angiotensin II receptor antagonist DuP 753 may not be due solely to angiotensin II receptor antagonism.
The Journal of pharmacology and experimental therapeutics, , Volume: 262, Issue:2, 1992

Formulation and design optimization of nano-transferosomes using pioglitazone and eprosartan mesylate for concomitant therapy against diabetes and hypertension.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, , Jul-01, Volume: 162, 2021

[An AT-II blocker in patients with type II diabetes and arterial hypertension].
Klinicheskaia meditsina, , Volume: 84, Issue:2, 2006

Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: a randomized, double-blind, placebo-controlled 12-month study.
Hypertension research : official journal of the Japanese Society of Hypertension, , Volume: 27, Issue:7, 2004

Eprosartan, an angiotensin II receptor antagonist, does not affect the pharmacodynamics of glyburide in patients with type II diabetes mellitus.
Journal of clinical pharmacology, , Volume: 37, Issue:2, 1997

Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: a randomized, double-blind, placebo-controlled 12-month study.
Hypertension research : official journal of the Japanese Society of Hypertension, , Volume: 27, Issue:7, 2004

Ameliorative effect of eprosartan on high-fat diet/streptozotocin-induced early diabetic nephropathy in rats.
European journal of pharmacology, , Mar-05, Volume: 750, 2015

[Candesartan - a novel AT(1)-angiotensin receptor blocker: peculiarities of pharmacology and experience of use in arterial hypertension].
Kardiologiia, , Volume: 44, Issue:1, 2004

Effect of angiotensin II antagonist eprosartan on hyperglycemia-induced activation of intrarenal renin-angiotensin system in healthy humans.
Hypertension (Dallas, Tex. : 1979), , Volume: 36, Issue:1, 2000

Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Proceedings of the National Academy of Sciences of the United States of America, , 12-08, Volume: 117, Issue:49, 2020

Eprosartan improves cardiac function in swine working heart model of ischemia-reperfusion injury.
Medical science monitor basic research, , Apr-25, Volume: 20, 2014

Effects of spironolactone and eprosartan on cardiac remodeling and angiotensin-converting enzyme isoforms in rats with experimental heart failure.
American journal of physiology. Heart and circulatory physiology, , Volume: 289, Issue:4, 2005

Renal damage is not improved by blockade of endothelin receptors in primary renin-dependent hypertension.
Journal of hypertension, , Volume: 21, Issue:12, 2003

Pharmacology of eprosartan, an angiotensin II receptor antagonist: exploring hypotheses from clinical data.
American heart journal, , Volume: 138, Issue:3 Pt 2, 1999

Effects of eprosartan on renal function and cardiac hypertrophy in rats with experimental heart failure.
Hypertension (Dallas, Tex. : 1979), , Volume: 32, Issue:4, 1998

Cardiology patient page. Angiotensin receptor blockers.
Circulation, , Jun-24, Volume: 107, Issue:24, 2003

Drug points: Dysgeusia and burning mouth syndrome by eprosartan.
BMJ (Clinical research ed.), , Nov-30, Volume: 325, Issue:7375, 2002

Protective and therapeutic role of mango pulp and eprosartan drug and their anti-synergistic effects against thioacetamide-induced hepatotoxicity in male rats.
Environmental science and pollution research international, , Volume: 29, Issue:34, 2022

[The effectiveness of eprosartan in patients with chronic glomerulonephritis].
Klinicheskaia meditsina, , Volume: 85, Issue:8, 2007

Renal damage is not improved by blockade of endothelin receptors in primary renin-dependent hypertension.
Journal of hypertension, , Volume: 21, Issue:12, 2003

Effects of eprosartan on glomerular injury in rats with reduced renal mass.
Pharmacology, , Volume: 59, Issue:2, 1999

Effects of spironolactone and eprosartan on cardiac remodeling and angiotensin-converting enzyme isoforms in rats with experimental heart failure.
American journal of physiology. Heart and circulatory physiology, , Volume: 289, Issue:4, 2005

Eprosartan reduces cardiac hypertrophy, protects heart and kidney, and prevents early mortality in severely hypertensive stroke-prone rats.
Cardiovascular research, , Volume: 50, Issue:3, 2001

Effects of eprosartan on renal function and cardiac hypertrophy in rats with experimental heart failure.
Hypertension (Dallas, Tex. : 1979), , Volume: 32, Issue:4, 1998

Effects of different AT1-receptor antagonists in the therapy of severe heart failure pretreated with ACE inhibitors.
Acta cardiologica, , Volume: 62, Issue:4, 2007

[Effect of a combination of teveten and prestarium in patients with chronic heart failure].
Georgian medical news, , Issue:123, 2005

Effects of spironolactone and eprosartan on cardiac remodeling and angiotensin-converting enzyme isoforms in rats with experimental heart failure.
American journal of physiology. Heart and circulatory physiology, , Volume: 289, Issue:4, 2005

Impaired neuronal and vascular responses to angiotensin II in a rabbit congestive heart failure model.
Journal of the renin-angiotensin-aldosterone system : JRAAS, , Volume: 4, Issue:4, 2003

Cardiology patient page. Angiotensin receptor blockers.
Circulation, , Jun-24, Volume: 107, Issue:24, 2003

Effects of the AT1-receptor antagonist eprosartan on the progression of left ventricular dysfunction in dogs with heart failure.
British journal of pharmacology, , Volume: 138, Issue:2, 2003

Potential of the angiotensin II receptor 1 blocker eprosartan in the management of patients with hypertension or heart failure.
Current hypertension reports, , Volume: 3 Suppl 1, 2001

ADEPT: Addition of the AT1 receptor antagonist eprosartan to ACE inhibitor therapy in chronic heart failure trial: hemodynamic and neurohormonal effects.
American heart journal, , Volume: 141, Issue:5, 2001

Control of cardiomyocyte gene expression as drug target.
Molecular and cellular biochemistry, , Volume: 212, Issue:1-2, 2000

Improvement of cardiac output in patients with severe heart failure by use of ACE-inhibitors combined with the AT1-antagonist eprosartan.
European journal of heart failure, , Volume: 2, Issue:2, 2000

Effects of eprosartan on renal function and cardiac hypertrophy in rats with experimental heart failure.
Hypertension (Dallas, Tex. : 1979), , Volume: 32, Issue:4, 1998

Effect of angiotensin II antagonist eprosartan on hyperglycemia-induced activation of intrarenal renin-angiotensin system in healthy humans.
Hypertension (Dallas, Tex. : 1979), , Volume: 36, Issue:1, 2000

Renal damage is not improved by blockade of endothelin receptors in primary renin-dependent hypertension.
Journal of hypertension, , Volume: 21, Issue:12, 2003

Effect of eprosartan on catecholamines and peripheral haemodynamics in subjects with insulin-induced hypoglycaemia.
Clinical science (London, England : 1979), , Volume: 108, Issue:2, 2005

PROTECTIVE EFFECT OF EPROSARTAN IN RENAL ISCHEMIA REPERFUSION INJURY BY REGULATING OXIDATIVE STRESS, INFLAMMATION, AND APOPTOTIC CASCADES IN A BILATERAL RAT MODEL.
Wiadomosci lekarskie (Warsaw, Poland : 1960), , Volume: 76, Issue:7, 2023

Protective and therapeutic role of mango pulp and eprosartan drug and their anti-synergistic effects against thioacetamide-induced hepatotoxicity in male rats.
Environmental science and pollution research international, , Volume: 29, Issue:34, 2022

Heat shock treatment protects against angiotensin II-induced hypertension and inflammation in aorta.
Cell stress & chaperones, , Volume: 9, Issue:1, 2004

Effects of eprosartan versus hydrochlorothiazide on markers of vascular oxidation and inflammation and blood pressure (renin-angiotensin system antagonists, oxidation, and inflammation).
The American journal of cardiology, , Mar-15, Volume: 89, Issue:6, 2002

[An AT-II blocker in patients with type II diabetes and arterial hypertension].
Klinicheskaia meditsina, , Volume: 84, Issue:2, 2006

Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity.
Circulation, , May-04, Volume: 109, Issue:17, 2004

ACE inhibition and glucose transport in insulinresistant muscle: roles of bradykinin and nitric oxide.
The American journal of physiology, , Volume: 277, Issue:1, 1999

Moxonidine normalizes sympathetic hyperactivity in patients with eprosartan-treated chronic renal failure.
Journal of the American Society of Nephrology : JASN, , Volume: 15, Issue:11, 2004

Effect of hepatic disease on the pharmacokinetics and plasma protein binding of eprosartan.
Pharmacotherapy, , Volume: 18, Issue:1

Exploring the possibility of drug repurposing for cancer therapy targeting human lactate dehydrogenase A: a computational approach.
Journal of biomolecular structure & dynamics, , Volume: 41, Issue:19, 2023

A self-assembled system for tumor-targeted co-delivery of drug and gene.
Materials science & engineering. C, Materials for biological applications, , Nov-01, Volume: 56, 2015

Effect of the multitargeted receptor tyrosine kinase inhibitor, ABT-869 [N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N'-(2-fluoro-5-methylphenyl)urea], on blood pressure in conscious rats and mice: reversal with antihypertensive agents and effect on tumor growt
The Journal of pharmacology and experimental therapeutics, , Volume: 329, Issue:3, 2009

Versatile reticular polyethylenimine derivative-mediated targeted drug and gene codelivery for tumor therapy.
Molecular pharmaceutics, , Oct-06, Volume: 11, Issue:10, 2014

Renal damage is not improved by blockade of endothelin receptors in primary renin-dependent hypertension.
Journal of hypertension, , Volume: 21, Issue:12, 2003

[Neurocirculatory dystonia (does this disease exist?)].
Kardiologiia, , Volume: 43, Issue:10, 2003

[The use of melaxen in combined therapy of arterial hypertension in subjects occupied in assembly line production].
Klinicheskaia meditsina, , Volume: 87, Issue:6, 2009

[Stress-associated hypertension in the work place: results of the STARLET project].
Deutsche medizinische Wochenschrift (1946), , Nov-17, Volume: 131, Issue:46, 2006

[Effect of eprosartan on psychophysiological functions of drivers with arterial hypertension].
Kardiologiia, , Volume: 46, Issue:10, 2006

[Stress-induced hypertension. The work site--a cardiovascular risk].
MMW Fortschritte der Medizin, , Mar-15, Volume: 143, Issue:11, 2001

Eprosartan: a review of its use in hypertension.
Drugs, , Volume: 69, Issue:17, 2009

Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES).
Stroke, , Volume: 36, Issue:6, 2005

[Antihypertensive treatment with eprosartan mesilate of patients in acute and late periods of ischemic stroke].
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, , Volume: 103, Issue:11, 2003

Effect of captopril and the nonpeptide angiotensin II antagonists, SK&F 108566 and EXP3174, on renal function in dogs with a renal artery stenosis.
The Journal of pharmacology and experimental therapeutics, , Volume: 263, Issue:2, 1992

The angiotensin type 1 receptor antagonist, eprosartan, attenuates the progression of renal disease in spontaneously hypertensive stroke-prone rats with accelerated hypertension.
The Journal of pharmacology and experimental therapeutics, , Volume: 301, Issue:1, 2002

Eprosartan improves cardiac performance, reduces cardiac hypertrophy and mortality and downregulates myocardial monocyte chemoattractant protein-1 and inflammation in hypertensive heart disease.
Journal of hypertension, , Volume: 22, Issue:3, 2004

Emerging role of angiotensin II type 1 receptor blockers for the treatment of endothelial dysfunction and vascular inflammation.
The Canadian journal of cardiology, , Volume: 18, Issue:12, 2002

Observational Study on Cognitive function And systolic blood pressure Reduction (OSCAR): preliminary analysis of 6-month data from > 10,000 patients and review of the literature.
Current medical research and opinion, , Volume: 23 Suppl 5, 2007

PROTECTIVE EFFECT OF EPROSARTAN IN RENAL ISCHEMIA REPERFUSION INJURY BY REGULATING OXIDATIVE STRESS, INFLAMMATION, AND APOPTOTIC CASCADES IN A BILATERAL RAT MODEL.
Wiadomosci lekarskie (Warsaw, Poland : 1960), , Volume: 76, Issue:7, 2023

Protective effect of Eprosartan against ischemic acute renal injury: Acting on NF-κB, caspase 3, and Sirtuin 1.
International immunopharmacology, , Volume: 115, 2023

Eprosartan: A closer insight into its neuroprotective activity in rats with focal cerebral ischemia-reperfusion injury.
Journal of biochemical and molecular toxicology, , Volume: 35, Issue:7, 2021

Eprosartan improves cardiac function in swine working heart model of ischemia-reperfusion injury.
Medical science monitor basic research, , Apr-25, Volume: 20, 2014

Inhibiting the HIV integration process: past, present, and the future.
Journal of medicinal chemistry, , Feb-13, Volume: 57, Issue:3, 2014

eprosartan

Description

Cross-References

Synonyms (78)

Roles (4)

Drug Classes (3)

Pathways (1)

Protein Targets (9)

Potency Measurements

Inhibition Measurements

Other Measurements

Bioassays (79)

Research

Studies (281)

Study Types

Safety/Toxicity (8)

Long-term Use (3)

Pharmacokinetics (15)

Bioavailability (9)

Dosage (26)

Interactions (3)

Article	Year
Risk reduction by preventing stroke: need for blockade of angiotensin II and catecholamines? Current medical research and opinion, , Volume: 23 Suppl 5	2007
[Candesartan - a novel AT(1)-angiotensin receptor blocker: peculiarities of pharmacology and experience of use in arterial hypertension]. Kardiologiia, , Volume: 44, Issue:1	2004
Effects of eprosartan on renal function and cardiac hypertrophy in rats with experimental heart failure. Hypertension (Dallas, Tex. : 1979), , Volume: 32, Issue:4	1998

Article	Year
Pharmacokinetic-pharmacodynamic modeling of the antihypertensive effect of eprosartan in Black and White hypertensive patients. Clinical pharmacokinetics, , Volume: 52, Issue:9	2013
Physicochemical determinants of human renal clearance. Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15	2009
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug metabolism and disposition: the biological fate of chemicals, , Volume: 36, Issue:7	2008
Pharmacokinetics and urinary excretion of eprosartan in Chinese healthy volunteers of different gender. Die Pharmazie, , Volume: 62, Issue:10	2007
Pharmacophore, drug metabolism, and pharmacokinetics models on non-peptide AT1, AT2, and AT1/AT2 angiotensin II receptor antagonists. Journal of medicinal chemistry, , Jun-30, Volume: 48, Issue:13	2005
Pharmacokinetics and protein binding of eprosartan in hemodialysis-dependent patients with end-stage renal disease. Pharmacotherapy, , Volume: 19, Issue:5	1999
A review of eprosartan pharmacokinetic and pharmacodynamic drug interaction studies. Pharmacotherapy, , Volume: 19, Issue:4 Pt 2	1999
Pharmacokinetics of eprosartan in healthy subjects, patients with hypertension, and special populations. Pharmacotherapy, , Volume: 19, Issue:4 Pt 2	1999
Effect of age and gender on the pharmacokinetics of eprosartan. British journal of clinical pharmacology, , Volume: 46, Issue:3	1998
Pharmacokinetics of intravenously and orally administered eprosartan in healthy males: absolute bioavailability and effect of food. Biopharmaceutics & drug disposition, , Volume: 19, Issue:6	1998
Pharmacokinetics and protein binding of eprosartan in healthy volunteers and in patients with varying degrees of renal impairment. Journal of clinical pharmacology, , Volume: 38, Issue:2	1998
Effect of ranitidine on the pharmacokinetics of orally administered eprosartan, an angiotensin II antagonist, in healthy male volunteers. The Annals of pharmacotherapy, , Volume: 32, Issue:3	1998
Effect of hepatic disease on the pharmacokinetics and plasma protein binding of eprosartan. Pharmacotherapy, , Volume: 18, Issue:1
Effect of fluconazole on the pharmacokinetics of eprosartan and losartan in healthy male volunteers. Clinical pharmacology and therapeutics, , Volume: 62, Issue:4	1997
Lack of effect of eprosartan on the single dose pharmacokinetics of orally administered digoxin in healthy male volunteers. British journal of clinical pharmacology, , Volume: 43, Issue:6	1997

Article	Year
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Molecular pharmacology, , Volume: 96, Issue:5	2019
Risk assessment and QbD based optimization of an Eprosartan mesylate nanosuspension: In-vitro characterization, PAMPA and in-vivo assessment. International journal of pharmaceutics, , Aug-15, Volume: 567	2019
Formulation and statistical optimization of self-microemulsifying drug delivery system of eprosartan mesylate for improvement of oral bioavailability. Drug delivery and translational research, , Volume: 6, Issue:5	2016
Interaction of angiotensin receptor type 1 blockers with ATP-binding cassette transporters. Biopharmaceutics & drug disposition, , Volume: 31, Issue:2-3	2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3	2010
Effects of enalapril and eprosartan on the renal vascular nitric oxide system in human essential hypertension. Kidney international, , Volume: 61, Issue:4	2002
Pharmacokinetics of eprosartan in healthy subjects, patients with hypertension, and special populations. Pharmacotherapy, , Volume: 19, Issue:4 Pt 2	1999
Effect of age and gender on the pharmacokinetics of eprosartan. British journal of clinical pharmacology, , Volume: 46, Issue:3	1998
Pharmacokinetics of intravenously and orally administered eprosartan in healthy males: absolute bioavailability and effect of food. Biopharmaceutics & drug disposition, , Volume: 19, Issue:6	1998

Article	Year
Safety and tolerability of eprosartan in combination with hydrochlorothiazide. Drug safety, , Volume: 25, Issue:8	2002
Improvement of cardiac output in patients with severe heart failure by use of ACE-inhibitors combined with the AT1-antagonist eprosartan. European journal of heart failure, , Volume: 2, Issue:2	2000
A review of eprosartan pharmacokinetic and pharmacodynamic drug interaction studies. Pharmacotherapy, , Volume: 19, Issue:4 Pt 2	1999

eprosartan

Description

Cross-References

Synonyms (78)

Roles (4)

Drug Classes (3)

Pathways (1)

Protein Targets (9)

Potency Measurements

Inhibition Measurements

Other Measurements

Bioassays (79)

Research

Studies (281)

Study Types

Related Drugs (2,736)

Drugs in this Class (382)

Drugs with this Function (421)

Drugs in Same Class and Function (17)

Drugs Involved in Assays Together (2,107)

Drugs Researched Together (112)

Related Conditions (125)

Safety/Toxicity (8)

Long-term Use (3)

Pharmacokinetics (15)

Bioavailability (9)

Dosage (26)

Interactions (3)